Integrating c-Met Molecular Imaging into the Optimisation of Cancer Therapy. by Arulappu, Appitha
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 












Download date: 06. Nov. 2017
1 
 
Integrating c-Met Molecular 
Imaging into the 





A thesis submitted to the King’s College London for 
the degree of Doctor of Philosophy 
 By  
Appitha Arulappu 
 
The Richard Dimbleby Laboratory 
 
Division of Cancer Studies and 
Randall Division of Cell and Molecular Biophysics, 
School of Medicine 













Dedicated to My Excellent Dad 
One who inspired, encouraged and 













First and above all, I would like to thank God for this opportunity. The 
projects I have been working on were very interesting but I felt very much out 
of my comfort zone.  I truly believe that God has been my help and guidance 
in those challenging times.  
I would like to thank Prof Tony Ng, for selecting me on this PhD programme, 
for his endless support and patience and encouraging me to work on a 
project I did not initially think I could achieve. I am truly grateful to have had a 
good supervisor with a great wealth of knowledge and wisdom.  
I would like to thank every member of the Dimbleby department and Randall 
Division for their help and support throughout the past few years and this 
includes Dr James Monypenny and Dr Gregory Weitsman who have both 
taught  me many useful things which include great laboratory skills and for 
teaching me to build up my work ethics, Dr Fabian Flores, for his great 
scientific support and friendship, Dr Rachel Evans, for her kindness, 
professionalism and proofreading my entire thesis, Dr Oana Coban, for her 
lively personality and authenticity, Dr Ruhe Chowdhury, for her baking skills, 
clinical knowledge and help, Dr Myria Galazi, for her kindness and friendship. 
I would also like to thank Dr Peter Gordon and Dr Jonathan Caron, for their 
cheerful attitudes and Tamara de Koning who has been a great friend and 
individual. I would also like to acknowledge Felix Wong and Ines Garcia, who 
have been great lab bench buddies. I would also like to thank past members 
of this team, Dr Hanna Milewicz, Dr Anthony Cheung, Dr Sheeba Khan, Dr 
4 
 
Paulina Szyszka and Dr Michel Eisenblaetter as it has been a pleasure to 
work with them. I would like to thank Dr Michaela Perani for her kind help 
and expertise, the physicists, especially Dr Viviane Devauges and Camille 
Perrin for being great individuals. Big thanks to Dr Rebecca Marlow, Erika 
Franscesch, Dr Patrycja Gazinska, Dr Enrique Miranda-Rota and Natalie 
Woodman for their teaching skills and valuable scientific support.  
As part of my PhD involved collaborating with GE Healthcare, I had the 
privilege to meet some amazing individuals, with great expertise in the 
imaging field, and experience the world of industry. I would like to give 
special thanks to Dr Sven Macholl who initially supervised me at the GE, and 
always made me feel very welcomed as well as providing a huge amount of 
support on the scientific side, both intellectually and technically. I would also 
like to thank Mark Battle, who took over Sven‟s role on the technical side, 
and helped me hugely in the completion of my project at the GE. I would also 
like to give my warmest thanks to Dr Susan Hoppmann, who has been very 
supportive during my time at the GE, imparting her invaluable knowledge and 
experience in medical imaging and proofreading part of my thesis. I would 
also like to thank the radiochemists Dr Graeme McRobbie and Dr Imtiaz 
Khan for the provision of the tracer and their cheerful nature. I would also like 
to acknowledge Joanne Nesbitt, Rochelle Lear and David Gendle who have 
provided great support for the in-vivo side of my project. I would like to thank 
Grethe Dalsgaard, the project leader in early clinical development at the GE 
who ensured that my project was going smoothly, despite the changes that 
were made during my time there.  I am very grateful for all those people, who 
showed great professionalism, scientific support and kindness.  
5 
 
I would also like to thank the radiochemists and imaging scientists based at 
St Thomas‟ hospital: Dr Michelle Ma for providing support in the 
radiolabelling of the fragment variable antibody and Dr Julia Blower for her 
help and useful suggestions. I would like to thank Dr Gilbert Fruhwirth who 
has been beyond helpful and his team, especially Alessia Volpe and Bruce 
Fanshawe for their undivided support in the SPECT imaging experiment.  
Thanks to my amazing „King‟s crew‟: Rebecca Alade, Saleha Hassan, 
Natasha Khalife and Tabetha Bhatti for being there through thick and thin. 
Huge thanks to my lovely friends Dami, Natalia and Lydia for their love and 
care. 
Last but not least, I would like to thank my mum and my sisters for moral 
support and for their supply of homemade food and laughter. Huge thanks to 
my amazing husband John who encouraged me to work hard, took me on 
holidays when I needed a break, and proofreading my entire thesis. 








Basal-like subtypes of breast cancer (BLBC) account for about 15-
20% of all breast cancer, affecting younger women (<50 years old) of 
predominantly African and Hispanic descent [1] with rapid relapse ([2]. c-Met 
is overexpressed in various solid tumors, lung, breast, ovary, kidney, colon, 
thyroid, liver, and gastric carcinomas [3]; [4]; [5]; [6]; [7]; [8]; [9]; [10]; [11]; 
[12]; [13]; [14]. In breast cancer, a higher c-Met expression level is displayed 
in BLBC in comparison to other intrinsic breast cancer subtypes [15] . In the 
first part of this thesis, the basal-like breast tumour xenograft mouse model 
was used to investigate early signs of locoregional recurrence of primary 
tumour using a 18F radiolabelled c-Met binding peptide, [18F]AH113804. 
[18F]AH113804 exhibited significantly higher uptake in the tumours (in 
comparison to mammary fatty tissue) with a target to background (muscle) 
ratio of approximately 3:1 (p<0.01). In addition to this, [18F]AH113804 was 
able to detect local tumor recurrence as early as six days after tumour 
resection [16]. Following publication of this work, I designed an in-house 
radiolabelled single chain Fv-Fc fusion against human c-Met, which was 
selected from a phage display library, and labelled with Cy5 dye initially. It 
was then labelled with the radioisotope 111In that was conjugated with the 
chelator CHX-A‟‟DTPA for an increase in radiolabelling efficiency. Both the 
optical and the radiolabelled version of the scFv-Fc were injected into dual 
tumour-bearing female mice. The tracer‟s uptakes at the c-Met positive 
tumour (basal-like breast tumour) and in the c-Met negative but ER positive 
breast adenocarcinoma), were visualised using an optical detector (for the 
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Cy5 labelled tracer) and a gamma camera (using the SPECT tracer). We 
detect a higher uptake in the c-Met positive basal-like breast tumour in 
comparison to the c-Met negative control tumours using both versions of the 
tracer. 
 
EGFR expression has been reported in at least 50% of basal-like breast 
cancers (BLBCs) [17]. Due to the essential role of EGFR in both proliferation 
and cell survival pathways in breast epithelium and other epithelia, EGFR 
inhibitors have been used in clinical trials to treat patients with BLBC [18]. 
Unfortunately, this was shown to be of limited success [19]. There is a need 
to gain a deeper understanding of EGFR signalling in order to identify 
potential therapeutic targets. In the third part of this thesis, assays were 
carried out to investigate further the effect of PTPN11 knockdown on EGFR 
and c-Met phosphorylation, cell proliferation and E-cadherin level of 
expression in basal like breast cancer cells. PTPN11 was identified as an 
EGFR modulator based on the outcome from a high content screen based 
on FRET sensing of EGFR activity in situ, monitored by fluorescence lifetime 
imaging (FLIM). Validation of this novel regulator of EGFR activity in BLBC 
confirmed a significant slowing of the kinetics of EGFR dephosphorylation 
upon ligand stimulation, as well as c-Met hyperphosphorylation in cells that 
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Chapter 1: INTRODUCTION 
 
1.1 Basal like breast cancer 
 
Breast cancer (BC) is not a single entity, but rather a class of distinct 
biological subtypes  [20]. It is a worldwide disease and has been associated 
with urbanisation, an increased in the life expectancy and personal  
behaviours such as smoking, obesity, alcohol consumption, hormone 
replacement  therapy and inactivity [21]. BC is the most commonly 
diagnosed cancer in women in the UK, affecting one in nine women [22].The 
Stanford group has pioneered the gene expression microarray-based class 
discovery studies which have led to the identification of at least five 
molecular breast cancer subtypes: luminal A, luminal B, normal breast-like, 
HER2, and basal-like [23]. It has been observed that the difference in 
histopathological and biological features between subtypes of breast cancer 
exhibit distinct behaviours causing different treatment responses and the 
devise of different therapeutic strategies [24] For example, the luminal 
tumours begin in cells that line the ducts and glands and tend to display a 
slow tumour growth while the basal-type sprout from the deep layers of the 
ducts and glands and grow much quicker than the luminal types [24]. Table 
1-1 provides a clear description of the characteristics and prognosis for the 
various breast cancer subtypes. BLBCs are characterized by high 
histological grade and mitotic indexes, pushing borders and large areas of 
necrosis [25]. Epidemiologically, BLBCs and triple negative breast cancer 
(TNBC) are more common in younger women (<50 years old) of African and 
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Hispanic descent [1]. Basal like breast cancer (BLBC) is a particularly 
aggressive subtype of breast cancer, and  accounts for less than 15% of all 
invasive breast cancers affecting younger women with rapid relapse [2]. 
Clinically, those patients have higher grade tumors, and present with higher 
tumor stage at diagnosis. Histologically, they display invasive ductal 
carcinomas, metaplastic and medullary cancers, and are often poorly 
differentiated [26]. Previous studies have shown that the basal-like is an 
independent marker of poor prognosis in breast cancer [27]. Gene 
expression profiling defines the basal like subtype  in three different 
categories:  1)  negative for estrogen receptor (ER), progesterone receptor 
(PR), and human epidermal growth factor receptor 2 (HER-2) (also called 
triple negative) 2) positive for one of more cytokeratins (CK5/6, CK14 and 
CK17) 3) lack ER and HER2 along with the expression of epithelial growth 
factor receptor (EGFR) and CK5/6 and 4) lack ER, PR, HER2 along with the 
expression of CK5/6 and/or EGFR [28].Up to 15%–45% of BLBCs have been 
shown to express ER and 14% of BLBCs express HER-2, which suggest that 
not all BLBCs are Triple Negative Breast Cancers (TNBCs) [29]. TNBC is 
characterised by a lack of expression of estrogen, progesterone receptor and 
human epidermal growth factor receptor. BLBC and TNCBCs are subtypes 
that overlap due to the similarity in their lack of hormone receptors, and have 









Table 1-1. Summary of the breast tumor molecular subtypes 
 
1.1.1 Recurrence patterns in BLBCs: 
 
Both TNBC and BLBCs are considered to be more aggressive than other 
breast cancer subtypes, with early recurrence patterns [31]. A study has 
shown that the rate of recurrence for triple-negative breast cancer was 
33.9% in comparison to 20.4% for other subtypes. Recurrence occurs most 
often in the first 5 years. After relapse, the overall survival is much shorter 
than in patients with other types of breast cancer [31]. 
It has been shown that basal-like breast cancers are more likely than other 
types of breast cancer to metastasize to the viscera (particularly to the lungs, 
brain and soft tissue), to be node negative and do not often metastasize to 
bone [28]. Locoregional recurrence (LRR) is defined as the reappearance of 
breast cancer in the breast where the primary tumour has been removed 
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surgically. LRR is a well-established predictor of distant outcomes [20] so it is 
important to detect the regrowth as early as possible. Local recurrence as a 
whole was shown to be a strong independent predictor of a higher likelihood 
of developing metastases as well as a reduction for overall survival rate [32]. 
From the early 1900s onwards, surgical excision of the breast tumours mass 
was the core method in treating breast cancer. This excision comprises 
radical mastectomy, which is the removal of the whole breast, including the 
underlying chest muscle and lymph nodes of the axilla, and breast-
conserving treatment (BCT), in which only part of the breast tissue, affected 
by the tumour, is being removed. Recently, some patients are treated with 
radiotherapy instead of surgery as a first line treatment. While the long term 
survival rate of patients that underwent BCT or mastectomy is the same, 
numerous studies have shown that there is a higher risk of local recurrence 
in young patients after BCT than those that has had mastectomy [33]. 
Additionally, other studies have shown a significant increase in LRR rate 
after BCT for patients lacking ER and PR expression in comparison to other 
subtypes [34, 35]. A recent study that identified 11,073 patients who had 
breast cancer surgery performed between November 1995 and December 
2011 showed that 787 of those patients ended up with locoregional 
recurrence [36]. The involvement of chest wall in the tumour regrowth would 
make another surgical intervention very risky. Additionally, Montagna et al. 
showed in their study that in patients with TNBC, locoregional recurrence 







1.1.2 Current treatments and potential future treatments for TNBCs 
and BLBCs: 
 
Following surgical removal of the breast tumour tissue via mastectomy or 
BCT, treatments for triple negative breast cancer and basal-like breast 
cancer include either radiotherapy and/or systemic chemotherapy with third 
generation (taxane containing) adjuvant [37]. Taxane based neoadjuvant 
therapy increase the pathological complete response (pCR) by 45% in BLBC 
in comparison to 6% in the luminal subtype [38]. A number of studies have 
shown the sensitivity of tumours with aberration in the BRCA1 gene, such as 
TNBCs, to platinum-based therapies [39]. It is thought that BRCA1 mutant 
cancer cells have a defect in the homologous recombination-based repair of 
double stranded DNA breaks, and would therefore be sensitive to platinum 
salts, that are inter-strand cross-linking agents. The addition of cisplatin to 
metronomic methotrexate and cyclophosphamide, in a randomised phase II 
trial (N = 126),  led to an improvement in median time-to-progression (TTP) 
of 6 months (from 7 to 13 months) and OS of 4 months (from 12 to 16 
months) in second-line metastatic TNBC patients. [40] 
Another type of treatment currently being assessed, in clinical trials, is the 
use of PARP inhibitors (PARPi). Poly(ADP-ribose) polymerases (PARPs) are 
nuclear enzymes which synthesise the ADP-ribose polymer driving the 
assembly of DNA-repair complex at sites of DNA damage, and supporting 
BER and single strand break repair (SSBR) pathways [41]. PARPi have the 
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ability to interfere with the DNA damage repair systems of cancer cells [42]. 
The data generated so far shows more promise in BRCA-related TNBCS 
than for sporadic TNBCs. Indeed, a recent study shows 63% of the BRCA1/2 
carriers have a reduced tumour size and a stable disease for more than 8 
weeks in comparison to only 13% of sporadic tumours [43]. 
Antiangiogenic agents are also being assessed in clinical trials as mean of 
therapeutic agents in TNBC patients. In particular bevacizumab, a 
monoclonal antibody (mAb) targeted against VEGF, was given in addition to 
the physician‟s choice of chemotherapy to Metastatic Breast Cancer (MBC) 
patients. This phase III clinical trial demonstrates that there is a median 
Progress Free Survival (PFS) of 6 months for TNBC treated with 
bevacizumab, in comparison to 2.7 months for first line of chemotherapy 
regimens [44]. More recently, the addition of bevacizumab to standard 
neoadjuvant chemotherapy significantly improved pathologic complete 
response (pCR) rates in women with basal-like breast cancer compared with 
non-basal-like subtypes, according to an analysis of the CALGB 40603 trial 
(2014 San Antonio Breast Cancer Symposium (SABCS)). Further data 
presented at the 2015 San Antonio Breast Cancer Symposium showed that, 
after 3 years of follow-up, the researchers have now found that women who 
had a pathologic complete response were 70% less likely to have the cancer 
come back (recurrence) and 80% more likely to be alive than women who 




Approximately half of BLBC express EGFR based on immunohistochemistry, 
are dependent on the EGFR pathway for proliferation and are sensitive to 
EGFR inhibitors [17]. The latter (e.g. cetuximab) have shown to have low 
efficacy as single agents in BLBCs and TNBC. However, in conjunction with 
cisplatin, as demonstrated in the phase II BALI-1 trial, there is an increase in 
PFS by 2.2 months in comparison to cisplatin alone [18]. 
Another popular targeted agent for treatment of BLBC and TNBCs is c-Met. 
c-Met and its ligand HGF are upregulated in at least 20-30% of BC [45]. 
Numerous studies have demonstrated a preferential overexpression of c-Met 
in basal-like subgroup [46]. Currently MetMAb is being assessed in a 
randomised phase II study for metastatic TNBC in combination with 
paclitaxel and bevacizumab [47]. Likewise ARG 197, an oral c-Met inhibitor 
is under clinical trial [48]. 
 
1.2 The implications of c-Met in BLBC: 
1.2.1 The structure of c-Met and its ligand HGF 
 
The hepatocyte growth factor (HGF), which is the ligand for the c-Met 
tyrosine kinase receptor is a potent inducer of invasive growth [49]. Initially 
secreted as a single-chain inert precursor, it is then converted into a 
functional heterodimer. HGF is highly distributed in the extracellular matrix of 
most tissues, mainly in its inactive form, and is sequestered by heparin-like 
proteoglycans. HGF/SF is believed to be a mesenchymal cell-derived 
cytokine [50]. HGF-MET signalling has many biological functions and 
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includes playing a protective role in liver cirrhosis, lung fibrosis and wound 
healing [51]. 
 
Due to the importance of c-Met in basal like breast cancer, it is worth 
discussing its structure, functionality and biological effects in detail. c-Met is 
classified as a member of a RTK subfamily [52]. It is expressed by a variety 
of normal and malignant cells [53] and is predominantly distributed in 
epithelial cells of many organs which include the liver, pancreas, prostate, 
kidney, muscle and bone marrow [50, 54]. Initially, c-Met is produced as a 
170 kDa precursor which is broken down into a 50 kDa extracellular α-
subunit and a 145 kDa transmembrane β-subunit [55];[56]. Both subunits are 
joined via a disulphide bond [56]. The extracellular portion of c-Met is made 
of three domain types: a Sema domain (which comprises the whole α-subunit 
and part of the β-subunit), a PSI domain (present in plexins, semaphorins 
and integrins) and four IPT domains (immunoglobulin-like fold shared by 
plexins and transcription factors) which connects the PSI domain to the 
transmembrane helix. The SEMA–PSI domain was shown to provide a 
binding site for the α-chain of the ligand HGF [57]. The intracellular domains 
include three further domains which are the following: the juxtamembrane 
region, the catalytic domain and the multifunctional carboxy-terminal docking 
site [49, 51]. (Fig 1-1) 
Those domains are functional and the juxtamembrane region has a key 
tyrosine residue (Y1003) which is implicated in downregulating c-Met; the 
catalytic domain holds the Y1234 and Y1235 residues and contains the 
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catalytic kinase domain; and finally, the multifunctional carboxy-terminal 
docking site which serve as a docking site to other signalling proteins [58].   
 
 
Figure 1-1. Domain structure of c-Met and hepatocyte growth factor 
(HGF). 
The c-Met receptor is formed into a disulphide-linked α/β heterodimer. The 
extracellular portion of c-Met is composed of three domain types: the N-terminal 
with a large semaphorin (Sema) domain, with the whole a-subunit and part of the b-
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subunit, a plexin semaphorin integrin (PSI) domain, and a transmembrane helix via 
four immunoglobulin plexin transcription (IPT) domains. Intracellularly, the c-Met 
receptor contains a tyrosine kinase catalytic domain with a juxtamembrane and 
carboxy terminal sequences. This portion of c-Met contains the catalytic tyrosines 
Y1234 and Y1235, which positively modulate enzyme activity. The juxtamembrane 
tyrosine 1003 negatively regulates c-Met by recruiting the ubiquitin ligase casitas B-
lineage lymphoma (c-CBL). The C-terminal tail that serves as a multifunctional 
docking site contains tyrosines Y1349 and Y1356, which recruit several transducers 
and adaptors following c-Met activation.  
 
1.2.2 c-Met signalling 
 
Following HGF binding, c-Met gets activated by receptor dimerisation which 
is followed by a trans-phosphorylation of Y1234 and Y1235 within the kinase 
activation loop. This activates the intrinsic kinase activity of c-Met. Two 
„docking‟ tyrosines in the carboxyl-terminal tail (Y1349 and Y1356) get 
phosphorylated (figure 1-2), activating the multisubstrate signal transducer 
docking site (Y1349VHVX3Y1356VNV) , which consists of the docking sites 
that bind Src homology-2 (SH2) domains, phosphotyrosine binding (PTB) 
domains, and c-Met  Binding domains (MBD) of signal transducers and 
adapter proteins [51, 52]. Analysis using a mutated version of this 
multisubstrate docking site suggests that Y1349 and Y1356 mediate the 
interactions with SHC, Src, and growth factor receptor-bound protein 2-
associated binder 1 (Gab1) while recruitment of growth factor receptor-bound 
protein 2 (Grb2), PI3-K, PLC-g, and SHP2 is mediated by Y1356 alone [59]. 
In addition, Y1365 regulates cell morphogenesis. The Y1003 residue, as 
observed in Figure 1-1, binds to c-Cbl, and therefore plays an important role 
in regulating c-Met internalisation. The activation of c-Met has been 
implicated to the best-known intracellular pathways which include the 
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Erk/mitogen-activated protein kinase cascade, the phosphoinositide 3-
kinase/Akt pathway, STAT3 and the Rac1/Cdc42 pathway [49, 60] (Fig 1-2). 
These signalling pathways modulate migration, cellular proliferation, invasion 
and tubulogenesis [56, 60]. It has been discovered that KRAS and the 
downstream MAPK pathway are activated through the binding of SHC and 
GRB2 to the activated c-Met [61]. In addition, the p85 subunit of PI3K binds 
to the activated c-Met directly or indirectly through GAB1 and consequently 
promotes cell survival [62]. Thereby the transcription of the anti-apoptotic 
proteins BCL2 and BCL-XL, which sustain the pro-survival signal, are 
prompted through the activation of the PI3K-AKT pathway [63] (fig 1-3). In 
addition to this, STAT3 gets phosphorylated by binding to c-Met thereby 
inducing tubulogenesis and invasion by migrating to the nucleus.[64] (Fig 1-
3).The c-Met-SRC-FAK interaction causes the induction of anchorage-
independent growth and cell migration [65]. c-Met generated signals can 
cause modifications of phosphorylation of important cytoskeletal regulatory 
and structural proteins. An example is the phosphorylation of focal adhesion 
kinase (p125FAK) at pY397 (autophosphorylation site, with binding to Src 
family SH2 and the p85 subunit of PI3-K) and pY861 (the major Src 
phosphorylation site) following c-Met activation by HGF and promotes cell 
proliferation, cell survival and migration [66]. Further to this, the activation of 
NF-kB has been shown to be essential for HGF-mediated proliferation and 








Figure 1-2. Structure and signaling machinery of the Met receptor. 
c-Met is an α/β heterodimer formed by a completely extracellular α subunit and a 
transmembrane β subunit that contains the tyrosine kinase activity. The extracellular 
region of Met encompasses a large Sema domain, a cysteine-rich domain and four 
repeats of an unusual type of immunoglobulin-like domain. The intracellular portion 
of Met includes the kinase domain – with two catalytic tyrosines (Tyr1234 and 
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Tyr1235) that enhance the receptor enzymatic activity following 
transphosphorylation – and key tyrosine residues in the carboxy-terminal tail 
(Tyr1349 and Tyr1356). Phosphorylation of these distal tyrosines creates docking 
sites for several interactors, many of which are schematized here. Shp2 is a protein 
tyrosine phosphatase (PTP) and is also known as PTPN11 (please also refer to 





Figure 1-3. c-Met (also known as HGF receptor) triggers several 
downstream pathways. 
The mitogen-activated protein kinase (MAPK) cascades consist of three 
subfamilies, each of which comprises three protein kinases that activate one 
another sequentially.  Phosphoinositide 3-kinase (PI3K) is a lipid kinase and 
associates with the multifunctional docking site of c-Met catalysing the formation of 
phosphatidylinositol (3,4,5)-triphosphate (PtdIns(3,4,5)P3). Production of 
PtdIns(3,4,5)P3 creates a docking site for Akt.  Signal transducer and activator of 
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transcription 3 (STAT3) monomers bind to c-Met through their Src-homology-2 
domain (SH2 domain) and become trans-phosphorylated. In response to c-Met 
stimulation and the activation of PI3K- and Src-dependent pathways, nuclear factor-
κB inhibitor-α kinase (IKK) is activated, and phosphorylates the nuclear factor-κB 





1.2.3 c-Met endocytosis 
 
After signalling, c-Met associates with E3 ubiquitin protein ligase Cbl, which 
leads to the phosphorylation of Tyr1003, causing the targeting of c-Met into 
an early endosome and then a multivesicular body which is subjected to 
lysosomal degradation. (Figure 1-4b) [49]. PKC, when activated, also causes 
the internalisation of c-Met, but promotes c-Met‟s signalling [49]. It induces 
the internalisation of c-Met into an early endosome, leading onto ERK 
activation, hence favouring the delivery of Erk to focal adhesion (FA) which 









Figure 1-4. c-Met endocytosis. 
A) c-Met recruited into early and favours the delivery of active extracellular signal-
regulated kinase (ERK) to focal adhesions (mediated by PKC), where it can mediate 
hepatocyte growth factor (HGF)-induced cell migration. B) Downregulation of active 
c-Met is initiated by c-Met association with casitas B-lineage lymphoma (CBL), an 
E3 ubiquitin (Ub)-protein ligase that bridges c-Met and endocytic adaptors.  
 
1.2.4 Overexpression of c-Met in cancer 
c-Met is overexpressed in a variety of carcinomas including lung, breast, 
ovary, kidney, colon, thyroid, liver, and gastric carcinomas [3-14, 68].  
Numerous studies demonstrate the overexpression and upregulation of c-
Met in the basal like breast cancer cell lines [69-73]. A recent study 
performed by CoIan et al investigated the expression level for c-Met in a 
large cohort of invasive breast cancer (1896 tumour samples) using tissue 
microarray technology, with the aim to find a correlation with a specific 
subtype of BC. In this study, they discovered that c-Met scoring was 
significantly higher in patients with tubular carcinoma (P = .003), and BL 
breast cancer (P = .037) [46]. In addition, a great number of clinical studies 
have demonstrated c-Met-receptor overexpression and pathway 
hyperactivation in tissues extracted from breast cancer patients [74] as well 
as a strong relationship between high HGF/c-Met signaling and tumor 
progression [56].  
In many cases HGF and c-Met are co-expressed in mammary tumors, and 
those tumours display a high histological grade and high proliferative index 
[45]. In axillary lymph node-negative patients, c-Met overexpression is 
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significantly associated with reduced survival, a 5-year survival rate of 62% 
compared with 97% of Met low-expressing patients. A recent comprehensive 
meta-analysis, composed of 6,010 cases, gives evidence to a link between 
c-Met overexpression and poor survival in BC patients, and more particularly 
TNBCs [75]. 
 
1.2.5 c-Met deregulation leads to the resistance to TKI 
 
Several studies suggest that c-Met deregulation plays a prominent role in the 
development of acquired resistance to targeted agents. This can occur 
through MET mutations, MET amplification, c-Met protein overexpression, 
increased HGF-dependent c-Met signalling [56] and the interaction with other 
TK receptors [76]. Studies have shown that c-Met amplification was 
responsible for acquired resistance to first-generation EGFR TK inhibitors in 
up to 20% of EGFR-mutant NSCLCs [77]. Likewise, a different study by 
Bardelli et al. showed that MET amplification caused acquired resistance to 
anti-EGFR monoclonal antibodies cetuximab and panitumumab in metastatic 
colorectal cancers [25]. These were observed in both in-vitro and in-vivo 
models.  
Additionally, the cross talk of c-Met with other tyrosine kinase (TK) receptors 




1.2.6 Anti-c-Met therapies 
c-Met inhibitors are being developed in preclinical and early clinical studies, 
and are being investigated as a monotherapy as well as in combination with 
other targeted agents or chemotherapy in numerous cancers, including 
breast cancer, colorectal cancer, Non-Small Cell Lung Cancer (NSCLC) and 
brain tumours [78].  
 c-Met targeted therapies in clinical trials for the treatment of advanced 
TNBC have taken place. Phase II clinical trials were recently completed for 
MetMab (onartuzumab) [79] , foretinib (XL880) [80], cabozantinib 
(alternatively known as XL184) [81] and tivantinib (also known as ARQ197) 
[82] in TNBCs. 
In greater detail, Cabozantinib, a multitargeted tyrosine kinase inhibitor (TKI) 
against MET, VEGFR2 and RET was under investigation in a phase II 
randomised trial in 45 Metastatic Breast Cancer (MBC) patients [81]. In this 
cohort, 64% of the patients displayed tumour regression with an objective 
response rate (ORR) of 14% along with a disease control rate of 48%. 
Onartuzumab, a c-Met monoclonal antibody was under investigation in 
breast cancer and other cancers (e.g. NSCLC). In NSCLC, the combination 
of onartuzumab with erlotinib demonstrated a benefit over erlotinib and 
placebo only as the progress free survival (PFS, HR=0.53) and overall 
survival (OS, HR=0.4) were improved in those patients [47]. Erlotinib is a 
quinazoline derivative that selectively and reversibly inhibits the tyrosine 
kinase activity of the EGFR [83].  
42 
 
Finally, phase II and III clinical studies, evaluating c-Met inhibition in 
gastroesophageal cancer, lung cancer and hepatocellular carcinoma have 
shown encouraging results with clear benefit for the individual patient [84-
86]. 
 
1.3 Epidermal Growth Factor Receptor (EGFR) 
 
1.3.1 EGFR link with c-Met: 
 
Initial studies have identified two different EGFR-TKI resistance 
mechanisms, a secondary mutation in EGFR, EGFR T790M, and 
amplification of the MET oncogene, which have been reported in ∼50% and 
20%, respectively, of patients acquiring resistance to EGFR-Tyrosine Kinase 
Inhibitors (TKIs) [87]. Lately, a third mechanism of gefitinib resistance 
induced by hepatocyte growth factor has been identified. Gefitinib is an 
EGFR TKI used in patients with NSCLC [88]. It has been reported that HGF 
activated c-Met and restored the phosphoinositide 3-kinase (PI3K)/Akt 
signaling pathway, inducing gefitinib resistance of lung cancer cells with 
EGFR-activating mutations. In breast cancer, studies have shown that 
'constitutive phosphorylation of Met contributes to EGFR TKI resistance and 
that decreasing Met kinase activity decreases EGFR tyrosine 
phosphorylation and proliferation in the presence of EGFR TKI‟ (e.g. 
gefitinib) [76] 
A recent study has shown that HGF-induced proliferation of basal-like breast 
cancer cells (HCC1954) was suppressed when treated with the SGX523 (c-
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Met inhibitor)/erlotinib (EGFR TK inhibitor) combination while the proliferation 
of these cells in the absence of HGF (serum free or induced by EGF alone) 
was completely suppressed by erlotinib alone. This suggests the existence of 
a cross-talk between c-Met and EGFR pathways, which is HGF-induced [89]. 
Physical interactions between c-Met, the EGFR family (EGFR and HER3, for 
instance) and other cell surface protein families, contribute to the 
mechanisms of how these receptor signal crosstalks underpin the process of 
oncogenesis and drug resistance [90].  
 
1.3.2 Brief description of EGFR and its family members’ 
involvement in cancer 
 
EGFR is part of the ErbB receptor family, along with HER2, HER3 and HER4 
(Fig 1-5). Reports have shown that the overexpression of EGFR, HER2 or 
HER3 in tumours of breast cancer patients correlate with a reduced survival 
rate [91]. On the other hand, breast cancer patients with upregulation of 
HER4 appear to have a good prognosis. This group also investigated the 
proliferative potential of the EGFR family members and identified that EGFR, 
HER2 and HER3 drive proliferation. On the other hand, the HER4 receptor 





Figure 1-5. EGFR family members - Epidermal Growth Factor Receptor 
Family. 
Conserved domains of the four different EGFR family members are indicated by 
similar shading. L = ligand binding domain, CR = cysteine-rich domains. TM = 
transmembrane domain. CT = C-terminal domain which contains the 
phosphorylation sites. JM = juxta membrane domain. Her2 does not bind a ligand. 
The kinase domain in Erb3 is defective. Alternative names for each receptor are 
written underneath each receptor. Ligands which bind the receptors are indicated 
above the receptors. EGF and HB-EGF stand for epidermal growth factor and 
heparin binding-EGF respectively.  
  
 
Mutations in the kinase domain of EGFR and amplification of EGFR have 
been detected in breast cancer [93, 94]. The EGFRvIII protein is detected in 





1.3.3 Structure of EGFR and its signalling: 
 
EGFR is overexpressed in epithelial tumours. The EGFR family exhibit the 
same receptor tyrosine kinase (RTK) molecular architecture, with a ligand-
binding extracellular domain (which has a regulatory portion binding to an 
allosteric regulator – ligand growth factor- for receptor dimerisation), a 
transmembrane helix, a cytoplasmic tyrosine kinase domain (that undergoes 
activation and transfers phosphate groups to Tyr residues) as well as an 
additional c-terminal tail and juxtamembrane regulatory regions (Fig 1-5). 
 
The amount of EGFR receptors in a normal cell vary from 40,000 to 100,000 
receptors [96]. However, there is an overexpression of EGFR in the majority 
of solid tumors, including breast cancer, head-and-neck cancer, Non-small 
cell lung cancer (NSCLC), renal cancer, ovarian cancer, and colon cancer 
[97]. 
 
EGFR binding to its respective ligand results in homo- or hetero-dimerization, 
followed by activation of the highly conserved intracellular kinase domain and 
then autophosphorylation of tyrosine residues by γ-phosphate from ATP [98]. 
EGFR has five autophosphorylation sites that have been identified, all of 
which are clustered near the carboxyl-terminal 194 amino acids. Those sites 
include tyrosine (Tyr) 1068, Tyr1148, and Tyr1173 (which are major sites), 
whereas Tyr992 and Tyr1086 are minor sites [99]. Depending on EGFR 
phosphorylation pattern, distinct downstream signaling cascades can be 
initiated. The phosphorylated Tyr binds to of a range of proteins, whose 
recruitment activate downstream signaling pathways such as 
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Ras/Raf/mitogen-activated protein kinase (MAPK) pathway (activated by 
Phosphorylation of Tyr1173), extracellular signal-regulated kinase (ERK), 
phosphatidylinositol 3-kinase (PI3K)/Akt pathway, signal transduction and 
activator of transcription (STAT), and other pathways. The role of ERK1 and 
ERK2 is to regulate cell growth and proliferation, whereas Akt and STAT 
direct cell survival and apoptosis. PI3K regulates cell migration along with 
cell proliferation and survival [100]. When EGFR is overexpressed and /or 
constitutively activated, those signalling cascades are amplified, contributing 
to cancer progression. Studies have shown that numerous cancer cell lines 
display an increase in the level of phosphorylated EGFR [101]. 
 
1.3.4 EGFR Trafficking: 
 
EGFR trafficking is an important topic: EGFR localisation in a given cell 
determines the cell fate and the distribution of EGFR is determined by the 
ratio of its internalisation and recycling rates.  The ErbBs (otherwise called 
EGFRs) family starts off by being co-translationally translocated through the 
endoplasmic reticulum (ER) membrane, then are transported to the Golgi 
apparatus (in which the extracellular domain undergoes N-linked 
glycosylation), to finally being sent to the plasma membrane. At steady state 
of cell growth conditions, the bulk of cellular ErbBs proteins are located in the 
plasma membrane. In most cells, EGFR is constitutively internalised at the 
rate comparable to the rate of basal membrane recycling. (internalisation rate 




A disrupted EGFR trafficking could potentially provide a molecular etiology 
for EGFR overexpression in cancers that overexpress EGFR. Mutations and 
deletions of proteins involved in trafficking have been reported to be 
associated with hepatocellular carcinomas, breast and prostate cancer [103]. 
 
1.3.4.1 Ligand-mediated endocytic pathway: 
 
A number of mechanisms within EGFR endocytic pathways regulate EGFR 
signalling. Indeed, one of the most important mechanisms is ligand-mediated 
endocytosis. Progression through the endocytic pathway is characterized by 
the shedding of clathrin, a decrease in the internal pH and the accumulation 
of hydrolytic enzymes. EGFR trafficking from early to late 
endosomes/multivesicular bodies (MVB) is dependent on its continued 
association with Cbl and its sustained ubiquitylation [104]. 
 
The formation of clathrin-coated vesicles (CCVs) is mediated by the AP2 
adaptor, which binds to the cytoplasmic domain of EGFR [102] while the 
GTPase dynamin triggers the detachment of the vesicle from the plasma 
membrane, or fission. The early endosome is then formed as the CCV sheds 
clathrin and fuse with an internal vesicle. This enables the endocytic pathway 
to proceed into the formation of the late endosome, facilitated by the 
involvement of both phosphoinositides [105] and regulatory proteins. Early 
and late endosomes differ by their internal pH (the late endosome having a 
very acidic environment) and by their kinetics and morphology. Indeed, the 
early endosomes are regulated by Rabex/Vps, STAM/Hse1, as illustrated in 
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figure 1-6, while the late endosomes are regulated by ESCRT-1 and 
ubiquitin-related proteins [106] among other proteins. In addition to this, early 
endosomes are often localised at the cell periphery and are more tubular 
while the late endosomes are more spherical and closer to the nucleus. 
Multivesicular bodies (MVBs) are a type of late endosomes and contain 
internal vesicles that are formed through the invagination of the limiting 
membrane and its budding into the lumen. It is important to mention that 
EFGRs can still associate with signalling proteins to activate intracellular 
effectors while at the limiting membrane of MVBs, but this feature is lost 
when EGFRs get sorted into the internal vesicle of MVBs, segregating the 
EGFRs‟ cytoplasm domain away from the signalling proteins and hence 





Figure 1-6. RTK: journey to the lysosome. 
Stimulation with ligand induces activation of RTKs like EGFR, autophosphorylation 
and recruitment of Cbl. Cbl is then phosphorylated and ubiquitylates the EGFR. 
Ubiquitylated receptors are sorted into clathrin-coated pits by a multiprotein complex 
that includes coat adaptors. Progression through the endocytic pathway is 
characterized by the shedding of clathrin. EGFR trafficking from early to late 
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endosomes/MVB is dependent on its continued association with Cbl and its 
sustained ubiquitylation. The guanine nucleotide exchange factor Rabex/Vps9 
regulates endosomal membrane fusion through activation of another GTPase, 
Rab5. MVB sorting is regulated through recognition of ubiquitylated cargo by 
Hgs/Vps27p, Tsg101/Vps23p and other components of ESCRT complexes. Fusion 
of the MVB with the lysosome results in degradation of the contents of the internal 
vesicles. Recycling of receptors back to the plasma membrane can occur 
throughout the endocytic pathway, with decreasing efficiency. (Modified from [106]).  
 
1.3.4.2 Regulation of receptor endocytosis mediated by 
phosphorylation and ubiquitylation: 
 
Phosphorylation and ubiquitylation are dynamic post-translational 
modifications, which may be reversed by phosphatases and de-ubiquitylating 
enzymes respectively [107]. Ubiquitin is a 76-amino-acid polypeptide that is 
conjugated post-translationally to a wide variety of substrates. Substrate 
ubiquitylation is mediated by a series of enzymatic reactions [108]. 
Treatment with EGF results in the recruitment of Cbl, a ubiquitin ligase, to 
phosphotyrosine 1045 of EGFR [109]. c-Cbl can also bind to EGFR indirectly 
through the adaptor protein Grb2 [110]. Subsequently, Cbl is itself subject to 
tyrosine phosphorylation by EGFR at residue 371, which stimulates the 
ubiquitin ligase activity [109]. Receptor ubiquitylation then regulates its 
endocytic degradation. Recognition of ubiquitylated cargo by Hgs/Vps27p, 
Tsg101/Vps23p and other components of ESCRT complexes [111] enables 
MVB sorting and subsequent degradation of EGFR when Cbl binds to CIN85 
adaptor, coupling Cbl to endophilins [112]. It has been suggested that 
ubiquitinated cargo is handed from ESCRT-0 to consequently ESCRT-1,2 
and 3 complexes to form concentric rings around HRS complexes, and result 
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in inward membrane invigination and finally degradation in the lysosome 
[113] 
 
1.3.4.3 Receptor recycling: 
 
As illustrated in Figure 1-6, most of the receptor recycling occurs after entry 
to the early endosomes. Nonetheless, it can also occur after entry to the 
MVB, considering that EGFR remains in the outer MVB membrane and are 
not sorted to internal vesicles [114, 115]. Receptor recycling does not require 
tyrosine kinase activity [115]. Binding of EGFR with PKC also enhances 
recycling. 
 
1.3.5 Use of FLIM/FRET to identify EGFR regulators 
 
1.3.5.1 Principles of FLIM/FRET 
 
Förster (or fluorescence) resonance energy transfer (FRET) is a non-
radiative, dipole-dipole coupling process in which the energy from a donor 
fluorophore molecule is transferred to an acceptor fluorophore that is 
positioned in close proximity (< 10 nm). The initial step of a FRET process 
consists of the absorption of the photon energy from the donor molecule, 
which goes through excitation from the ground state to a higher electronic 
state. Once it reaches thermal equilibrium, the energy is transferred from the 
excited donor to the acceptor, generating an excited acceptor. The latter 
releases the energy by emitting a photon before returning to ground state. 
52 
 
The average length of time spent in the higher electronic state is termed as 
fluorescence lifetime (tau or τ) [116-119]. 
 
FRET efficiency is inversely proportional to the sixth power of the molecular 
distance between donor and acceptor and the fluorescence life-time of the 




Where R0 is the Förster radius (at which 50% of the excitation energy is 
transferred to the acceptor); r is the separation between the fluorophores; τfret 
is the lifetime of the interacting fraction and τd is the lifetime of the donor in 
the absence of acceptor. FRET can only be observed when the two 
fluorophores are within nanometre range, indicating interaction between the 
molecules [120]. 
 
A few methods have been established to detect FRET, for example acceptor 
photobleaching, fluorescence polarization imaging and fluorescence lifetime 
imaging microscopy (FLIM). 
 
FLIM is an imaging technique that provides a high resolution and sensitive 
readout of the donor fluorescence signals and produces an image based on 
the differences in the exponential decay rate of the fluorescence from a 
fluorescent sample. The fluorescence lifetime can be measured by frequency 
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domain or by time domain-based methods. A more thorough explanation is 
provided by Peter and Ameer-Beg 2004 [120]. 
 




A genome-scale library of siRNA reagents was used to identify EGFR 
regulators.  A high-content SP-FLIM screen using the Picchu-X sensor 
(Cheung et al, publication under submission) was used to detect changes in 
EGFR activity between the control siRNA and the protein siRNA, by 
comparing the lifetime difference and homogeneity of linear regression 
slopes before and after the EGF treatment, enabling the detection of 
candidates for the involvement in EGFR signalling. 
 
This assay led to the identification of 22 potential targets, including EGFR  
(Cheung et al, publication under submission). For this particular project, 
PTPN11 was selected for further validation, as described in chapter 6, to 
establish its biological importance in basal-like breast cancer in relation to 







1.4 Protein Tyrosine Phosphatases 
 
1.4.1 Description of protein tyrosine phosphatases (PTPs) 
 
PTPs regulate equilibrium of tyrosine phosphorylation [121]. They are 
important antagonists of tyrosine kinase-dependent signaling, regulating cell 
proliferation, migration and transformation [122]. The PTP family comprises 
around 100 genes in humans [123] which are subdivided into pTyr-specific 
enzymes, dual specificity phosphatases (DUSPs), the low molecular weight 
PTPs [124] and the rhodanese-derived PTP cdc25 [125]. 
 
The first crystal structure of a protein phosphatase that was isolated is the 
37kDa PTP1B [126]. PTP1B is a cytoplasmic PTP, whose C-terminal 
segment is involved in subcellular targeting and in the direct regulation of 
PTP1B activity [126]. In addition to the PTPs‟ role in RTK dephosphorylation, 
PTPs also regulate cell adhesion. For example DEP-1, another PTP, can 
associate with and have the ability to dephosphorylate the cadherin-catenin 
complex at epithelial junctions, and therefore promotes the cadherin- 
mediated adhesion [127]. 
 
Evidence has shown that PTPs can either behave as an oncogene or as a  
tumour-suppressor gene [128]. In the case of DEP-1, numerous studies 
show its involvement as a tumour suppressor. Balavenkatraman et al 
mentions in his review that DEP-1 re-expression in cultured breast cancer 
cells leads to up to 10 fold reduction in cell growth. Those findings were also 




PTPN12 is another example of PTP with a role of a tumour suppressor. A 
review mentioned its role in TNBC in which the restoration of PTPN12 leads 
to an inhibition in cell proliferation and tumorigenicity in-vivo. It was also 
found that the ectopic expression of PTPN12 led to a decrease in the colony 
formation by TNBC cells [121]. Additionally, another study indicated that the 
low expression level for PTPN12 was strongly associated with worse 
prognosis, increased tumour size and other malignant features [129]. 
 
1.4.2 PTPN11, a versatile phosphatase 
 
Src homology 2 domain-containing phosphatase (SHP-2, encoded by the 
protein tyrosine phosphatase, nonreceptor type 11 [PTPN11], or SHP2, 
gene) is composed of two SH2 domains (N-SH2, C-SH2), a PTP domain, a 
C-terminal tail with tyrosyl phosphorylation sites (Y542 and Y580) and a 
proline-rich motif. PTPN11 is a widely found cytoplasmic tyrosine 
phosphatase (PTP) which regulates tyrosine phosphorylation and is 
expressed ubiquitously [130]. Many studies have exposed the importance of 
SHP2 in the full activation of the Ras/Erk pathway when initiated by receptor 
tyrosine kinases (RTKs) and cytokine receptors [131]. 
 
1.4.3 Mechanism by which PTPN11 gets activated 
 
In unstimulated cells, Shp2 is kept inactive through an interaction of the N-
terminal SH2 domain with the phosphatase domain, blocking access to the 
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catalytic site [130]. Upon stimulation of cells, interaction of the SH2 domains 
with specific phosphotyrosine binding sites on activating proteins induces a 
conformational change in the N-SH2 domain that releases this autoinhibitory 
interaction and allows substrate access to the catalytic site (Figure 1-7)  
[132]. Overexpression of PTPN11 binding proteins and PTPN11 mutations 
disrupt this normal auto-inhibitory mechanism causing several human 
diseases, including cancer [133]. 
 
Figure 1-7. Regulation of SHP2 activity by its SH2 domains. 
In its basal state, WT SHP2 is auto-inhibited by the binding of its N-SH2 domain to 
the PTP domain. Addition of an appropriate SH2 domain ligand leads to exposure of 
the PTP domain and SHP2 activation  
 
1.4.4 PTPN11 role in cancer 
 
Some of PTPN11 regulated signalling pathways have been uncovered. 
Figure 1-8 illustrates 4 important mechanisms that PTPN11 regulates in a 
cell. The major signalling pathway that PTPN11 regulates is the Ras/Erk 
MAP kinase cascade, in which PTPN11 dephosphorylates RasGAP binding 
sites on specific receptors and adaptor proteins or alternatively, 
dephosphorylates Sprouty, which is a negative regulator for Ras/ERK. In 
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addition to this, PTPN11 has the ability to directly dephosphorylate Src, or 
via the regulation of Csk, hence enhancing Erk activation. 
 
Figure 1-8. Shp2-regulated signalling pathways. 
The major signaling pathway activated by Shp2 downstream of receptor tyrosine 
kinases (RTKs) and growth factors (GF) is the Ras/ERK MAP kinase cascade. Shp2 
has also been described to regulate PI3K, in the regulation of Jak/Stat signaling 
pathways and in the activation of NF-κB. Activation is indicated by arrows, inhibition 
by black lines, activating and inhibitory relationships by black squares, direct 
interactions by solid lines, and indirect interactions by dashed lines. 
 
PTPN11 mutants can cause cancer. Indeed, somatic PTPN11 mutations are 
found in ∼35% of patients with sporadic JMML [134], „a clonal pediatric 
myeloproliferative disorder (MPD) characterized by massive expansion and 
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tissue infiltration of myeloid cells, and a macrocytic anaemia with persistent 
fetal hemoglobinemia‟ [135]. These PTPN11 mutants are gain-of-function 
mutants and the concept to which those Shp2 mutants cause MPD is 
beginning to emerge. It has been found that the SH2 domain requirement 
may reflect the need for leukemogenic Shp2 to bind to Gab2, a major Shp2 
binding protein (Gab1 (referred to in Figure 1-2), and Gab2 are two members 
of Gab family docking proteins in human), as the potent leukemogenic allele 
Shp2E76K cannot induce tumour formation in Gab2−/− BM cells [136].  Despite 
the rarity of PTPN11 mutations in most human malignancies, the latter is an 
important observation as Gab2 was found to be frequently amplified in 
human breast cancer. In a PTPN11-dependent manner, GAB2 over-
expression increases the proliferative potential of human MCF10A cells 
[137]. Another observation is that GAB2 cooperation with HER2/Neu over-
expression was needed to evoke an invasive-like phenotype in these cells. 
Consistent with these findings, GAB2 over-expression specifically enhances 
ERK activation while PTPN11 shRNA blocks the biological and biochemical 
effects of GAB2 over-expression ex vivo, clearly demonstrating the 
importance of the interaction between PTPN11 and Gab2 [138]. 
 
Despite some clear evidence of increase in tumour progression due to 
PTPN11‟s overexpression in human cancers such as leukemogenesis [134, 
136] , gastric cancers [139] and  breast cancer[140],  another study has 
highlighted PTPN11 potential role as a tumour suppressor in 
hepatocarcinogenesis [141]. This study showed the development of 
spontaneous macroscopic adenomas in PTPN11hep-/- mutants in one year old 
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(and over) mice. However, early in life (less than a year old), this mutant 
would generate regenerative foci and nodular regenerative hyperplasia [142]. 
The mechanism behind this tumour suppressor role that PTPN11 seems to 
display has not yet been elucidated. 
 
1.4.5 PTPN11 interaction with EGFR 
 
PTPN11 is involved in the EGFR signalling pathway promoting Ras 
activation by blocking the Ras GTPase-activating protein (RasGAP)-induced 
downregulation of Ras, via dephosphorylation of a docking site Tyr992 on 
the EGFR [143]. Another study has shown that high concentration of EGF 
downregulates PTPN11 protein expression level [144]. An interesting study 
has shown an increase in phosphorylated EGFR when PTPN11 is 
knockdown in colon cancer cells [101], denoting some type of interaction 
between EGFR and PTPN11. This same increase is not seen when another 
member from the phosphatase family is being knockdown (SHP-1), which 
emphasises on the importance of PTPN11‟s interaction with EGFR.  Finally, 
a study, undertaken by Mann et al, uses the SILAC method to provide 
evidence of EGFR interaction with PTPN11. This study uses the SH2 domain 
of the adapter protein Grb2 (GST-SH2 fusion protein), that specifically binds 
phosphorylated EGFR and Src homologous and collagen (Shc) protein to 
detect proteins that are bound to Grb2 (and are therefore indirect EGFR 
interactors) after EGF stimulation. The binding of Grb2 to Shc occurs only 
after the latter has already been recruited to and phosphorylated by the 
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activated EGFR which makes this strategy specifically enrich proteins 
involved in EGF signalling [145]. 
 
1.5 Failure of drug trials and the need for in-vivo imaging 
 
The BALI-I trial involved the administration of cetuximab (an EGFR 
monoclonal antibody) with cisplatin in patients with metastatic TNBC. Despite 
the overall response rate being better (a two-fold increase) than the one 
observed when patients were given cisplatin only, this trial failed to reach its 
primary endpoint, which consisted of a significant increase in overall 
response [18, 146]. 
A recent phase III trial, undertaken by Roche, investigated the effect of 
onartuzumab‟s addition to Tarceva (erlotinib) as a second- or third-line 
therapy for patients with non-small cell lung cancer (NSCLC) [147]. 
Unfortunately, despite promising results from Phase II, no clinical benefit was 
demonstrated in Phase III. The onartuzumab/erlotinib combination could not 
show an overall survival benefit [148]. However, following the publication of 
these results, it was found that the design of this trial was somehow faulty, as 
the researchers enrolled many patients without elevated c-Met level in this 
trial. It was actually observed that the c-Met-positive patients who received 
both drugs had an increased overall survival time of 12.6 months in 
comparison to 3.8 months for c-Met-positive patients who received erlotinib 
only [149]. 
This particular scenario demonstrates the importance of stratification prior to 
the choice of therapy in patients. Many clinical trials face failures due to a 
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poor recruitment and due to the inability to monitor the expression level of a 
particular target during treatments in those patients. Repeat biopsy would be 
useful to determine the molecular signature at progression of the patient but 
is not feasible as this procedure is invasive. However, the use of in-vivo non-
invasive molecular targeted imaging, in clinical trials would provide a feasible 
way to monitor the efficacy of a drug. 
 




Mammogram is the first line imaging investigation, in the UK, for almost all 
abnormalities in patients aged 40 or above when investigating possible 
breast cancer lesions. However, the breast tissue tends to be denser below 
the age of 35 and reduces the sensitivity of mammography. Hence, an 
ultrasound is used as a primary imaging method for women of this age 
group. The radiologist assesses the mammogram and gives a grade to 
indicate the likelihood of the malignancy, which ranges from M1 (normal) to 
M5 (malignant) [150]. Mammography is also used for surveillance, after 
surgical treatment of primary breast cancer. Recurrence can occur up to 20 
years after surgery. The computer-aided detection (CAD) has been designed 
and uses computer algorithms to analyse digital mammograms in order to 
bring any suspected abnormalities to the radiologist. The UK-bases CADET 
II trial shows that double-reading screening mammograms give a similar 
cancer detection rate than a single reading from CAD. 
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Digital breast tomosynthesis (DBT) has been developed to allow radiologists 
to further assess the mammographic morphology of different pathologies, as 
a 2D mammography masks pathology due to the overlaying with the normal 
glandular tissue [151]. The principle behind DBT is to acquire multiple 
images at different angles to the compressed breast and stack them so this 




As mentioned previously, an ultrasound is used to detect abnormalities in 
women with dense breast. However, it is not recommended for every patient 
as a thorough screening ultrasound examination of both breasts is very time 
consuming. Additionally, an ultrasound is more likely to yield false positive 
than a mammography. Nevertheless, the ultrasound is the optimal modality 
to assess abnormalities in patients with implants in augmented or 
reconstructed breasts, as the ultrasound can distinguish breast lesions from 
implant complications [150, 152, 153]. 
 
1.6.3 Magnetic Resonance Imaging (MRI) 
 
Breast MRI has the highest sensitivity for cancer but is expensive and has a 
low availability. It also has a high false positive rate but its high sensitivity for 
invasive cancer detection and its ability to provide detailed high resolution 
soft tissue in multiple planes makes the MRI a very useful tool in clinical 
imaging. Currently, women with lobular breast cancer might get a MRI scan 
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to help doctors decide whether breast conserving surgery (BCS) is an option. 
Women with breast tissue that is too dense to get accurate information from 
a mammogram might be eligible for a MRI scan. 
For a breast surgical intervention, radiologists may aid surgeons to localize 
impalpable lesions by performing an ultrasound with a guide-wire inserted 
through an introducer needle under local anaesthetic [150, 154-157].  
 
1.6.4 Computed Tomography (CT) 
 
Computed tomography (CT) is a diagnostic and anatomical imaging modality 
that is essentially a 3D version of an X-ray. In a CT, the X-ray tube and 
detectors rotate around the patient. The CT scanner would then record the x-
ray absorption by the patient‟s body per each direction of the x-ray beam. 
The image is then reconstructed from a large number of measurements of 
attenuation coefficient. The main role of CT in breast cancer would be a 
whole body staging investigation. Lately, breast CT scanners have been 
developed to yield images of the breast for a similar dose to standard 
mammography [150, 158, 159]. 
 
1.6.5 Positron emission tomography (PET) 
 
Recent years have shown the power Positron emission tomography (PET) 
has as a metabolic imaging technique and retains the fastest growing 
diagnostic speciality. PET is highly sensitive and only requires 10−11 – 10−12 
mol/L levels of probe for detection [160]. PET is a gamma imaging technique 
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that gives in-vivo measurements in absolute unit of the radiotracer [158, 
159]. PET uses radiolabelled biological agent that emit positrons (and are 
produced mainly by cyclotrons), the anti-matter counterpart for electrons. 
After emission, the positron loses its kinetic energy through numerous 
collisions with electrons present in the neighbouring tissues. After almost 
losing all its kinetic energy, the positron interact with an electron, producing a 
positronium which is then annihilated, causing the emission of two photons of 
511 keV each in opposite direction (this is to conserve momentum). Those 
annihilated photons are detected by the detectors surrounding the subject, 
and precisely locate the source of the annihilation event (Figure 1.9). The 
detectors electrics are linked and the „coincidence events‟ will be stored in 
arrays that correspond to projections that will be reconstructed using 
standard tomographic techniques [161]. PET has evolved considerably in the 
clinics. From its initial applications in neurology and cardiology, it has now 
evolved into having a primordial role in assessing oncology patient. 90% of 
clinical studies performed in clinical PET centres represent oncology PET 
studies [159, 162]. The unique versatility of PET is that it has the ability to 
assess a number of physiologic and biochemical processes in-vivo. Indeed, it 
is possible to measure tissue blood flow, oxygen metabolism, glucose 






Figure 1-9. The physical principles underlying PET imaging. 
A biologically active molecule labelled with a positron emitting radionuclide is 
administered into the subject. Once injected, the radioisotope emits a positron, 
which upon traveling a certain distance in the neighbouring tissue, annihilates with a 
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nearby electron, emitting two antiparallel 511 keV gamma-ray photons. Pairs of 
annihilation photons are detected in co-incidence by a multi-ring PET camera, and 
reconstructed into a whole-body image to map the distribution and concentration of 
the radiotracer.  
 
As PET has high sensitivity, it revolutionises the way patient‟s treatment is 
managed. Studies show that PET guide decisions on surgical resection for 
metastatic colorectal cancer, the staging and treatment of lymphoma, the 
surgical treatment for non-small cell lung cancer etc. In addition, PET 
scanners are becoming a greater deal more sensitive than they used to be, 
enabling faster patient throughput. In addition to this, due to the progress 
made in instrumentation, it is now possible to combine anatomy and 
molecular events into a single image through fused imaging modalities 
through the use of PET/CT, PET/MRI and SPECT/CT. 
 
1.7 Imaging probes used in the clinic 
1.7.1 FDG-PET 
 
In clinical practise, it is standard to use 18F-fluoro-deoxyglucose ([18F]-
FDG). Once injected into the patient, this radiolabelled glucose analogue 
would be taken up avidly by tissues with increased metabolic activity, such 
as cancer cells, as they consume more glucose than the surrounding , less 
„active‟ tissues [163]. However, 18F-FDG PET on its own lacks the superior 
anatomic clarity that is provided by the CT, therefore both are used. 
Currently, 18F-FDG PET is not used in breast cancer screening [164]. It has 
been introduced for diagnostic purposes as a complementary aid to 
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mammography and breast ultrasound [165]. 18F-FDG PET can be used in 
patients with inoperable breast cancer, as it is most useful when the results 
of conventional imaging methods are unclear. It also has a role in 
progressive disease and in early breast cancer, when standard imaging 
results are inconclusive. Unfortunately, there is limited evidence for the use 
of 18F-FDG PET in assessing recurrent or metastatic disease [163]. Studies 
have shown that the identification of recurrent BC from inflammatory or 
infectious processes, and the identification of small lesions (tumor size <10 
mm) still impose challenges for FDG-PET [166-168]. Another limitation of 
FDG-PET is its lack of uptake in metabolically inactive malignant tissues 
[169]. 
In order to overcome the limitations presented by FDG-PET, imaging 
scientists have lately been focusing on the design of target molecules which 
can specifically localise to cell-surface markers, and include growth factor 
receptors, differentiation and activation markers and adhesion molecules 
[169]. 
 
1.8 Other imaging probes currently investigated in pre-




Others, such as FLT hold a great potential role in molecular imaging. While 
FDG accumulates in chemotherapy-induced inflammatory tissues, hence 
causing misinterpreted results, 18F-FLT has been used to demonstrate 
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proliferative activity in numerous tumours and is not susceptible to uptake 
due to inflammatory changes [170]. 18F-FLT‟s specificity for cell proliferation 
is in its relationship to thymidine kinase 1, which sequesters FLT for 
phosphorylation [171]. A recent meta-analysis show 18F-FLT PET/CT 
sensitivity to assess chemotherapy ranging from 56.3% to 92.2% [171]. Its 
pooled sensitivity (77.3%) is lower than the 18F-FDG PET (84%), while its 
specificity (68.5%) is slightly higher than the 18F-FDG‟s (66%). The relative 
lack of specificity is due to the increased FDG uptake in inflammatory cells 
[172]. 
Even though PET-CT scans are widely used in the imaging of many types of 
cancer, its role as imaging modality in breast cancer is still progressing. Up 
to now, PET-CT is not used for the assessment of stage I breast cancer due 
to its low sensitivity in detecting small (<1cm) and low grade breast lesions. 
PET-CT also has a role in the staging, and in patients with known breast 
cancer recurrence [173]. Despite the fact that MRI avoids the use of ionising 
radiation, and offers excellent soft tissue discrimination, it lacks the functional 
information that PET can yield, making PET particularly useful in the 
assessment of the response to therapy in-vivo. 
 
1.9 Other imaging modalities currently investigated in pre-







The single Photon Emission Computed tomography (SPECT) imaging uses 
nuclides such as 99mTc, 123I, 111In which decay while emitting single y-ray 
photons of different energies. Those standard radionuclides emit gamma-ray 
photons with energies that are much lower than 511 keV (found in PET). 
99mTC, for example, only emits 140 keV photons. Those photons that exit the 
subject‟s body will pass through a collimator and will be detected by a 
position-sensitive detector (typically a scintillation camera). A typical SPECT 
system will consist of one or more scintillation cameras with the acquisition of 
multiple two-dimensional planar projection images around the patient. Those 
projection data are then reconstructed into 3D images [174]. A SPECT 
imaging system can have from one to four scintillation cameras. The higher 
the number of cameras, the higher the detection efficiency or improved 
spatial resolution of the SPECT system would be. Despite the fact that PET 
is more sensitive than SPECT, SPECT radionuclide has the advantage of 
emitting photons with different energies, enabling the use of several 
biomarkers at once when performing the imaging. In addition, SPECT display 
a much lower cost of radioisotopes and gamma-scanning instruments than 
PET [169]. 
1.9.2 Optical Imaging 
 
1.9.2.1 Optical molecular imaging 
 
Optical imaging is also one of the non-invasive methods used in the pre-
clinical studies, due to being cost-effective in comparison to nuclear medicine 
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approaches. An antibody or antibody fragment can be detected using 
bioluminescence (luciferase - with a sensitivity of 10−15 to 10−17 mol/L), 
quantum dots or fluorescence (near infrared dyes, with a sensitivity of 10−9 to 
10−12 mol/L) for optical imaging [175]. Despite the high sensitivity of those 
probes, its major disadvantage is the poor tissue penetration (which is 
usually less than 1 cm), as the visible light scatters and gets absorbed [169]. 
The reaction that takes place in bioluminescence consists of enzymes, 
luciferases, catalysing a light-producing reaction. This light is produced after 
injection of luciferin, which is a substrate for the enzyme [169, 176]. Table 2 
displays the advantages and disadvantages between PET, SPECT and 
optical imaging modalities. 
1.9.2.2 Intraoperative imaging-guided cancer surgery 
 
Much effort is devoted to improve the use of optical imaging in intraoperative 
cancer surgery [177]. Currently, the pathology report is the standard for the 
direct result of a surgical resection [178], which takes about 4-7 days to 
obtain. This is not ideal as a surgical intervention could be greatly improved if 
only the surgeon could get direct feedback at the time of surgery. Indeed, a 
complete surgical resection of breast cancer is a powerful determinant of 
patient outcome. 
The use of NIR (Near-Infra-Red) fluorescence is currently being assessed in 
intraoperative image-guided surgery [178]. NIR light cannot be seen directly 
with the naked eye and therefore many imaging systems for intraoperative 
NIR FMI are being developed [179] [180]. Several preclinical studies have 
demonstrated the beneficial use of therapeutic antibodies conjugated with a 
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NIR fluorescent dye, such as the intravenous injection of the antibody-
IRDye800 bioconjugates in nude mice bearing human breast cancer to act 
as optical contrast agents for the detection of the borders of malignant tissue 
intraoperatively [181]. This preclinical study has shown that the 
bioconjugates were specific for the tumor cells and that it was possible to 
accurately differentiate malignant areas from normal tissue in vivo. This led 
to a clinical study in which its feasibility in patients with breast cancer is being 
assessed (NCT01508572).  
Additionally, photoacoustic imaging is currently of interest in the diagnosis, 
treatment, assessment and follow up of breast cancer [182]. In photoacoustic 
imaging, non-ionizing laser pulses (such as a short near-infrared (NIR) light 
pulse) are absorbed by a small molecular target from the tissues. This is then 
converted to heat leading to transient thermoelastic expansion, decaying 
broadband acoustic pressure waves. The latter are detected by ultrasonic 
transducers which are analysed to produce images [182]. Initial findings 
show that photoacoustic tomography provides molecular imaging at high 







Table 1-2. Summary of common pre-clinical imaging modalities 
 
 
1.10  Key gaps in imaging modalities 
 
To improve patient‟s survival, understanding the molecules and pathways 
that drive cell proliferation in breast cancer and those that allow the tumour 
cells to become resistant to treatment is necessary. Hence, developing better 
ways of using imaging for breast cancer diagnosis and for response to 
treatment would have a major beneficial impact on the survival rate and 
quality of life of the patient. In order to detect changes in tissue that correlate 
with the onset of the disease or its progression, it is necessary to 
characterise a suitable molecular imaging agent-target interaction. An 
imaging probe can interact with target biomarkers to define, temporally, the 
quantitative expression level and spatial localisation of specific targets for a 
therapeutic drug [184]. Hence selection of a specific and most sensitive 
imaging probe facilitates personalised patient‟s treatment. Numerous studies 
are now devoted to identify a molecular agent that targets specific proteins 
that are for example, overexpressed in a particular cancer [185] . PET 
radiopharmaceutical will be selected depending on the application of the 
study. The diagnosis, grading of malignancy, the staging or residual disease 
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and the detection of recurrence are criteria that will be considered for the 
choice of the PET radioisotope to be used. Other criteria such as the 
assessment of the response to therapy, the identification of the site of the 
disease or the detection of the primary tumour when the metastases are 
present will also need to be taken into account [186]. 
 
1.11  Antibody and antibody-fragments in nuclear imaging: 
Various targeting molecules of varying size and composition, such as 
antibodies, small-molecule ligands, peptides, affibodies, aptamers, single 
chain Fv, F(ab')2, F(ab'), diabodies and minibodies (Fig 1-10) can be used 
for whole-body imaging [169, 187]. The progression of recombinant DNA 
techniques led to the design of antibody fragments, which show faster 




Figure 1-10. Schematic presentation of an intact antibody and 
engineered antibody. 
This consists of scFv (25 kDa), diabody (50 kDa), minibody (80 kDa), scFv-Fc (105 
kDa) and intact antibodies (150 kDa). Larger fragment antibodies correlate with slow 
pharmacokinetics and blood clearance. 
 
1.11.1 Full length antibody 
Intact antibodies have a high specific targeting ability. The antibody that is 
mostly found in our serum is IgG, has a Y-shape linker and has two antigen-
binding sites present on the two Fab tips (Fig 1-10). The IgG‟s Fc domain 
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mediates the recruitment of effector functions.  IgG is mainly used in 
therapeutics [187]. IgG antibodies demonstrate a strong affinity to its target 
due to their bivalency. Indeed, IgG has the ability to bind to two antigens as 
well as having a high avidity to numerous cell surface receptors, for example 
[189]. The affinity differs from the avidity as the affinity measures the strength 
of interaction between an epitope and an antibody‟s antigen binding site. On 
the other hand, the avidity of an antibody gives a measure of the overall 
strength of an antibody-antigen complex. 
Despite monoclonal antibodies‟ highly specific targeting ability, they tend to 
circulate in blood for a very long time, sometimes for days. The interaction 
between the Fc domain of the IgG and the yF receptors, leads to an 
interaction with the neonatal Fc receptor (FcRn). FcRn will then transport the 
IgG in intact form across cells preventing them from degradation [190]. This 
can make them unsuitable imaging probes in patients. A study has shown 
the inverse correlation of the size of the protein, which was used as an 
antibody-based imaging agent, and its blood rate clearance in the subject. It 
shows that the clearance rate of Fab‟ is greater than F(ab‟)2 which itself is 
greater than IgG [191]. 
For an optimal tumour targeting, biodistribution and rapid clearance, it is 
possible to design antibody fragments of intermediate size that will prove to 




1.11.2 Antibody Fragments 
1.11.2.1 ScFvs: 
 
The single chain Fv fragment (Fig 4 & 5) is the smallest functional antigen-
binding domain of an antibody (~30 kDa), in which the variable heavy (VH) 
and variable light (VL) domains are joined together by a flexible peptide 
linker which is 12 to 25 residues long. The orientation of the V-domain can 
affect the expression, the stability and the antigen binding activity [193]. The 
scFv displays the same binding specificity of the parent antibody and offers 
several improved pharmacokinetic properties, such as better tissue 
penetration and rapid blood clearance [194]. However, due to their 
monovalency, it has a modest retention time in the target tissue causing the 
image to be of an inferior quality. In addition, its short size also leads to a 
short in-vivo half-life decreasing the exposure of the target molecule to the 
scFv. Hence, scFvs have been engineered to produce multivalent and 
multifunctional multimers (diabodies, triabodies and tetrabodies) which 
possess higher avidity and demonstrate a lower blood clearance, without 
affecting tissue penetration abilities [195]. Despite the faster clearance of 
scFvs making them difficult to be used for therapeutic applications, it is a 
much wanted property when it comes to in-vivo diagnostic applications [194]. 
The future of scFv also lies in providing binding specificities to targets that 






On the other hand, bivalent fragments such as scFv-fusion proteins and scFv 
dimers make great candidates as imaging probes, as their larger size make 
them circulate longer in the blood, without ill effects to the patients, and 
therefore enable a higher tumour accumulation, and signal-to-noise 
background [169]. The diabodies (Fig 1-10), also called scFv dimers, form 
stable non-covalent dimers as the linker has been shortened to less than 10 
residues between the variable domains enabling the scFv to open up and to 
cross-pair with another scFv molecule [196]. They show slightly longer blood 
clearance than scFv molecules and demonstrate a higher tumor uptake than 
the scFv monomer, due to their larger size (55 kDa). Studies show that scFv 
dimers display a better target uptake than monomers. ScFv dimers are 
bigger in size and therefore have a longer biological half-life and due to their 
bivalency, display a higher avidity [192]. 
Numerous studies have shown the successful use of radiolabelled diabodies. 
Cai et al have coupled 18F to a diabody fragment, that targets HER-2, called 
[18F]FB-anti-HER2 Cys-Db, and injected it into HER2-expressing tumor 
xenografts in mice [197]. Using this radiolabelled diabody, Cai et al were able 
to show high contrast images at 2, 4 and 6 hours post injection as well as 
fast tumour localisation. The biodistribution data also shows that the probe 
preferentially binds to the tumours that overexpress HER2, rather than the 
HER-2 negative C6 control tumours, with a difference in the ratio uptake of 
2.9 [197]. 
Another example is a diabody derived from the full length antibody J591, 
which is targeted against an extracellular epitope of Prostate-specific 
membrane antigen (PMSA) [198]. PMSA is an established marker for 
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prostate cancer. Fung et al shows that when mAb J591 is radiolabelled either 
with 89-Zr or 124-I, the average tumour to blood ratio reaches a peak of 7.7 
and 8.5 respectively [199] at 96 hours after injection. On the other hand, 
Kampmeier et al shows in their study that their diabody J591Cdia, chelated 
to 99-Tech, otherwise called [99mTc(CO)3]+-labelled J591Cdia, shows 
specific accumulation in PSMA positive tumours from 4h post injection 
onwards. The highest uptake of the radiolabelled diabody was observed at 
8h post injection, with an uptake of 12.1%±1.7%ID/g, a tumour to blood ratio 
of 8.0 and a tumour to muscle ratio of 16.8 [198]. The pharmacokinetics of 
this diabody seems more favourable than its parental antibody for imaging 
purposes, without compromising the sensitivity and specificity of detection of 
the target. 
The reduction of scFv linker length (between zero to five residues) has been 
a successful design as it causes self-assembly into either bivalent dimers 
(diabodies, 55kDa), trivalent trimmers (triabodies, 80 kDa) or tetravalent 
tetrabodies (110 kDa).  It has been shown that diabodies of a zero-residue 
form are more stable in human serum at 37°C than ones with linkers five 
residues in length. 
A major disadvantage of radiolabelling smaller antibody fragment is the risk 
of reactive residues to be found in critical regions of the antibody. To 
circumvent such issue, it is possible to modify specific sites of the diabody for 






A minibody (Figure 1-10) is slightly larger than a diabody, with a molecular 
mass of 60 kDa, which exceeds the renal clearance threshold (<60 kDa). A 
minibody is a scFv that is joined with a IgG CH3 domain [169]. Minibodies 
with different specificities would display a tumour uptake that is dependent 
on the antigen-antibody system while their pharmacokinetics will be similar 
[201]. Iodinated anti-CEA (anti–carcinoembryonic antigen) minibody was 
produced to target colon cancer cells [192]. The anti-CEA scFv was fused to 
the human IgG1 Ch3 domain, using two peptide linkers, and enables 
stabilization of the dimerization. This anti-CEA minibody assembled into a 
chimeric protein with a molecular mass of 80 kDa. Two forms of the anti-CEA 
minibody were designed by Wu et al, a non-covalent LD (in which a simple 
two-amino acid residue linker was used) and a covalent Flex minibody (in 
which a human IgGl hinge region was used). In the Flex minibody, a human 
IgG1 hinge region was incorporated into the molecule forming disulphides 
bridges between the subunits and stabilised the dimer. The tumour targeting 
and biodistribution of these minibodies were assessed in athymic 
mice/LS174T xenografts. The results show they both display different rates 
for blood clearance. The LD minibody cleared a lot quicker from the blood 
circulation than the FLEX minibody but not to its advantage. The tumour to 
blood ratio for the FLEX minibody was 65 by 48h after injection, in 
comparison to 47 for the LD minibody, at a comparable timepoint [192]. It is 
thought that the difference in blood clearance between these two minibodies 
could be due to the difference in the separation of the scFv within each 
minibody, the scFv units in the LD minibody were joined to the two CH3 
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domains at 40 A apart while it was of 23 A in the FLEX minibody. In addition 
to this, the access of key residues in the CH3 domains might have been 
masked in the LD minibody explaining its quick blood clearance and 
consequentially its lower tumour targeting ability in comparison to the FLEX 
minibody [192]. 
1.11.2.4 Single chain Fv-Fc: 
 
In order to minimize slow blood clearance of the antibody, deletions of 
domains to reduce its size are performed. Kenanova et al have mutated the 
Fc-FcRn binding site of chimeric anti–carcinoembryonic antigen (CEA) 
antibodies, producing five mutants in a single-chain Fv-Fc format.   A wild 
type was also designed in the single chain Fv-Fc format (Fig 5),  where the 
anti-CEA scFv (VL-linker-VH) fragment was joined to the intact Fc region 
(CH2 and CH3 domains) of human IgG1 via a hinge region [202]. The 
presence of an intact Fc domain enables interactions with the neonatal Fc 
receptor (FCRn), which prevent IgGs from degrading as much as other 
serum proteins, by diverting them from the lysosomal degradation pathway 
[203]. 
This study shows that the mutants CEA scFv-Fc, for which the Fc-FcRn 
binding site were mutated, display a faster serum clearance than that of wild 
type. The double mutant had a 50-fold less remaining blood activity at 72 
hours after injection in comparison to the wild-type (P < 0.0001) [202]. It is 
also interesting to see that at 48 hours after injection, the tumour-to-
background ratio is 0.6:1 for the wild-type scFv-Fc, while the ratio for the 
double mutant scFv-Fc is of 11.7:1 at its last timepoint (52h post injection). 
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Hence, the double mutant scFv-Fc produced clear and high-contrast images 
at earlier timepoints than the wild type scFv-Fc. This study clearly 
demonstrates that a scFv-Fc is an excellent substitute for intact antibodies as 
the tumour targeting ability of the scFv-Fc is comparable to the parental 
intact antibody, with the advantage of a much faster blood clearance rate, 
with the introduction of specific mutations [202]. 
In order to optimize for the efficiency of mAbs and their fragments in cancer 
therapy, it is crucial that those agents are able to identify tumour-associated 
antigens at low levels. It has been a  bigger challenge so far to use antibody 
therapy in solid tumour than in circulating cancer cells due to the low 
accessibility of the imaging agent to the solid tumours [189]. 
 
1.12  Non-Antibody derivatives: a brief outlook 
Other molecular agents that could be used for diagnosis and possibly 
therapeutic purposes in nuclear medicine are the non-antibody based 
engineered proteins [204]. They consist of affibodies, knottin, fibronectin 
domain, Designed Ankyrin Repeat Proteins (DARPs) and natural ligands 




An affibody molecule is a small non-immunoglobulin single domain protein 
(6.5 kDa), and has three alpha-helical Z-domain scaffold (Fig 6) [205]. They 
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present major advantages over antibodies in the field of molecular imaging. 
Antibodies, especially the IgG, are large, multidomain protein and can 
display a complex glycosylation. Only a small part of the bulky antibody is 
used for antigen recognition. Due to the large size of antibodies, 
manufacturing is more expensive, difficult and they display poor heat stability 
[206].  Affibodies, otherwise called alternative scaffold proteins, are small, 
highly stable, lack cysteine residues and can be produced easily, which 
makes them a potential candidate for non-invasive imaging, provided they 
demonstrate high specificity and affinity to the target of interest. 
Recent studies show that affibodies are good candidates for HER-2 specific 
molecular imaging in comparison to antibodies, antibody fragments and 
DARPins (see section 1.12.2). Sorensen et al recently demonstrated that a 
Ga-68 labelled affibody against HER2, [68Ga]ABY-025, specifically 
discriminates HER2 positive metastases from HER2 negative lesions with a 
mean SUVmax uptake of 15.0±3.4 and 2.7±2.1 respectively at 4 hours post 
injection [207]. There was a significant correlation between the uptake of 
[68Ga]ABY-025 and the HER-2 scoring from the staining of the biopsies. 
Hence, PET [68Ga]ABY-025 led to a change in the HER2-targeted treatment 
in 3 out of 16 patients and allowed a PET acquisition to be made on the 
same day of the injection. 
In addition to this, another study proves the fast clearance rate and the 
consequential higher tumour to organ ratio when using radio-iodinated 
affibody of HER2. This HER2 affibody is only 6.5 kDa. The latter shows slow 
blood hepatobilliary clearance. However, it has also been shown that such 
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fast clearing fragments tend to have a low accumulation in tumours as they 




The designed ankyrin repeat proteins (DARPins) are recombinant binding 
proteins with ankyrin repeats (Fig 6). Those repeats stack together and form 
a contiguous binding surface. DARPins are made of 4-6 repeat units of 33 
amino acids, which form one β turn followed by 2 anti-parallel α-helices 
[204]. 
A recent study, conducted by Goldstein et al, shows a higher tumour-to-
blood ratio than any other reported HER2 radioligands [208-210] when 
HER2-positive tumour xenografts were injected intravenously with 111In-
(HE)3-G3 DARPin, a radiolabelled DARPin that targets HER2, within 24h of 
administration [211]. This small radioiodinated high affinity protein 
demonstrates its ability to image both trastuzumab-treated patients and non-
treated patients as the DARPin G3 and trastuzumab bind to different 
epitopes of the HER2 domain IV [211]. In addition, 111In-(HE)3-G3 display 
favourable kinetics for HER2 imaging with its short half-life in serum, high 
tumour-to-blood ratio , a low non-targeted tissue uptake and a lower normal 
liver uptake, advantageous here due to the liver being a common site in 




1.13  c-Met, a pre-clinical molecular imaging target of interest: 
Several studies have focused on the use of c-Met molecular targeted 
imaging for diagnostic or therapeutic purposes in cancer. c-Met molecular 
imaging offers the potential for quantification of c-Met expression in living 
tissue.  Liu et al used a Cy5-labelled (λmax ex = 648 nm) peptide against c-
Met, GE137, to detect submillimeter deposits of ovarian cancer in-vivo. 
GE137 is a 26 amino acid cyclic peptide (AH111972) and is water soluble. It 
has a high affinity (Kd = 2 nM) to human c-Met (a low nanomolar dissociation 
constant) and is selected from a phage display library. It does not activate 
downstream signalling pathway. This probe also gives a signal-to-noise ratio 
greater than 1.5 at a submillimetre resolution level. However, it is not 
possible to assume that this probe could not miss microscopic tumour 
deposits in this study [212]. The in-vitro assay also shows cytoplasmic 
accumulation of GE137 which enables a prolonged GE137 retention and 
consequently a high signal-to-noise uptake that lasted for 8 hours after 
injection. Another recent study, performed by Burggraaf et al, uses the same 
probe in colorectal cancer [213]. In their study, they present results following 
fluorescence-guided colonoscopy using the imaging agent GE-137 in 15 
patients with high risk of colorectal neoplasia. After the first pass inspection 
with white light, 101 lesions were detected, however, after a second round 
inspection using the GE137 with fluorescence, a further 22 lesions were 
detected, and 17 of them are only detectable with the fluorescence imaging. 
Staining of the biopsies of those lesions shows a clear correlation between 
histological classification of lesions and the level of fluorescence observed in 
them in-vivo (P = 0.00003). This study concludes that GE-137 is safe in 
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humans, and has the potential to increase the sensitivity of polyp detection 
during colonoscopy [213]. Part of my study will explore the use of this same 
peptide, GE-137, radiolabelled with fluorine-18 [16]. This agent was used to 
investigate the detection of early stage locoregional recurrence in basal-like 
breast cancer. 
In a different study, an anticalin that is specific to c-Met (a binding affinity of 
0.6 nmol/L), PRS-110, was labelled with Zr-89 [214] and injected into high 
MET-expressing H441 non–small cell lung cancer xenografts. PRS-110 acts 
both as an antagonist of HGF dependent Met signalling and acts as a ligand 
dependent inhibitor in c-Met tumour progression. In-vitro assays show that 
89Zr-PRS-110 is taken up by the c-Met positive cells, H441, despite the fact 
that this tracer is a non-MET-receptor-activating binder as it is monomeric. In 
this study, we find that 89Zr-PRS-110 uptake is significantly higher in the 
MET-expressing tumour models H441 and U87-MG in comparison to the 
MET-negative A2780 tumours [214]. 
Another interesting study is the use of recombinant human HGF (rh-HGF), 
labelled with 64Cu as a PET tracer, which detects c-Met expression in-vivo. 
PET imaging acquired 9h after the injection of this tracer shows a 
significantly higher uptake in the higher-Met-expressing tumours (U87MG) in 
comparison to the low-Met-expressing tumours (MDA-MB-231). 64Cu-NOTA-
rh-HGF uptake in the U87MG tumour was much faster than that shown with 
the use of 89Zr-PRS-110 [214], and displayed a significantly higher tumour-
to-muscle ratio (13.5  ±6.1 at 9 h after injection (n= 4) [215]. 
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1.14  Summary: 
 
BLBC accounts for 15% of all invasive breast cancers, and affects younger 
women with rapid relapse [2] and early recurrence patterns [31]. Studies 
have shown that locoregional recurrence was predictive of a higher risk of 
subsequent events and death in patients with TNBC [36]. Due to a lack of 
hormone receptors, .BLBC and TNBCs have limited therapeutic options [30]. 
 
 c-Met is overexpressed in a variety of carcinomas including breast cancer 
[4]. Numerous studies have demonstrated a preferential overexpression of c-
Met in the basal-like subgroup [46, 56]. Several studies suggest that c-Met 
deregulation plays a prominent role in the development of acquired 
resistance to targeted agents. Indeed, in breast cancer, studies have shown 
that 'constitutive phosphorylation of Met contributes to EGFR TKI resistance 
and that decreasing c-Met kinase activity decreases EGFR tyrosine 
phosphorylation and proliferation in the presence of EGFR TKI‟ (e.g. 
gefitinib) [76]. Due to c-Met overexpression in many cancers, a number of c-
Met inhibitors are being developed in preclinical and early clinical studies, 
and investigated as a monotherapy as well as in combination with other 
targeted agents or chemotherapy in breast cancer, colorectal cancer, Non- 
Small Cell Lung Cancer (NSCLC) and brain tumours [78]. 
Current imaging modalities used in clinical practise in breast cancer include 
Mammography [150] , Ultrasound [152], Magnetic Resonance Imaging (MRI) 
[154], Computed Tomography (CT) [158] and Positron emission tomography 
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(PET) [162]. FDG-PET is currently being used in the clinic for the detection 
and staging of many cancers [216]. However, due to its inability to detect 
small lesions (<10mm) [166-168] and its incapacity to provide a direct 
readout for the expression level of a specific protein, it seems necessary to 
develop molecular targeted imaging probe with high specificity to the protein 
target of interest.  
Molecular imaging with anti-c-Met probe allows for the non-invasive and 
whole-body assessment of c-Met tumour burden. It will also allow for better 
stratification for patient selection for anti-c-Met therapy, as well as optimising 
dose and schedule for anti-c-Met treatment. It will supply a complementary 
option to obtain real-time information to assess the immediate response to 
therapeutic interventions. The collection of biopsies is not always feasible 
due to the lack of detection of recurrent or metastatic lesions and is an 
invasive procedure. An imaging probe against c-Met would circumvent this 









Chapter 2: Aims 
 
In this thesis, we will be: 
 
1. Investigating the use of a radiolabelled c-Met binding peptide tracer, 
[18F]AH113804, in the in-vivo detection of locoregional recurrence in BLBC at 
its early stages (see Chapter 4). 
 
2. Validating the use of a fragment variable antibody, with an engineered Fc, 
otherwise named as scFv-Fc, against human c-Met in BLBC. Two versions 
of this tracer were designed, the optical version, Cy5-labelled scFv-Fc,  and 
the radiolabelled version, 111In-CHX-A‟‟-DPTA-scFv-Fc (see Chapter 5).  
 
3. Investigating the effect of PTPN11 knockdown in EGFR and c-Met 




Chapter 3: Material and Methods 
 
3.1 : Reagents 
 
Reagents for Cell Culture 
Dulbecco‟s Modified Eagle Media - DMEM (Life Technologies Ltd) 
RPMI Media 1640 (Life Technologies Ltd) 
Full medias contain 10% Penicillin/ Streptomycin (10,000IU Penicillin and 
10,000μg/ml Streptomycin) (Life Technologies Ltd) 2mM L-Glutamine (Life 
Technologies Ltd), and 10% heat inactivated Foetal Bovine Serum (Sera 
Laboratories International Ltd) 
Trypsin/EDTA (0.25% trypsin, 0.02% EDTA) (PAA) 
Puromycin  (ThermoFisher Scientific) 
 
Reagents for cellular transfection 
Opti-MEM-1 (Gibco) 
FuGene 6 (Roche Diagnostics) 
Lipofectamine RNAiMAX (Life Technologies Ltd) 
Pei reagent (Polysciences) 
 
Reagents for Molecular Biology 
DH5α bacterial cells (Invitrogen) 
LB agar and LB broth (Sigma) 
Ampicillin (Sigma) used at 100μg/ml 
PureYield Plasmid Miniprep System Kit (Promega) 
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PureLink HiPure Plasmid FilterMaxiprep Kit (Life Technologies Ltd) 
 
Ligands for receptors 
EGF: recombinant human epidermal growth factor (PeproTech, USA) used 
at 100ng/ml 
HGF: recombinant human hepatocyte growth factor (R & D Systems) used at 
50ng/ml 
 
Cell signalling inhibitors 
SGX523 (Millipore): anti-CMET, used at final concentration of 5μM in DMSO 
 
Reagents for Western Blotting 
Five-fold sample buffer: 100mM Tris (pH 6.8), 10% w/v SDS, 50% Glycerol; 
after protein determination in the sample, 100mM Dithiothreotol (DTT) and 
0.002% w/v bromophenol blue were added 
Gels: 30% Acrylamide/Bis solution 37.5:1 (BioRad) ammonium persulphate 
(Sigma) 
Precision Plus protein dual colour standard (BioRad) 
Running buffer: 25mM Tris Base, 0.19M glycine, 0.1% SDS 
Transfer buffer: 25mM Tris Base, 0.19M glycine, 20% w/v methanol 
Wash buffer: Tris-buffered saline (TBS): 0.02mM Tris, 0.05M NaCl, 0.01M 
KCl, pH 7.4 
TBS-Tween (TBST): TBS containing 0.1% Tween-20 
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Blocking solution: 4% Bovine Serum Albumin (BSA) (BioSera) made up in 
TBS-Tween 
Amersham Hybond ECL nitrocellulose membrane (GE Healthcare) 
Re-blot Plus (Millipore) 
Pierce ECL Western Blotting substrate (ThermoScientific) 
Coomassie stain: 0.25% w/v Coomassie brilliant blue R-250, 7% acetic acid, 
40%methanol, made up to 1L in distilled water) 
Destain solution (7% acetic acid, 10% methanol, made up to 1L in distilled 
water) 
 
Reagents for Dot Blot: 
TBS:20 mM Tris-HCl and150 mM NaCl at pH 7.5 
TBS-T: 0.05% Tween20 in TBS 
BSA/TBS-T: 4% BSA in TBS-T 
Nitrocellulose membrane (BIO-RAD) 
 
Reagents for cell proliferation: 








Table 3-1. List of Primary Antibodies 




p c-Met Tyr1234/1235 Rabbit 145 
Cell 
signalling 
c-Met   Rabbit 140, 170 
Cell 
signalling 
pEGFR Tyr1173 Rabbit 175 
Cell 
signalling 
EGFR   Rabbit 175 
Cell 
signalling 
e-cadherin   Mouse 135 Abcam 
PTPN11   Rabbit 71 
Cell 
signalling 
pAKT S473 Mouse 60 
Cell 
signalling 
AKT   Rabbit 60 
Cell 
signalling 
Tubulin   Mouse 57 In-house 
pErk T202/Y204 Rabbit 44/42 
Cell 
signalling 
Erk   Mouse 44/42 
Cell 
signalling 
GAPDH   Mouse 37 Sigma 
 
Dilutions used for Western Blotting: 
Phospho c-Met (1:500), total c-Met (1:1000), phospho EGFR (1:1000), total 
EGFR (1:1000), E-cadherin (1:1000), PTPN11 (1:500), AKT (1:1000), 
phospho AKT (1:1000), Tubulin (1:10,000), GAPDH (1:1000), Erk (1:1000), 
phospho Erk (1:1000). 
 
Secondary antibodies for Western Blotting: 
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 Goat anti-rabbit antibody, used in 1: 2000 
 Goat anti-mouse antibody, used in 1:3000 
 
Reagents for immunofluorescence staining 
Primary antibody: mouse anti-flag (1:400), total Met (1:100), phospho c-Met 
(1:50), total EGFR (1:100), e-cadherin (1:50) 
Secondary antibodies: Cy3 anti-rabbit, goat Cy5 anti-mouse, 
Mowiol: 10% (w/v) Mowiol 4-88, 25% glycerol, 100mM Tris-HCl pH 8.5 
(Calbiochem) 
DABCO: 2.5% (w/v) 1,4-diazabicyclo[2.2.2]octane (Sigma-Aldrich) 
TBS: Tris-buffered saline (25mM Tris, 100mM NaCl, pH 7.5) 
4% (w/v) paraformaldehyde (PFA) (Sigma-Aldrich) 
Sodium Borohydride (Sigma-Aldrich) 
Immersol 510 Immersion oil (Zeiss) 
 
3.2  Cell culture 
 
MCF-7 and HEK293 were cultured in DMEM medium, HCC1954, HCC1954 
with luciferase, shPTPN11-HCC1954 (GFP-tagged), shNT-HCC1954 (GFP-
tagged) and shC-Met-HCC1954 (GFP-tagged) were cultured in RPMI 
medium. 
BT20 was cultured in MEME. All media were supplemented with 10% foetal 
bovine serum (FBS), 2mM L-glutamine and penicillin/streptomycin 
antibiotics. Cell lines with knockdown (including control non-targeted 
HCC1954) were supplemented with 1µg/ml Puromycin. The HCC1954-
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luciferase tagged cell line was supplemented with 7.5µg/ml Blastocydin. The 
cell cultures were kept at 37°C in humidified air containing 5% CO2. 
Media were changed frequently to remove dead cells and to refresh 
nutrients. The cells were split once they became 80-90% confluent. 
  
3.2.1 Transient transfection and cell treatments 
 
To achieve 50–80% confluence required for transfection, cells were plated at 
4x103 MCF-7 cells per well in 96 well plates or 5x104 cells per well in 24 well 
plates. FuGENE 6 (Promega) reagent was used for plasma c-Met DNA 
transfection. The number of cells for plating and the amount of DNA/reagent 
used were adjusted according to the table below.  
 
Table 3-2. Guidelines on cell transfection according to surface area of 
the cells that have been seeded. 
 
 
Pei reagent (Polysciences) was used for transfecting DNA for scFv-Fc 
against human c-Met. 10x106 HEK293 cells were seeded onto a corning flask 
with DMEM media (with 10%FBS serum, 2mM L-glutamine and 1% 
penicillin/streptomycin). The following day, the media was replaced with fresh 
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DMEM media onto the corning flask. 300µg of the scFv-fc DNA plasmid was 
resuspended and incubated in 10ml of DMEM serum free media for 5 
minutes in a 50 ml falcon tube, while 900µl of the PEI buffer was 
resuspended and incubated in another 10ml of DMEM serum free media for 
5 minutes too. After those 5 minutes, the PEI buffer that was incubated in the 
DMEM free serum media was added onto the DNA (which was diluted in the 
DMEM media). The mixture DNA:Pei reagent was thoroughly resuspended 
and left incubated for another 20 minutes before adding it into the corning 
flask.  
 
3.2.2  RNA Interference (RNAi) 
 
siRNA Knockdown was achieved by treating cells with three different 
predesigned sequences targeting the sequence of interest. In the control 
group, cells were treated with scrambled non-targeting siRNA. Cells were 
transfected following the manufacturer's instructions. Briefly, basal like breast 
cancer cells were seeded in 6-well plates 1 day before transfection in RPMI 
media that was supplemented with 10% fetal calf serum without antibiotics. 
2µg of targeting (siPTPN11) or non-targeting siRNA was mixed with 6µl of 
Lipofectamine RNAiMAX (Invitrogen) in 100µl Opti-MEM medium (Invitrogen) 
for 20 min at room temperature and then added to the cell culture medium at 
a final concentration of 20 nmol/liter. The cells were incubated at 37°C for 
24-72 hours in 5% CO2 prior to any further experiments or fixation.  At the 
end of this incubation, protein expression was determined by immunoblotting 
analysis to assess knockdown efficiency. 
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3.2.3 Stable infection 
 
Cells with stable knockdown of PTPN11 and non-targeting cells were 
provided by Dr Ruhe Chowdhury and Dr James Monypenny. In brief, viral 
particles (transfer vector, packaging vector, enveloping vector and Rev 
expressing vector) with specific shRNA or non-targeting were generated by 
transfection into 293T cell cultures. The supernatants, which contained viral 
particles, were collected and added to target cells (seeded in a t-25 flask) for 
infection. 48hr post infection, media were refreshed daily with puromycin 
selection (1μg/ml) for five days for the selection of antibiotic resistant cells 
due to the expression of a resistance gene associated with shRNA. Cells 
were cultured in 1μg/ml puromycin from here onwards to maintain the protein 
knockdown. I generated a stable knockdown of c-Met-HCC1954 cell line 
using the viral particles provided by the Breakthrough laboratory (Breast 
cancer NOW, Guy‟s hospital) and cells of interest (HCC1954) were infected 
as described previously.  
 
3.3 Cell Lysates 
 
Cells were seeded into 6 well plates and when at 90% confluency were lysed 
using cell lysis buffer. Cell debris was removed by centrifugation at 3,000rpm 
for 10 mins at 4°C. The supernatant was placed in 1.5ml eppendorf tubes 
and gel sample buffer was added. Samples were boiled for 3 mins and 




3.3.1 Protein expression- immunoblotting 
 
The expression of proteins was tested by western blotting. 1.7 x 105 cells 
were seeded in 6-well-plates if they were to be transiently transfected. If not, 
3 x 105 were seeded in 6-well plates. At 80% confluence, the monolayer of 
cells was then exposed to biochemical treatment of inhibitors or ligands. The 
cells were washed twice with ice-cold PBS and protein extracts were 
prepared in 1 X SDS lysis buffer solutions. Protein concentrations were 
measured by the BCA protein assay kit using known concentrations of BSA 
protein as standards. For immunoblot, cell lysates were heated at 95˚C for 
15min, and then 100mM DTT reducing agent and 0.004% bromophenol blue 
was added onto the samples. The samples were then electrophoresed on 
self-made 7.5% or 10% Tris-glycine SDS-polyacrylamide gels. Gels were run 
on an Invitrogen X-Cell mini-gel system, which were initially subjected to 
constant voltage electrophoresis at 120V until the blue loading dye reached 
the resolving gel in which case the voltage was then increased to 180V and 
run until the samples reached the bottom of the gel. 
 
After separation, proteins were electrophoretically transferred onto 
nitrocellulose transfer membrane at 300mAmp for 2hr on ice using the 
Invitrogen XCell II Blot Module. Membranes were blocked 60min in 4% BSA 
in TBS-Tween and then incubated with specific primary antibody overnight at 
4°C followed by appropriate secondary antibody for 45min at room 
temperature. Detection of bound antibody was with horseradish peroxidase-
conjugated secondary antibodies and enhanced chemiluminescence 
(ThermoScientifc Fisher) with G-Box, Syngene. It was possible to re-use the 
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transfer membrane for a second incubation with different primary antibody. 
The protein bound to the transfer membrane were stripped off with Re-BLOT 
Plus Strong solution, diluted 1:10 with TBS-Tween, for 15min at 37°C, 
followed by blocking and antibody incubation steps as above. Western blot 
results were analysed and normalised with Quantity One software (Bio-Rad 
Ltd). 
 
3.4 Dot Blot Assay 
 
Firstly, we needed to have a nitrocellulose membrane ready and drew a grid 
by pencil to indicate the region that will be blotted. Then, using a narrow-
mouth pipette tip, 2 µl of samples were spotted onto the nitrocellulose 
membrane at the centre of the grid. 
 
Following this, the membrane was let dry for 20 minutes. The membrane was 
then soaked in 4% BSA in TBS-T for 1hour at RT to block non-specific sites. 
The membrane was then incubated with primary antibody dissolved in 
4%BSA/TBS-T overnight at 4°C. The membrane was then washed three 
times with TBS-T (3 x 5 min). After this, the membrane was incubated with a 
secondary antibody conjugated with HRP for 1 hour at RT. The membrane 
was then washed three times with TBS-T (15 min each), and once with TBS 
(5 min). It was then incubated with chemiluminescence (ThermoScientifc 
Fisher) for 1 minute before being detected with G-Box, Syngene ECL 




3.5 Cell proliferation assay 
 
Cells were cultured in 96-well plates, in a final volume of 100µl/well, at 37ºC, 
with a cell density of 4x103 per well. 5 plates were set up; one each to be 
assessed at 24, 48, 72, 96 and 120 hours.  Media containing inhibitor or 
ligand was refreshed every 24 hours and a 96-well plate was assessed every 
24 hours for the duration of the experiment. In order to assess a plate, 10µl 
of Cell Proliferation Reagent Alarmar Blue was added to each well and the 
plate was returned and incubated at 37ºC for 4 hours. The plate was then 
removed, shaken thoroughly and the fluorescence of the samples measured 
on a plate reader (POLARstar Galaxy, BMG LabTechnologies) at excitation 
wavelength 544 nm and emission wavelength 590 nm to obtain the relative 
fluorescent units (RFU). A control blank was included on all plates to 
normalise the values. Each experimental group consisted of triplicates and 
were repeated in four independent experiments. The growth rate for each 
cell line, with and without stimulation was calculated to compare their k 
values. The equation used to calculate the k value was : ln(N4/N1)/(t4-t1).   
N4 stands for the amount of fluorescence at day 4, N1 stands for the amount 
of fluorescence at day 1, t4 stands for the day the assay was completed 
while t1 stands for the day when the assay has started.  
 
3.6 Immunofluorescent Staining 
 
Cells were seeded onto the ethanol washed and autoclaved coverslips 
(Section 2.2.3) at a density of 5x104/ml per well in a 24 well plate. The 
following day, cells were fixed with 4% paraformaldehyde (PFA) for 20 mins 
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at room temperature. Following this, cells were washed three times (3 
minutes per wash) with phosphate buffer saline  plus calcium and 
magnesium (PBS+/+). Cells were then incubated with sodium borohyrate 
(1mg/ml) for 5 min to reduce auto-fluorescence followed by 3 washes with 
PBS+/+, 5 mins each. The cells  were then permeabilised for 10 mins using 
0.3% triton X- 100 and followed with another 3 washes with PBS+/+, 5 mins 
each. Non-specific binding was blocked by incubating for 30 mins at room 
temperature with 1% bovine serum albumin (BSA):TBS. After blocking, 
coverslips were incubated for 2 hours at room temperature with the primary 
antibody diluted in 1% BSA:TBS. The unbound antibody was removed by 
washing three times with PBS+/+ (5 mins each wash) and cells were 
incubated for 1h at room temperature with either the appropriate fluorophore 
conjugated secondary antibody in 1% BSA:TBS or with the mouse anti-flag 
antibody (when staining for the detection of scFv-Fc). When required, nuclei 
were stained with Hochst33342 at concentration of 0.1μg/ml for 3 mins at 
room temperature prior to mounting. The coverslips 
were then washed two times with PBS+/+ and once with distilled water 
before the mounting with mowiol mounting medium mixed with 2.5% DABCO 
as an antifading agent, and dried overnight at room temperature. The slides 
were then stored in -20°C for long term storage.  
 
The fluorescence was visualised using an “open” microscope automated 
FLIM system with epifluorescence using the TRI2 software. Confocal images 
were taken using a Nikon Eclipse Ni-E Upright with NIS (Nikon Instrument 
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Software) Element 64-bit software. Image analysis was performed using 
ImageJ software. 
 
3.7 Preparation of high-content phage display library screen, 
for the production of scFv-Fc against human c-Met, 
using automated liquid handling robot 
 
For the high-content scFv-Fc against human c-Met screen, JANUS 
Automated Workstation (PerkinElmer) was employed for the efficient 
automation of sample preparation and to ensure accuracy of the pipetting 
across all wells. Its dual-arm system offered a 96-tip Modular Dispense 
Technology (MDT) Dispense Head or a 4- tip Dispense Arm for optimal 
precision pipetting, processing from tubes to vials and from vials to plates. 
The three 96-well plates that were provided by McCafferty et al, and consist 
of 240 clones with varying affinity for human c-Met were defrosted at room 
temperature on ice for 1 hour. This stock solution per well was diluted with 
the addition of 20µl of distilled water in each well, and each plate was then 
span down. The concentration of the wells was then assessed using a 
NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific) and 
absorbance was measured at 260nm. The mean average of the DNA 
concentration in each well across each plate was 60ng/ul.  
3000 HEK293 cells were robotically pipetted to three new 96 well plates, 
under sterile conditions. One day later, JetPEi (10µl/well) at the ratio 3:1 
were robotically pipetted to another three 96 well plates, and incubated with 
DNA plasmid (0.24µg/well) from the scFv-Fc phage display library for 20min. 
At the end of this incubation, the transfection mixtures were added and 
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resuspended in each of the wells from the 96 well plates that were seeded 
with HEK293 cells the day before.  Those plates were then stored in an 
incubator at 37°C in humidified air containing 5% CO2. They were left there 
for 3 days and then span down and 180µl per well was collected and 
transferred into 3 new 96 well plates. The initial 96 well plates were stored in 
the freezer at -20°C while the new plates were stored at -4°C. 
One day after transfection, MCF-7 cells were seeded into 384-well-plate 
using the automated liquid handling robot. 5000 MCF-7 cells resuspended in 
200µl of media were added onto each of the 240 wells and kept in an 
incubator at 37°C in humidified air containing 5% CO2. After 24hr, Fugene 6 
transfection reagent was used to transfect c-Met plasmid DNA (pCAGGS c-
Met, at a concentration of 0.05µg/well) and Raf1-GFP (the latter was used as 
a positive control for efficient transfection) in 3:1 ratio. Cells were incubated 
for an additional 24h for sufficient c-Met overexpression and were then fixed 
with 4%PFA to perform the immunofluorescence staining of both c-Met and 
anti-flag from the scFv-Fc. The protocol outlined in section 3.5 in material 
and methods was followed for the immunofluorescence staining. The primary 
antibody used was the supernatant for the clones from the phage display 
library. After an hour incubation, and followed by three 5 minutes washes 
with PBS, the cells were incubated with the mouse anti-flag antibody at a 
dilution of 1:400. An hour later, more washes were performed, as stated in 
the protocol, and cells were incubated with the fluorophore conjugated 
secondary antibody goat anti-mouse Cy3 at a 1:400 dilution. This last 





3.8 Plasmid purification and transformation 
 
DNA construct was transformed into DH5α competent cells and plated on 
Luria- Bertani (LB) agar plates containing appropriate antibiotic (Ampicillin 
(1mg/ml) .  Bacterial colonies were incubated in LB medium (4ml for miniprep 
or 200ml for Maxiprep) and were allowed to grow overnight at 37°C. 
Miniprep and Maxiprep Kits were used to isolate plasmid DNA from bacterial 
cultures, following the manufacturer‟s protocol (Protocol overview: cells were 
harvested from bacterial cultures by centrifugation and cell pellets were 
resuspended in buffer containing RNase A; cells were lysed and mixed with 
precipitation buffer then flowed through an anion-exchange column fitted with 
the filtration cartridge unit; cell lysates were clarified and negatively charged 
phosphates of the DNA backbone interacted with the positive charges on the 
surface of the anion exchange resin; DNA was eluted under high salt 
condition and was desalted and concentrated by alcohol precipitation using 
70% isopropanol prior to centrifugation; DNA pellets were washed with 70% 
ethanol and were air-dried after centrifugation; DNA was resuspended in 
nuclease-free water). DNA extract was quantified and its purity was 
determined with the NanoDrop 1000 spectrophotometer (Thermo Fisher 
Scientific). For quantity, absorbance was measured at 260nm and purity was 
determined by the ratio of absorption at 260nm:280nm. Pure DNA has a ratio 






3.8.1 Sequencing of maxipreps 
 
Once the plasmids were produced, they were sent for sequencing to 
Eurofins. Briefly, the plasmids for scFv-Fc were diluted down to 100 ng/µl (in 
dH2O). 10µl of 10µM of reverse primer and 15µl of the dilute DNA were 
mixed into an eppendorph. The pervious step was repeated using the 
forward primer (10µl of 10µM of forward primer) in a different eppendorph. 
Once the mixtures were made, a sticky tag was positioned on those samples 
and sent for sequencing to Eurofins. The primers used were the following: 
pBIOCAM5 1404 REVERSE (sequence: GAA CAG GAA CAC GGA 
GGGTC) 
pBIOCAMS 1219 FORWARD (sequence: TTA ACA GTA GCA GGCTTG 
AGG) 
 
3.8.2 Coomassie staining 
 
Polyacrylamide gels were left in Coomassie blue staining for 10 minutes on a 
shaker. The solution was then removed and replaced with a de-stain 
solution, on a shaker for 5 minutes. It was then removed and replaced by 
fresh de-stain solution and left until the bands on the gel became visible.  
 




Corning flasks (Sigma-Aldrich) were used to scale up the production of scFv-
Fc against human c-Met. Pei reagent was used to transfect the plasmid, as 
described under the section 3.2.1 „Transient transfection and cell 
treatments’. Five days after transfection, the supernatants from 4 corning 
flasks were collected, which was a total of 1.6L. These supernatant were 
then span down for 10min at 4000 RPM to remove cells and debris. They 
were then filtered through a 0.22 µm membrane filter using a vacuum pump. 
Once done, this was followed by the purification step. A HiTrap Protein A 
column (5ml preferably – GE Healthcare) is then used with a peristaltic 
pump. The column is then equilibrated with 5 column volumes of binding 
buffer (0.02M sodium phosphate, pH 7.0) on a high speed. The filtered 
sample is then applied to the column and the speed of the peristaltic pump is 
then reduced to 5 ml/min. Once the entire sample has gone through the 
column, the column is then washed with 5–10 column volumes of the binding 
buffer to remove impurities and unbound material. The bound Ig is then 
eluted with 5 column volumes of elution buffer and collected in vials that 
contain neutralisation buffer (100 µl of 1M Tris-HCl pH 9.0). The Ig purified 
eluted solution will then have its concentration determined by UV absorbance 
at 280 nm using a spectrophotometer (Nanodrop). The HiTrap column is 
then re-equilibrate with 5–10 column volumes of binding buffer. The column 
is then washed with 20% ethanol and stored at + 4-8°C. 
 




Tumour xenografts, cells and tissues were stained with scFv-Fc against 
human c-Met (an antibody fragment), labelled directly fluorophores. The 
antibody fragment was conjugated to Cy5-dye (GE Healthcare) according to 
protocol (FlurolinkTM) at pH 9.5 by Dr Gregory Weitsman. Briefly, un-
conjugated dye was separated from the labelled antibody on a PD-10 
desalting column (GE Lifesciences). A 10µl aliquot of the labelled antibody 
was diluted and absorption measured at 280nm and 650 nm for Cy5. The 
dye:protein final ratio was estimated by the following equations:  (Cy5 D/P) 
final = [0.68 (A650) ] / [A280 – (0.05 x A650)] where Ax is the absorbance at 
wavelength x. The final ratio of protein:dye was aimed for 1:2 for acceptor 
fluorophore Cy5-labelled protein. Final dye/protein ratio was of 2.4:1, with a 
concentration of 1.11mg/ml.  
 
3.9.2  In-vivo breast cancer xenograft model establishment for 
whole- body optical imaging  
 
Animal studies were carried out in accordance with UK Research Councils' 
and Medical Research Charities' guidelines on Responsibility in the Use of 
Animals in Bioscience Research, under UK Home Office license. Animals 
were maintained in either the Hodgkin, New Hunt‟s House or Rayne BSU, 
Kings College London.  
Female six to eight week old NSG mice were purchased from Charles River 
Laboratories (UK). The animals were maintained under sterile conditions in 




Mycoplasma negative HCC1954 cell line (positive control) engineered to 
stably express luciferase (supplied by Dr Rebecca Marlow) and MCF-7 cell 
line (negative control) were used to establish in-vivo tumour models for 
longitudinal imaging (bioluminescence or SPECT). To establish 
subcutaneous models, four million cells of HCC1954 were suspended in 50μl 
sterile PBS was injected into the 4th mammary fat pad in the right hand side 
and four million cells of MCF-7 cells also suspended in 50μl sterile PBS was 
injected into the 4th mammary fat pad on the left hand side at day 0.  Mice 
were monitored post procedure, the day following injection and at least twice 
weekly thereafter. Subcutaneous tumours were measured using calliper‟s 
(mm) and volume calculated using the formula Volume= (length*width)2)/2). 
Mouse monitoring comprised of the assessment of weight, behaviour and 
palpable tumour size up to three times per week. In accordance with the PPL 
evidence of weight loss greater than 10%, moderate signs of behavioural 
distress and/or palpable tumour diameter ≥15mm (single tumour or 
combined tumours) precipitated humane killing by Schedule 1 method. 
 
3.9.3 Bioluminescence and Fluorescence imaging 
 
Bioluminescent and fluorescence imaging were performed using (IVIS® 
Lumina Series III, Perkin Elmer). Imaging and quantification of signals was 
controlled by the acquisition and analysis software Living Image®.  




30mg/ml stock solution D-Luciferin  Firefly, potassium salt (Caliper life 
Sciences, Hopkinton, USA) for use in in-vitro and in-vivo experiments was 
prepared by dissolving 1g of D-Luciferin in 33.3mls DPBS without 
magnesium or calcium and mixed prior to filtering through a 0.2μm syringe  
filter (Merck Milliporem Watford, UK). Aliquots were frozen and stored at -
80˚C. Prior to use aliquots were protected from light and thawed on ice. 
 
3.9.5 In-vivo bioluminescence and fluorescence imaging  
 
Following cell injection at day 0, animals were serially imaged to monitor 
tumour formation using bioluminescence imaging (IVIS™ Lumina Series III, 
Perkin Elmer) until an experimental end point defined by severity limit 
(Tumour Max Diameter 10mm). Animals were imaged in cohorts of 2-4 mice. 
At each imaging session mice were intraperitoneal injected with D-Luciferin 
Firefly, potassium salt (Caliper life Sciences, Hopkinton, USA) 150mg/kg (30 
mg/mL stock) at time 0. In addition, at time 0, 25ug of Cy5-labelled-scFv-Fc 
against human c-Met tracer (predetermined by a previous experiment) was 
injected into the tail vein of each animal.  Animals were then anaesthetised in 
a clear Plexiglas anaesthesia box (2% isofluorane) and once fully 
anaesthetised transferred to the nose cones (2% isofluorane) attached to the 
manifold on the warmed stage of the light tight imaging chamber. Imaging 
times ranged from 1-30 seconds and was performed at 10 minutes post 
luciferin injection. On completion, mice were returned to their cages and 
monitored until recovery.  
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Bioluminescence and fluorescence imaging were performed at time 0h, 2h, 
4h, 8h and 24h post i.v injection of Cy5 labelled scFv-Fc against human c-
Met. Following their final imaging session, mice were culled using a schedule 
1 method. Removal of all tissues of interest was confirmed by ex vivo 
fluorescence imaging of tissues and the residual cadaver using the IVIS® 
camera system. Excised tissues of interest were snap-frozen and prepared 
for immunofluorescence staining. 
Light emitted from bioluminescent tumours was detected by the IVIS® 
camera system, integrated, digitalised and displayed. Fluorescence from the 
Cy5 labelled tracer was also detected by the IVIS camera system, Image 
analysis was performed using the Living Image® software (Xenogen). 
Settings used for fluorescence were the following, exposure: 3 seconds, 
binning factor: 4 and excitation filter: 640 using Living Image® software. 
Serial scans across were reviewed and the colour scale normalised across 
the longitudinal series to facilitate visual comparison across scans. For 
quantitative comparison an appropriately sized region of interest (ROI) was 
selected to encompass subcutaneous tumour or lung areas and the total flux 
(photons per second) within these ROIs was measured.  
 
 
3.9.6 Preservation of fresh frozen tissue  
 
Tissues (e.g. primary tumours) were dissected out and embedded in the 
optimal cutting temperature (OCT) compound. The tissue was then 
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immersed into isopentane which had been cooled by suspension in liquid 
nitrogen. Tissue was not removed from the isopentane until freezing was 
complete (5 seconds or less depending on size). We then transferred the 
snap frozen sample from the isopentane to a pre-chilled storage container for 
transfer to a -80°C freezer until further use. Frozen tumours were cut into 4-
5µm sections with a cryostat for immunostaining. 
 
3.9.7 Confocal microscopy 
 
Confocal fluorescence images were acquired on a confocal fluorescence 
laser scanning microscope (A1 Confocal; Eclipse Ni-E Upright; Nikon) 
equipped with 4x, 10x, 20x dry objectives and 40x, 60x and 100x oil 
immersion objectives. Aperture was set to one Airy unit for the longest 
wavelength. The various colour filters that were used for detecting the 
different fluorophores were as follow (excitation wavelength): DAPI (405- 
450nm), FITC (488- 510nm), Cy3 (543- 573nm) and Cy5 (633- 738nm). 
Images at each wavelength were acquired with the use of a constant 
exposure time. Images were visualised using NIS Elements and analysed 
using ImageJ.  
 
3.10   Radiolabelling 
 
The scFv-Fc was reconstituted in HEPES buffer (0.1 M, pH 8.5) using 
disposable PD10 size exclusion columns. Fractions containing the scFv-Fc 
were combined and applied to a Vivaspin column (30 kDa molecular weight 
cut off, 2 mL). Four successive ultracentrifugation cycles were performed to 
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ensure that no residual buffer salts from previous scFv-Fc preparation 
remained. This was particularly important, as any residual amine-containing 
compound, such as tris buffer salts, react with SCN-pBn-CHX-DTPA, 
effectively prohibiting reaction between SCN-pBn-CHX-A‟‟-DTPA and the 
scFv-Fc. The chelator SCN-pBn-CHX-A‟‟-DTPA (0.3 mg), in 20 molar 
equivalent excess, was reacted with the scFv-Fc (2 mg) in HEPES buffer 
overnight at ambient temperature. Following this, the reaction solution was 
applied to a PD10 size exclusion column, eluted with ammonium acetate (0.2 
M), and fractions (0.5 mL) collected. 
The purified conjugate CHX-A‟‟DTPA-scFv-Fc was either stored at −20°C or 
immediately used for radiolabelling. 
 
3.10.1 Quality control of 111In-CHX-A’’DTPA-scFv-Fc against human 
c-Met 
 
Radiochemical purity was determined by size exclusion-high-performance 
liquid chromatography (SE-HPLC) (Fig 3-1). The HPLC system used 
consisted of an Agilent 1200 Series HPLC system and a Phenomenex 
Biosep 2000 (300 × 7.8 mm2- Phenomenex, Macclesfield, UK) size-exclusion 
column with an isocratic mobile phase of 0.1M phosphate buffer containing 2 
mM EDTA, pH 7 and a flow rate of 1 mL/min. The retention time of the 
immunoconjugate was typically 7-8 min and that of the unbound 111In 
impurities was approximately 11-12 min. This was coupled to a radiation 




Figure 3-1. Flow chart of a HPLC system. 
The HPLC instrumentation includes a pump, injector, column, detector and 
integrator or acquisition and display system. A high-pressure pump (solvent delivery 
system) is used to generate and meter a specified flow rate of mobile phase. An 
injector (sample manager or autosampler) is able to introduce (inject) the sample 
into the mobile phase stream that carries the sample into the HPLC column. The 
column contains the chromatographic packing material needed to effect the 
separation and is called the stationary phase. A detector enables the visualisation of 
the separated compound bands as they elute from the HPLC column. The mobile 
phase exits the detector and can be sent to waste, or collected, as desired. 
 
3.10.2 Serum stability testing of the radiolabelled compound 
 
The stability of the labelled compound was evaluated in human serum. 
Stability of the 111In-CHX-A‟‟DTPA-scFv-Fc was determined by incubating the 
111In-CHX-A‟‟DTPA-scFv-Fc  for 3h, 7h and 24 hours in human serum before 
performing SEC-HPLC analysis to determine radiochemical purity (as 
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described in section 3.10.1). HPLC-UV analysis of the conjugated product 
was performed to monitor for degradation products or other impurities. 
Concurrently, a solution of Indium-111 in ammonium acetate (0.33 M, 8 MBq, 
300 μL) was added to human serum and incubated at 37 °C for 3h, 7h and 
24 hours followed by analysis using size-exclusion HPLC. 
 
3.11  In-vivo SPECT imaging 
 
Animals bearing subcutaneous mammary tumours were imaged using c-Met 
targeted radiotracer at a time point estimated from the IVIS data and animal 
monitoring to be optimal for tumour establishment. On the day of imaging the 
tracer, 111Indium-CHX-A‟‟DTPA-scFv-Fc, was radiolabelled by Dr Michelle 
Ma. On day of scanning, mice were transferred from the Rayne BSU to the 
imaging laboratory and anaesthetised with isofluorane, O2 flow rate of 1.0-
1.5L/min and isofluorane levels of 2-2.5%. Under anaesthesia mice were 
injected intravenously with tracer. Syringe weights prior to and subsequent to 
injection were recorded for each mouse to permit calculation of the delivered 
injected volume. Residual activity in the syringe and on the gauze used to 
compress the injection site was measured using the capintec and recorded 
for each mouse.  
 
For image acquisition, mice were positioned on the bed of the 
NanoSPECT/CT Silver Upgrade (Mediso Ltd., Budapest, Hungary) equipped 
with a multiplexed multipinhole (nine pinholes, aperture 1.0 mm) collimator.  
Imaging was performed under 2% isofluorane anaesthesia. Helical SPECT 
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images were acquired over 30-40 minutes (SPECT 60-70 seconds per 
frame, CT images 55kVp, 1000ms and 1 degree angular stepping.).  On 
completion of their final scan, mice were culled using a schedule 1 method. 
The weight and activity of each culled mouse was measured using a gamma 
counter (1281 gamma counter, LKB Wallac, Turku,Perkin Elmer, UK 
Finland).  Mouse organs (gut, liver, kidneys, spleen, lungs, heart, tail and 
palpable tumour sites) were removed and weighed. The residual carcass 
weight and activity were noted. Tumour tissues were snap frozen for 
subsequent histological verification and stored in the hot lab -80°C freezer. 
Radionuclide images were reconstructed and fused with CT images prior to 
image analysis, performed using VivoQuant™ version 1.23 software. 
 
3.12   Statistical Analyses: 
 
Microsoft Excel and GraphPad were used to calculate mean, standard 
deviation and standard error of the mean and generate graphs for visual 
comparison of mouse groups. Other statistical analysis such as the one-way 
ANOVA test was used to compare means between more than two 
independent groups. For parametric data, means of two independent groups 
were compared using the Student‟s t-test. Mean values with standard 















Chapter 4: c-Met PET Imaging 
Detects Early Stage Loco-Regional 
Recurrence of Basal-Like Breast 
Cancer 
 
4.1 Introduction  
 
Basal-like breast cancer (BLBC) and triple negative breast cancer (TNBC) 
remain the greatest challenge among all the molecular subtypes of breast 
cancer, due to their clinically aggressive nature and poorly characterized 
molecular pathogenesis [217]. Unlike oestrogen (ER)-positive luminal tumors 
and HER2-positive tumours, the basal-like subtype and TNBCs typically lack 
expression of the molecular targets that confer a response to highly effective 
hormonal targeted therapies such as trastuzumab (HER2 amplification), 
tamoxifen (ER) and aromatase inhibitors (ER) [218]. However, numerous 
studies pinpoint the overexpression of c-Met and EGFR in these subtypes 
and sensitivity to EGFR and c-Met tyrosine kinase inhibitor (TKI) [69, 219].  
Additionally, TNBC patients display a high rate for locoregional recurrence 
(LRR), after mastectomy or breast conserving surgery (BCS) [31, 220, 221]. 
Locoregional recurrence is a major issue as it is associated with a poor 
survival rate [222].  
71%-91% of triple negative breast cancer, defined as lacking ER-, 
progesterone (PR)- and HER-2 receptors, have a basal-like phenotype [223]. 
Dent et al identified a defined pattern for locoregional recurrence in patients 
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with TNBC [31]. The pattern is characterised by rapidly rising rate in the first 
2 years following diagnosis, followed by a peak at 2 to 3 years, and a decline 
in recurrence risk over the next 5 years, along with a negligible risk of 
recurrence thereafter [31].  
Predictions for LRR in breast cancer are currently based on clinical factors 
such as tumour size, axillary lymph node involvement, hormone receptor 
status, age at diagnosis, lymphovascular invasion. However, those 
predictions are not reliable, especially for patients with 1 to 3 axillary lymph 
nodes involved [224]. Complementary imaging, such as mammography may 
be considered in symptomatic patients and patients at high risk for recurrent 
disease [225]. Unfortunately, mammography can only detect 25-45% of 
recurrences as the post-operative and post-radiation changes of breast 
conservation therapy decrease mammography‟s sensitivity and specificity 
compared with a standard screening population [226]. Other non-invasive 
methods, such as the use of circulating serum tumour markers in the 
detection of LRR has been discouraged due to a lack of evidence for its 
suitability [225]. There is therefore a clear need to find a modality, which is 
sensitive and non-invasive for the detection of a LRR at its early stages.  
 
In this project, we focus on the use of a c-Met binding peptide PET tracer for 
the detection of early locoregional recurrence in BLBC. PET has many 
advantages which are its non-invasiveness, its high sensitivity, requiring only 
10−11 – 10−12 mol/L levels of probe for detection [160] and the ability to yield 
excellent quality images allowing a quantitative assessment of tracer binding. 
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In our study, the radionuclide 18F was selected for the radiolabelling of the c-
Met peptide binding tracer, [18F]AH113804. Well standardised, 18F labelling 
chemistry can be adapted for the automated preparation of a wide variety of 
18F tracers in high yields and high radiochemical purity. This makes 18F 
suitable for PET imaging [227]. In addition, with a half-life of T1/2 = 109.8 min, 
18F poses less constraints on synthesis time and allows the investigation of 
processes of slower tracer kinetics up to about 6h. The relatively long half-life 
of 18F also enables the distribution of 18F radiopharmaceuticals to clinical 
services within a few hours of transport [227]. Additionally, 18F emits positron 
particles with a low kinetic energy during nuclear decay (mean energy of 250 
keV, Emax 635 keV), hence making it safer than other radioisotopes for 
handling purposes, and it has a short path in soft tissues (less than 0.3 mm) 
prior to annihilation which is conveyed into a high spatial image resolution 
[228]. 
18F-FDG was first manufactured in 1978 [229] and has become the most 
commonly used radiopharmaceutical for PET oncology studies. The use of 
FDG-PET/CT has recently been adopted by many clinics, although not used 
in primary breast cancer screening [164]. However, it has been introduced 
for diagnostic purposes as a complementary aid to mammography and 
breast ultrasound [165]. Despite 18F-FDG PET‟s ability to detect cells with 
increased metabolic activity, such as cancer cells, studies have shown its 
struggle in the differentiation of recurrent BC from inflammatory or infectious 
processes and its inability to identify small lesions (<10 mm) [166-168]. This 
is regardless of PET resolution as the newest PET/CT systems have a 
spatial resolution which is as good as 4mm [230].  
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Lately, huge interest has been drawn onto c-Met, a tyrosine kinase receptor, 
and its clinical significance in BLBC and TNBC [46, 56, 219]. A study 
conducted by Kim et al found that c-Met is most frequently expressed in 
BLBC (57.5%) and that c-Met expression was mainly localised to the cell 
membrane, with some weak expression in the cytoplasm. In this study, they 
identified a correlation between c-Met expression with ER (p<0.001) and PR 
(p<0.001) negativity and no correlation between HER2 expression with c-Met 
expression. There was also a strong correlation with EGFR expression 
(p<0.001) and CK5/6 (p<0.001) [219]. The knockdown of c-Met in high c-Met 
expressing BLBC cell lines, such as HCC1954 and BT549  resulted in a 
significant decrease in cell proliferation and migration (P < 0.05), indicating a 
potential contribution of c-Met in the tumorigenicity of BLBCs [219]. In 
addition to basal-like breast cancer, c-Met is overexpressed in many other 
solid cancers which include lung, ovary, kidney, colon, thyroid, liver, and 
gastric carcinomas [3-11]. 
Hence, due to c-Met‟s involvement in a wide range of cancers, much focus 
has been given to the development of c-Met inhibitors in preclinical and early 
clinical studies. c-Met inhibitors are being investigated as a monotherapy and 
in combination with other targeted agents or chemotherapy in breast cancer, 
colorectal cancer, Non-Small Cell Lung Cancer (NSCLC) and brain tumours 
[78]. Most of the c-Met inhibitors showed promising results when used in 
drug combinations, which is likely due to the complexity of tumour biology. c-
MET inhibitors have demonstrated very few side-effects in patients [231]. 
120 
 
Tivantinib (also known as ARQ197) [86], cabozantinib (known as XL184) 
[81], MetMab (onartuzumab) [232] and foretinib (XL880) [80] have recently 
completed their phase II clinical trials for the treatment of advanced TNBC. 
In a phase 2 randomised trial in 45 Metastatic Breast Cancer (MBC) patients, 
[233] 64% of the patients, that were administered Cabozantinib, displayed 
tumour regression with an objective response rate (ORR) of 14% along with 
a disease control rate of 48%. 
Additionally, a phase II clinical trial in NSCLC showed that the combination of 
onartuzumab (anti-c-Met mAb) with erlotinib (anti-EGFR TKI)  led to  an 
increase in progress free survival in comparison to erlotinib and placebo only 
(PFS, HR=0.53). The overall survival (OS, HR=0.4) was improved in those 
patients [148]. However, surprisingly the phase III did not confirm the efficacy 
results observed in the phase II and needs further investigation [147].  
Furthermore, there is increasing evidence for the involvement of c-Met as a 
mechanism of resistance to anticancer treatment [234]. C-Met targeted 
therapies show promising results and have a great future in cancer.  
Additionally, a recent report demonstrates that there is a significant 
increased risk of recurrence (1.52-fold) in TNBC and is associated with c-Met 
overexpression [75]. These accumulated evidences make c-Met an ideal 
target for the detection of tumour locoregional recurrence in BLBC as well as 
for the screening of treatment monitoring method of the efficacy of anti-c-Met 
therapies in-vivo.  
121 
 
[18F]AH113804, a c-Met molecular targeted agent used in this project has a 
high affinity for human c-Met (Kd≈2 nM). This highly specific c-Met binding 
peptide has previously been conjugated with the fluorescent cyanine dye, 
named GE-137, and used for the detection of polyps in humans [213]. In this 
optical clinical study, this low-molecular weight small peptide showed 
favourable pharmacokinetics and safety profile. The use of GE-137 led to the 
identification of another 9 adenoma polyps, which overexpress c-Met, that 
were not detected by light alone [213].  
 
Based on the sum of evidence regarding the suitability of c-Met as a 
molecular target in basal-like breast cancer and the positive features 
displayed by GE-137 as an optical molecular targeted agent, we assessed 
[18F]AH113804-driven PET for the early detection of loco-regional recurrence 
in BLBC, using the HCC1954 tumour xenografts. This study has now been 
published in the Journal Nuclear of Medicine [16], named as „c-Met PET 
Imaging Detects Early Stage Loco-Regional Recurrence of Basal-Like Breast 
Cancer‟, in which I am the leading first author. To avoid redundancy of the 
material, King‟s College London regulations state that I can incorporate my 
publication as part of my thesis chapter, found below. Extensive work, which 
include an additional eleven supplementary figures are found in this 
publication.  Material & Methods related to this project are also described in 
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Loco-regional recurrence of breast cancer poses significant clinical problems 
due to frequent inoperability once the chest wall is involved. Early detection 
of recurrence by molecular imaging agents against therapeutically targetable 
receptors, such as c-Met, would be of potential benefit. The aim of this study 
was to assess [18F]AH113804,a peptide-based molecular imaging agent with 
high affinity for human c-Met, for the detection of early-stage loco-regional 
recurrence in a human basal-like breast cancer model, HCC1954. Methods: 
HCC1954 tumor-bearing xenograft models were established, and 
[18F]AH113804 was administered. Distribution of radioactivity was 
determined via positron emission tomography (PET) at 60 min post 
radiotracer injection. PET and CT (computerized tomography) images were 
acquired 10 days after tumor inoculation, to establish baseline distribution 
and uptake, and then on selected days after surgical tumor resection. CT 
images and caliper were used to determine the tumor volume. Radiotracer 
uptake was assessed by [18F]AH113804 PET imaging. c-Met expression was 
assessed by immunofluorescence imaging of tumor samples and correlated 
with [18F]AH113804 PET imaging results. Results: Baseline uptake of 
[18F]AH113804, determined in tumor-bearing animals after 10 days, was 
approximately 2-fold higher in the tumor as compared to muscle tissue or the 
contralateral mammary fat pad. The tumor growth rate, determined from CT 
images, was comparable between the animals with recurrent tumors, with 
detection of tumors of low volume (<10 mm3) only possible by Day 20 post 
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tumor resection. [18F]AH113804 PET detected local tumor recurrence as 
early as six days after surgery in the recurrent tumor-bearing animals, and 
exhibited significantly higher [18F]AH113804 uptake (in comparison to 
mammary fatty tissue) with a target to background (muscle) ratio of 
approximately 3:1 (p<0.01). The c-Met expression of individual resected 
tumor samples, determined by immunofluorescence, correlated with the 
respective [18F]AH113804 imaging signals (r=0.82; p<0.05). Conclusion: 
[18F]AH113804 PET provides a new diagnostic tool for the detection of c-
Met-expressing primary tumor and has potential utility for the detection of 
loco-regional recurrence from an early stage. 
 
Keywords 
PET/CT imaging, basal-like breast cancer, HCC1954, c-Met, AH113804, 




The proto-oncogene c-Met is a receptor tyrosine kinase activated by the 
ligand hepatocyte growth factor (HGF). The HGF/c-Met signaling axis has 
been described as a promoter of cancer cell growth, angiogenesis, invasion 
and metastasis [235]. Overexpression of c-Met is associated with poor 
prognosis and a more malignant tumor phenotype [236, 237]. Several c-Met 
inhibitors are currently under evaluation in clinical trials, either as stand-alone 
therapies or in concomitant treatment [79]. c-Met is overexpressed in various 
solid tumors [238], including breast cancer (BC), with higher expression in 
Basal-like Breast Cancer (BLBC) than in other intrinsic cancer subtypes [239] 
. BLBC, which accounts for up to 15% of all BCs, exhibits a high rate of loco-
regional recurrence after initial therapy [31, 220, 221, 240]. 
Although treatment of localized disease has improved over the past 
decades, up to 45% of BC patients suffer a local, regional or systemic 
relapse within 8 years after initial therapy [220]. While systemic relapse in the 
form of distant metastasis is still regarded as incurable according to current 
treatment guidelines, loco-regional recurrence of BC should be treated with 
curative intention [241]. Treatment success crucially depends on the earliest 
possible diagnosis, before chest wall involvement or further organ invasion 
prevents any form of aggressive treatment [242]. Established guidelines for 
post-therapy monitoring in BLBC feature mammography and clinical 
examination which frequently fail to identify local tumor relapse at a 
sufficiently early stage [243]. 
Magnetic resonance imaging (MRI) and FDG-PET/CT offer a 
comparably higher sensitivity and specificity for detection and 
127 
 
characterization of BC relapse [225]. However, differentiation of recurrent BC 
from inflammatory or infectious processes, and the identification of small 
lesions (tumor size <20 mm) still impose challenges for FDG-PET [167, 168]. 
c-Met targeted imaging could provide such a tool to further improve the 
performance of post-treatment surveillance, and could aid patient 
stratification for targeted therapy. 
For this study we chose the novel, peptide-based molecular imaging 
agent [18F]AH113804 (Fig 1A) which binds to human c-Met with high affinity 
(Kd≈2 nM), has a favorable kinetic profile, exhibits specific uptake in c-Met 
positive tumor tissue and rapid systemic clearance [244]. This enables for 
diagnostic PET imaging as early as one hour after administration [244]. The 
safety, pharmacokinetics and imaging characteristics have all been assessed 
using GE-137, the fluorescent-labelled analogue of AH113804, in healthy 
volunteers and in patients at high risk of colorectal neoplasia [244].These 
initial studies in humans suggested that GE-137 was safe, and that it may 
improve visualization of colonic polyps, which display a high level for c-Met 
[244]. 
In this study, we assessed [18F]AH113804-driven PET for the early 
detection of loco-regional tumor recurrence in a preclinical model of BLBC. 
 
MATERIALS AND METHODS 
Cell culture 
Human basal-like subtype breast cancer cells HCC1954 (CRL-2338) 
were obtained from the American Type Culture Collection and cultured in 
RPMI 1640 (Invitrogen) with 10% fetal calf serum (Bodinco BV) and 2 mM L-
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Immunoblotting was performed as described in ref [245]. Detection of 
bound antibody was with horseradish peroxidase-conjugated secondary 
antibodies and enhanced chemiluminescence (ThermoScientifc Fisher) with 
G-Box, Syngene. 
 
Tumor xenograft model 
All animal studies were performed in compliance with the UK Home 
Office Animals (Scientific Procedures) Act 1986. Female SCID (Severely 
Immunodeficient) mice (17 to 19 g at time of first procedure, Charles River 
UK) were subcutaneously injected with 4×106 cells in 0.1 mL of a 1:1 mixture 
of medium and Matrigel (BD Biosciences) in the second right mammary fat 
pad. Tumor size was measured twice per week by caliper. The volume for 
the tumor was estimated as length*width2/2. Further details on the tumor 
xenograft model are given in the Supplementary Methods.  
 
Radiosynthesis of [18F]AH113804 
Synthesis of the peptide is described in the supplementary section of 
ref [244]. Details of the radiosynthesis of [18F]AH113804 are given in the 
Supplementary Methods. 
 
CT and PET imaging 
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Small-animal PET/CT imaging was performed using microPET P4 
(Concorde) and microCAT II (ImTek Inc.) systems as described earlier [246]. 
Each animal was injected intravenously (iv) with approximately 7 MBq (0.1 
mL) [18F]AH113804. Further details of the imaging procedure are given in the 
Supplementary Methods.  
Tumor and contralateral mammary fat pad uptake are presented as 
target-to-muscle retention ratio (TMRR). Further details are given in the 
Supplementary Methods.  
 
Ex vivo tissue analyses 
Details of all ex vivo tissue analyses are given in the Supplementary 
Methods. These include histology of formalin-fixed, paraffin-embedded tumor 
and quadriceps muscle, and [18F]AH113804 autoradiography and 
immunofluorescence staining of snap-frozen tumor tissue. 
 
Statistical analysis 
Unless otherwise stated, group averaged data are presented as mean 
± standard error of the mean (SEM). The observed skewed distribution of 
TMRR measures was lessened by logarithmic transformation, see 
Supplementary Methods. All statistical analyses were performed in R version 
3.1.2 (R Project for Statistical Computing, Vienna, Austria). 
 
RESULTS 
Synthesis of [18F]AH113804 
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Total synthesis time on the automated platform was 49 min. For all 
synthesis runs, the decay corrected end-of-synthesis yield was between 38 
and 41%, with a radioactive concentration (RAC) between 600 and 800 
MBq/mL. The radiochemical purity was always >90%, the chemical content 
between 15 and 20 µg/mL, and specific activity approximately 100 GBq/µmol 
for each test item. 
 
c-Met expression level in HCC1954  
Human c-Met protein expression level was assessed in HCC1954, 
compared to HT-29 (high c-Met expressing) and U87 (moderate c-Met 
expressing) cell line lysates. The data shows upregulation of c-Met in the 
HCC1954 cell line (Suppl Fig 1). Burggraff et al. assessed the specificity of 
GE-137, performing a competition study in HT-29 tumor bearing mice which 
showed a reduction in tumor uptake of GE-137 when co-administrated with 
an excess of unlabeled peptide [244]. 
 
Tumor targeting of [18F]AH113804 
Baseline uptake of [18F]AH113804 (Fig 1A) was assessed in 8 tumor-
bearing animals using PET imaging at 10 days post tumor inoculation (Fig. 
1B). Levels of radioactivity at 60 minutes pi were 4.9±0.6% ID/mL in kidney, 
2.9±0.3% ID/mL in liver, and 2.0±0.2% ID/mL in blood. PET imaging (Fig 1C) 
revealed a significant difference between the uptake of [18F]AH113804 at the 
tumor site (1.5±0.2% ID/mL, white arrowhead) compared to both 
contralateral mammary fat pad (0.8±0.1% ID/mL, blue arrowhead) and 
muscle (0.8±0.1% ID/mL) at 60 minutes p.i. Ex vivo biodistribution studies, 
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following PET imaging on Day 50 post tumor resection, confirmed 
[18F]AH113804 accumulation in tumor was significantly higher compared to 
muscle (2.5±0.6% ID/g vs. 0.9±0.2%ID/g at 70 min pi, n=3. p<0.05. Suppl Fig 
2). 
 
Early-stage recurrent tumor growth is first detected with [18F]AH113804, 
later by CT, and last by palpation 
Following tumor resection 14 to 16 days after inoculation, 5 animals 
were found to exhibit recurrent tumor growth, confirmed by necropsy after 
final imaging. The remaining 3 animals did not exhibit any tumor re-growth 
(by caliper measurements).  However, there was lack of correlation between 
tumor size by caliper and uptake of the tracer at the tumor site (Suppl Fig. 3). 
Tissue from the site of injection for one of the non-recurrent mice was 
stained. Negativity for tumor cells and human c-Met expression by IHC was 
confirmed (Suppl Fig. 4). In this case, the %ID/g in the ROI was 0.6 (c.f. the 
%ID/g at the contralateral site was 0.5).  
Analysis of [18F]AH113804 PET images provided evidence for the 
presence of loco-regional recurrence from Day 6 post-resection in these 5 
animals (Figure 2A). There was some degree of variation in the uptake of 
radioactivity at the tumor site in individual animals on each study day (Suppl 
Table 1). However, overall uptake on each day was comparable to that 
observed in the tumors pre-resection. The TMRR was significantly higher at 
the tumor resection site in comparison to the contralateral mammary fat pad 
on Day 6 (2.7±0.3 vs. 1.0±0.3, p<0.001; n=5; Fig 2B). Uptake of 
[18F]AH113804 at the site of resection remained clearly visible in the PET 
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images on subsequent days,  with the TMRR significantly smaller in the 
contralateral mammary fat pad on Day 13 (1.6±0.2 vs 0.9±0.2, p<0.01), Day 
20 (1.6±0.1 vs 0.9±0.2, p<0.001) and Day 36 (1.5±0.8 vs 0.9±0.2, p<0.01). 
At Day 50 post tumor resection, the TMRR was also higher for the tumor site 
(1.7±0.7) than for the contralateral mammary fat pad (1.0±0.0), although this 
difference was not statistically significant. No specific [18F]AH113804 
retention was detected in the contralateral mammary fat pad with levels of 
radioactivity in this region comparable to muscle tissue for all time points 
(Suppl Fig 5). 
By Day 20 post tumor resection, the mean tumor volume determined 
by CT measurement was approximately 7.0±12.5 mm3 (Fig 3A&B). Palpable 
tumor recurrence was detected from Day 29 post tumor resection (Fig 3A). 
 
[18F]AH113804 retention in tumor tissue versus systemic clearance 
Systemic clearance of [18F]AH113804 was studied in selected tumor-
bearing mice over the first 60 min pi by dynamic PET imaging. Figure 4A 
shows the distribution of [18F]AH113804 at 15 min (13-18 min) and 60 min 
(55-65 min) p.i. A decrease in [18F]AH113804 signal is observed in the major 
perfused organs, and retention of [18F]AH113804 at the tumor site (Fig 4B). 
Figure 4C displays the change in TMRR from 5 min to 60 min pi in relation to 
TMRR at 5 min p.i. While the tumor TMRR continuously increased, TMRRs 
for lungs, liver, heart and others decreased. 
 
Autoradiography and immunohistochemical analysis confirm 
[18F]AH113804 accumulation in c-Met positive tumor tissues 
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A heterogeneous pattern of [18F]AH113804 distribution was observed 
within the tumor, with viable tissue in the tumor periphery exhibiting a 
positive signal while the central tumor regions exhibited only low activity 
(Figure 5A). H&E staining and immunohistochemistry of consecutive tumor 
slides  revealed a large number of c-Met positive tumor cells (Figure 5B, left 
and right panels respectively). Both recurrent and primary tumors showed 
necrotic areas in H&E devoid also of c-Met (IHC) and displaying low 
[18F]AH113804 uptake (Suppl. Fig 6&7). 
 
Ex vivo histology correlates with the PET images 
Following immunofluorescent staining (Figure 6A), c-Met expression 
levels were quantified across whole tumor slides (Figure 6B).A significant 
correlation was found between c-Met expression and in-vivo PET (r =0.82, 
p=0.023. n=7), suggesting [18F]AH113804 signal in tumor at 60 min pi to be 
representative of c-Met expression. A similar correlation was observed 
between c-Met expression determined by IHC and [18F]AH113804 signal in-
vivo (r=0.83, p=0.0015) (Suppl Fig 8). 
In addition, it was found that the variation in the c-Met expression 
levels observed across the tumor samples (displayed in Fig 6B) was due to 
the tumor size. Indeed, a correlation (r = 0.83; p = 0.0005) was identified 
between the total c-Met intensity level and the surface area of the tumor 





Early detection and identification of tumor relapse enables improved 
loco-regional recurrence control resulting in an increased quality of life and 
better overall survival for BC patients [247]. Current surveillance guidelines 
have been shown to be less effective in the detection of loco-regional 
recurrence than the more expensive, yet more sensitive, approaches such as 
MRI or radionuclide imaging (Single-photon emission computed tomography, 
PET) [225, 243]. It is believed that either individually, or as a companion test 
for established diagnostic approaches, targeted molecular imaging of specific 
tumor markers bears the potential to positively change BC follow-up; 
especially in patients presenting with a high risk of relapse such as BLBC 
patients [247, 248]. 
 
[18F]AH113804 is known to have a high affinity for human c-Met, as 
demonstrated in studies by Evans et al., where the in-vivo affinity of 
[18F]AH113804 was determined via receptor blocking in HT-29 xenograft 
tumour mouse models [249] . [18F]AH113804 clears fast from plasma and 
non-target tissues (such as liver, lungs and heart), allowing for high contrast 
imaging after injection, and improving the sensitivity for tumor detection, as 
confirmed by PET imaging in this study. 
 
Our study shows that [18F]AH113804-driven PET imaging allowed for 
early detection of loco-regional tumor recurrence in HCC1954 tumor-bearing 
mice after surgery. [18F]AH113804 uptake and retention in the lungs and 
heart, reflecting the non-specific blood pool distribution of [18F]AH113804 
decreased constantly over the observation period. In contrast, a constant 
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signal was observed within the region of tumor regrowth, indicative of 
specific accumulation of [18F]AH113804 due to target binding. [18F]AH113804 
allows for excellent tissue penetration, and the in-vivo PET imaging revealed 
satisfactory tumor to non-target (muscle) tissue ratio from one hour p.i. 
 
We were able to detect statistically significant differences in tumor 
uptake compared to contralateral mammary fat pad at Days 6, 13, 20 and 36 
after tumor resection. The lack of statistical significance at the latter 
timepoints is most likely due to the lower, inhomogenous distribution of 
radioactivity in the tumors. PET images from some of those recurrent tumor 
bearing animals (images not shown) showed evidence of peripheral uptake 
only, indicative of necrosis in the tumor core. 
 
Currently [18F]FDG is used in PET diagnostics for detection and 
staging in cancer. Numerous studies have revealed that other, more target-
specific tracers would be beneficial for the detection of loco-regional 
recurrence [156]. In a study of patients with breast cancer, it was shown that 
tumour size was an important factor when correctly diagnosing patients 
[250]. A review of 111 patients showed that a tumor size of less than 10 mm 
was a significant predictor of a false negative [18F]FDG PET result [168]. In 
our study, a specific signal from [18F]AH113804 could be detected, even 
when the recurrent tumor was not yet observable via CT. A previous study by 
Cullinane et al. found [18F]FLT to be superior over [18F]FDG in assessing the 
effect of the c-Met inhibitor crizotinib in human glioblastoma and human 
gastric cancer pre-clinical models [251]. When tumor size decreased within 1 
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week of treatment, [18F]FDG uptake remained unchanged while [18F]FLT 
PET showed a marked decrease in uptake. [18F]FLT is reflective of cell 
proliferation, and as such was indicative of tumor therapy response. Still the 
use of [18F]FLT as a marker for proliferation has been heavily debated, with 
reports suggesting that results should be viewed with caution [252].  Such 
studies denote the importance of targeting radiotracers such as 
[18F]AH113804 for accurate tumor detection and patient monitoring. 
 
Our study demonstrates correlation between c-Met from the tumor 
samples and the maximum uptake (% ID/mL) from [18F]AH113804 at those 
sites in the corresponding PET images. A recent study using an optical 
analogue of AH113804 (GE-137) also showed a good concordance between 
the expression of c-Met and the optical signal detected [212, 244]. 
 
Other groups have investigated the use of both monoclonal antibodies 
and anticalins as probes for c-Met imaging. 89Zr-db-/76Br-ornartuzumab and 
89Zr-PRS-110 were developed and assessed for visualization of c-Met 
positive tumors in preclinical models [214, 253]. Optimal imaging time points 
were identified to be between 2 and 5 days after tracer administration, thus 
hampering potential routine clinical use as diagnostic agents. In contrast, the 
biodistribution of [18F]AH113804 permitted early imaging after tracer 
administration. Similarly, Li et al. explored the use of c-Met targeting scFv-
cys dimers in Non-Small Cell Lung Cancer xenografts. Despite showing very 
high affinity for c-Met, good contrast immunoPET imaging was achieved only 




The ubiquity of c-Met dysregulation in malignant disease and its 
known influence on tumor progression make c-Met an attractive target for 
diagnostic targeting and therapeutic intervention in multiple cancer types. 
Phase II and III clinical studies, evaluating c-Met inhibition in 
gastroesophageal cancer, lung cancer and hepatocellular carcinoma have 
shown encouraging results with clear benefit for the individual patient [79-
81]. 
 
It is hypothesized for BC, as well as for those cancer types that react 
more favourably to c-Met inhibition, that stratification of patients according to 
aberration in the c-Met axis resulting in target overexpression would strongly 
increase the efficiency of targeted treatment. 
[18F]AH113804 mediated PET signals proved to reflect the c-Met expression 
in individual tumors in our BC model, suggesting that this tracer could also 
serve as such a companion diagnostic for patient selection and for 




This study demonstrates that [18F]AH113804 PET provides a new 
diagnostic tool for the detection of c-Met-expressing primary tumor and has 
potential utility for the detection of loco-regional recurrence from an early 
stage. Further preclinical work is warranted to determine whether 
138 
 
[18F]AH113804 uptake in the regrowth provides a useful predictive tool for 
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Figure 1. Biodistribution of [18F]AH113804 and HCC1954 tumor. 
 (A) Molecular structure of [18F]AH113804. (B) Distribution of [18F]AH113804 
in selected organs and tissues in HCC1954 tumor xenografts 10 days p.i. 
Statistically significant differences were observed in the uptake of 
[18F]AH113804 in tumor versus muscle and contralateral side (Students t-
test, mean±SEM, n=8, *: p<0.05). (C) CT and PET/CT images of a 
representative tumor-bearing mouse 10 days p.i. demonstrates 
[18F]AH113804 signal at the tumor site (white arrow), but not at the 





Figure 2. Early detection of tumor regrowth using [18F]AH113804 for 
PET imaging. 
 (A) PET/CT images of a transverse section of a representative 
tumor-bearing mouse, 4 days before tumor resection and at selected days 
after resection, show [18F]AH113804 signal at the tumor site at 60 min p.i. 
For clarity, the PET signal only in the ROI is shown. (B) Target-to- muscle 
ratio in the tumor and contralateral sites. Statistically significant differences 
between both sites observed at Days 6, 13, 20 and 36 (Students t-test, 
mean±SEM,  Day 4 pre-resection: n=8, Days 6 and 13 post resection: n=5, 





Figure 3. Detection of loco-regional tumor recurrence via CT and 
caliper measurements. 
(A) Growth curve of mean tumor volume obtained from caliper and CT 
measurements of the same group of animals, before and after primary tumor 
resection (mean±SEM, n=5 per study day, except days 20 and 36: n=4, day 
50: n=3). (B) Coronal CT slices of a representative tumor-bearing mouse 
before and after resection show the presence (white arrow) and regrowth of 







Figure 4. Biodistribution of [18F]AH113804 in a recurrent HCC1954 
tumor-bearing mouse. 
 (A-left) Representative CT image of a HCC1954 xenograft mouse, acquired 
at Day 36 post resection. Recurrent tumor observed (White arrowhead). (A- 
middle and right) PET/CT at 15 min and 60 min p.i. of [18F]AH113804, with 
retained radioactivity in the tumor visible by 60 min p.i.. (B) Dynamic ROI 
analysis of PET/CT shows a constant concentration at the tumor site but 
steady decline in all other organs (n=1). (C) Data of panel B normalized to 







Figure 5. Autoradiography and immunohistochemistry demonstrate 
[18F]AH113804  retention in c-Met positive HCC1954 tumor tissue. 
 (A) Autoradiography performed ex vivo on a resected tumor confirms 
retention of the [18F]AH113804 radiotracer in tumor tissues. A heterogeneous 
distribution of tracer within the tumor section could be observed, not visible at 
the limited spatial resolution of PET imaging. (B) H&E staining (upper) and c-
Met immunostaining (lower) of paraffin-embedded tumor and control skeletal 
muscle tissue (left and right columns respectively). H&E staining reveals the 
large, mitotic and disorganized phenotype characteristic of tumor cells, while 
immunohistochemistry reveals membranous c-Met staining in these cells. 






Figure 6. Uptake of [18F]AH113804 correlate with the c-Met expression 
level in the corresponding resected tumor samples. 
 (A) Immunofluorescent staining for c-Met in resected tumor samples (Day 
14, n=7). Low, medium and high c-Met staining examples highlighted panel 
B. (B) A positive correlation is found between (a) the Max %ID/mL of tumor 
ROIs from in-vivo PET images, and (b) the c-Met protein expression level 
from immunofluorescent staining in the same tumors after resection. 





















Suppl Figure 1. Western blot of c-Met expression. 
Highest expression level of c-Met is found in HT-29, less in HCC1954 and 











































Suppl Figure 2. [18F]AH113804 activity (% ID/g) from ex vivo assay of 
dissected organs and tissue samples from HCC1954 tumor bearing 
mice. 
Organs were excised at 70 min p.i. on Day 50 post tumor resection. A single 
t-test was performed to compare uptake of [18F]AH113804 uptake in tumor 
and muscle. A statistically significant difference was observed (p<0.05, n=3). 































Suppl Figure 3. No correlation observed between tumor size by caliper 
measurement and the uptake of the tracer at the tumor site. 
This graph shows the mean tumour measurement of all tumour-bearing mice 
at 6 timepoints, with its matching mean uptake of the tracer (measurement 
taken at day 4 pre tumor resection, day 0, day 6, day 13, day 20, day 36 and 














































          
 
Suppl Figure 4. Immunohistochemical staining of mammary fat pad 
from a mouse that did not have a recurrent tumor after resection. 
The left panel represents the H&E staining of the sample that shows a clear 
presence of adipose tissue and ducts. No tumor cells were detected. The 
right panel shows staining for c-Met. No significant c-Met staining was 






Suppl Figure 5. Progressive increase in uptake of [18F]AH113804 at the 
tumor site post tumor resection. 
PET and CT image of a same tumor bearing mouse acquired on Day 6, Day 
20 and Day 36 post resection showing uptake of [18F]AH113804 at 60 min 






























               
 
 
Suppl Figure 6. H&E staining E (left) and immunohistochemical staining 
for human c-Met (middle and right) on a representative tumour sample 
that was collected at day 14 post tumour inoculation. 
The tumour sample displays an area at its core devoid of cells. It also 
displays tumour cells at the periphery with fairly strong human c-Met staining. 
Presence of necrosis and membranous c-Met staining on tumor cells is 







Suppl Figure 7. Immunohistochemical staining for c-Met on a 
representative recurrent tumor sample. 
Left panel shows the whole tumor sample while the right panel shows a 
magnified area of this tumor sample. The tumor sample displays a core of 
necrosis. The right panel shows membranous staining for c-Met around the 
tumor cells while the necrotic area shows no staining for c-Met. Scalebars 












































Suppl Figure 8. Uptake of [18F]AH113804 in tumors correlates with the 
c-Met expression level in samples of the same HCC1954 tumors. 
IHC detection of c-Met expression in FFPE preparation of tumor samples. 
Statistical analysis gave a Pearson‟s correlation coefficient of 0.85 (P= 






















































































Suppl Figure 9. Correlation between the surface area of viable tumour 
cells and the total c-Met intensity. 
The surface area measured includes areas with tumour cells only while 
excluding areas without cells, necrotic areas, and stroma. Statistical analysis 
gave a Pearson‟s correlation coefficient of 0.83 (P = 0.0008, n = 12). P and r 




   
 
 
Suppl Figure 10. ROIs drawn in tumor and contralateral mammary fat 
pad. 
A. Representative CT (left) and CT/PET image (right) of  HCC1954 tumour 
xenograft bearing mouse at day 36 post tumour resection. The ROI drawn at 
the tumour site (white arrow) was then replicated at the contralateral 
mammary fat pad (pink arrow) using the coronal and transverse section. B. 
ROI volumes for the tumour (t1) and the contralateral site (c1) are very 
similar. The ROI were drawn manually separately but attention was given to 
draw similar sized shape ROI for both sites and then checking that the 
volume of the respective ROI were very similar using the analysis section of 






                           
Suppl Figure 11. Identification of an outlier through the fitting of a 
regression line. 
Red dots fall between the upper and lower 1 percentile of all residuals while 
the grey dot is identified as an outlier. Statistical analysis performed in R 




Supplementary Table 1. Uptake of radioactivity (%ID/mL) in HCC1954 

































































-4 1.4 (0.2) 1.0 2.5 8 
6 2.1 (0.1) 1.6 2.4 5 
13 1.5 (0.2) 0.9 2.2 5 
20 1.5 (0.3) 1.1 2.5 4 
36 1.9 (0.7) 1.0 4.1 4 





Supplementary Table 2. Number of mice used in this study and imaged 
at different PET imaging timepoints. Inclusion of the number of mice 
with visible recurrent tumors after tumor surgery. 
PET Imaging timepoint Number of mice 
imaged 
Number of mice 
with recurrent 
tumors 
10 days post 
implantation 
8 N/A 
6 days post resection 8 5 
13 days post resection 8 5 
20 days post resection 6 4 
36 days post resection 6 4 








Tumor xenograft model (continuation): 
Initial PET scans with [18F]AH113804 were acquired 10 days after 
tumor inoculation. Fourteen to sixteen days after tumor cell implantation, 
animals underwent surgery for tumor excision, and were subsequently 
allowed to recover under sufficient analgesia.  
The animals were anaesthetized using 2.5% isofluorane in medical 
oxygen during the surgery. Area of the tumor site was cleaned using 
povidone-iodine. A 1 cm incision was then made around the tumor. A cotton 
swab was used to expose the tumor from the mammary fat pad. The tumor 
was then removed gently and completely from the mammary fat pad using 
scissors.  In some cases, when the tumor was stuck to the skin, the skin was 
also removed to ensure that there would be no visible remnant of the tumor. 
Sham surgery was not performed on the contralateral mammary fat pad as 
the project license would not allow 2 surgeries to take place in one animal.  
  The animals were monitored for up to 50 days post tumor resection for 
local tumor recurrence, with PET imaging carried out on selected days post 
resection (Suppl. Table 2). 
For autoradiography studies, female nude mice were inoculated with 
HC1954 cells in the second right mammary fat pad, according to the 







Radiosynthesis of [18F]AH113804 (continuation): 
[18F]AH113804 (chemical structure presented in Fig. 1A) was 
synthesized on a FASTlab automated synthesizer (GE Healthcare, Chalfont 
St Giles, UK) in a 2-step process. First, [18F]fluorobenzaldehyde was 
synthesized from [18F]fluoride and purified on a MCX+ (Mixed Cation 
Exchange, Waters) cartridge. Then, [18F]fluorobenzaldehyde was conjugated 
to the peptide precursor and [18F]AH113804 was purified and formulated.  
 
[18F]Fluoride was recovered from irradiated target water on a QMA 
cartridge (Waters) and then eluted using Kryptofix and KHCO3 into a cyclic 
olefin copolymer reaction vessel and dried under a flow of nitrogen at 120 °C. 
Subsequent reaction with trimethylammonium benzaldehyde triflate in DMSO 
resulted in [18F]fluorobenzaldehyde. 
In the second step, the peptide precursor was dissolved in an aqueous 
solution of aniline hydrochloride and added to the purified 
[18F]fluorobenzaldehyde to give crude [18F]AH113804. Purification was done 
on a tC18 SPE (Solid Phase Extraction) cartridge with acetonitrile in PBS 
(21.4% v/v) followed by PBS to remove residual acetonitrile. [18F]AH113804 
was eluted into PBS (34 mL) from the tC18 cartridge with ethanol (2.4 mL) 
followed by PBS (2.6 mL) to give the formulated product (total volume 39 mL, 
ca. 6% EtOH). 
 
CT and PET imaging: 
Anesthesia (approximately 2% isoflurane in oxygen) was induced 
shortly before and maintained throughout imaging. PET imaging at 55-65 min 
post injection (pi) of [18F]AH113804. A whole body CT scan followed 
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(projection exposure time 400 ms, tube voltage 45 kVp). Animals were 
allowed to recover from anesthesia. Occasionally static PET imaging was 
replaced by a dynamic series at 5-65 min pi [18F]AH113804. 
PET data were attenuation and scatter corrected, then reconstructed 
by filtered back projection. Images were manually coregistered and analyzed 
by Regions of Interest (ROI) employing AMIDE 
(http://amide.sourceforge.net).  
Imaging was performed at baseline (10 days post tumor inoculation, 
i.e. 4 days pre-resection) and on Days 6, 13, 20, 36 and 50 post tumor 
resection. 
3D ellipsoid ROIs were placed on the tumor in CT images to estimate 
tumor volume (Suppl Fig 10). Additional ROIs were placed in skeletal muscle 
(left forelimb), liver, left and right kidney, and heart (blood pool). All ROI PET 
data were expressed as decay corrected radioactivity concentration 
normalized to the injected dose (% ID/mL). 
Biodistribution of [18F]AH113804 was obtained for the mice on the final 
imaging day (Day 50 post resection). Following PET/CT imaging, animals 
were sacrificed (approx. 70 min p.i.). Organs and tissues of interest were 
excised, weighed and radioactivity measured using a custom-built twin-
crystal gamma counter. Ex vivo [18F]AH113804 uptake is expressed as 
percentage radioactive dose per gram of tissue (% ID/g). 
 
Autoradiography: 
Autoradiography was performed on tumors harvested from nude mice 
25 days after tumor inoculation. Mice were sacrificed 40 min after injection of 
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approximately 7 MBq [18F]AH113804 and corresponding PET imaging. 
Tumors were excised, snap frozen and cut into 8 μm thick sections. Sections 
were then imaged in a Micro Imager (Biospace Lab, Paris) which provides a 
spatial resolution of 25 µm for 18F. Image acquisition duration was 90 min. 
 
Histology: 
Hematoxylin and eosin staining and c-Met immunohistochemistry 
were performed on consecutive 3µm thick tissue sections, employing the 
monoclonal rabbit antibody D1C1 (Ventana; diluted 1:30) against total c-Met. 
Antigen retrieval was employed (Standard Cell Conditioning 1/ Ventana). 
DAB (3,3'-diaminobenzidine) served as chromogen. Slides were processed 
with an automated system Ventana (BenchMark ULTRA, Roche, 
Switzerland), scanned with a Hamamatsu Nanozoomer 2.0 HT (Hamamatsu 
Photonics, Hamamatsu, Japan) and initially analyzed with Hamamatsu 
NDP.view2 viewing software. Quantitative analysis of the c-Met expression 
level was made using HistoQuest 4.2 (Tissugnostic, Vienna, Austria) 
software.  IHC detection and quantification of c-Met expression in FFPE 
preparation of tumor samples are described in the section below. 
 
Immunohistochemistry Data Analysis: 
All the histological slides were digitalized at magnification x20 (0.46 
µm/pixel) using Hamamatsu Nanozoomer 2.0 HT. Digital images in ndp 
format were submitted for quantitative image analysis using HistoQuest 
software. HistoQuest uses patented algorithms to detect the individual cells 
of interest and assesses intensity of antigens in the cell nucleus, membrane 
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and cytoplasm. The program automatically detects tissue which is subjected 
to color separation module to differentiate between the blue and the brown 
shade. Nucleus detection algorithm on the hematoxylin shade was used to 
detect all cell nuclei and was defined as master channel. A ring mask around 
each nucleus was used to analyze the staining intensity of non-master 
chromogen (DAB) in given cellular location. The staining intensity is 
measured as mean intensity of all pixels of a cell and the range of values is 
from 0 to 255. 
c-Met staining intensity was analyzed within 1.7 mm²  regions of 
interest (ROI) that were visually identified over the tumor enriched region. 
Staining intensity was analyzed in ring masks around each nucleus using an 
algorithm that identifies stained cytoplasmic and membranous areas. Raw 
data included minimum and maximum pixel value for every individual cell 
within the ROI. The average minimum and maximum pixel values were 
calculated for the whole region. The obtained data correlated with values 
acquired from PET scans. 
 
Immunofluorescence: 
Tissues were permeabilized and stained similar to the procedure 
outlined previously [245]. A monoclonal rabbit c-Met antibody (1:100, D1C2, 
Cell signaling), followed by an incubation with a goat anti-rabbit Cy3 
secondary antibody (1:500, Sigma), were used. Total fluorescence in each 
sample was measured and total c-Met-related intensity was corrected for 
differences between each animal using the same threshold. It was quantified 
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SEM was calculated to estimate the precision of the sample mean. 
Paired t-test of log-transformed TMRR was conducted to evaluate the 
difference between tumor and contralateral mammary fat pad uptake (Fig 
2B). The correlation between total c-Met intensity from frozen tumor samples 
and the corresponding max %ID/mL for the uptake of [18F]AH113804 at the 
tumor site (Fig 6B) is visualized with a scatter plot and Pearson correlation 
coefficients were calculated. The analysis was restricted to observations 
which fell between the upper and lower 5 percentile of all residuals, 
assigning any observation beyond this range as an outlier. This resulted in 
exclusion of one observation and the remaining seven observations were 
used in the final analysis (Suppl. Fig. 11). A two-sided P-value <0.05 was 





4.3 Concluding Remarks 
 
This study has identified for the first time a unique radiolabelled c-Met 
binding peptide (Kd≈2 nM), [
18F]AH113804, which has the ability to detect 
locoregional recurrence in BLBC tumour xenografts as early as six days after 
surgical removal of the primary tumour. Early detection of the locoregional 
recurrence in patients with BLBC and TNBC is a clinical problem that needs 
to be addressed. Locoregional recurrence was found to be associated with a 
poor survival rate [222] and studies have shown a higher rate for 
locoregional recurrence in TNBCs patients [31, 220, 221] in comparison to 
other intrinsic breast cancer subtypes. 
 
We observed a decrease in the retention of [18F]AH113804 in the blood pool 
over time accompanied by an accumulation at the tumour site. This 
suggested the specificity of the tracer at the tumour site, which was later 
confirmed by ex-vivo immunostaining. The in-vivo PET images revealed a 
satisfactory tumour to non-target tissue ratio uptake, with a 2-fold difference. 
The difference was significant between the uptake of the tracer at the tumour 
site and at the control site.  It was necessary to validate for the specificity of 
the tracer in the c-Met positive tumours by conducting ex-vivo staining of c-
MET in the resected and pre-resected tumours. We were able to identify a 
strong correlation between c-Met expression level from the tumours with the 




The importance of this study lies in a current lack of c-Met specific 
radiolabelled tracers in the clinic. Several radiolabelled antibodies against c-
Met have already been tested preclinically for in-vivo tumour targeting. An 
anticalin, PRS-110 (Pieris Pharmaceuticals, Inc.) with monovalent specificity 
for c-Met, and a binding affinity of 0.6 nmol/L, was labelled with 89Zr (half-life, 
78.4 h) for the imaging of H441 NSCLC (which expresses high c-Met level) 
and U87MG glioblastoma (which expresses lower c-Met level) tumour 
xenografts [214]. In this study, they used a „control tracer‟, 89Zr-Tlc-PEG that 
was used as a negative control due to its inability to bind to c-Met and it was 
used alongside the c-Met binding tracer, 89Zr-PRS-110, for comparison 
purposes in c-Met‟s specificity in-vivo. The anticalin was conjugated with a 
PEG moiety to extend its half-life. 96 hours post tracer‟s injection, they 
observed a tumour accumulation of 5.9 % injected dose per gram (%ID/g) in 
the high c-Met expresser H441 xenografts using 89Zr-PRS-110. An uptake of 
3.9%ID/g by the non-c-Met-binding 89Zr-Tlc-PEG was observed in the same 
tumour. However, the outcome from this c-Met binding tracer did not look 
convincing due to similar uptake of the c-Met binding tracer and the control 
tracer in the lower c-Met expresser U87 MG model (1.2%ID/g vs 1.8%ID/g 
respectively). This suggests non-specific binding or higher retention of the c-
Met binding tracer, 89Zr-PRS-110, in non-targeted tissues, which is a major 
flaw for its use in clinical imaging.  
 
Other choices such as DN30 and onartuzumab have also been labelled with 
89Zr for imaging c-Met expression in-vivo, and displayed a good tumour 
uptake. The radiolabelled monoclonal antibody DN30 (Kd = 2.64 nM) 
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showed accumulation in tumours that express c-Met [255]. However, as 
DN30 is a partial agonist and consequently displayed biological effects, 
onartuzumab was selected for radiolabelling. Onartuzumab, a c-Met-
selective humanized 1-armed monoclonal antibody with a molecular weight 
of 100 kDa, is a pure antagonist with monovalent binding to c-Met [255]. The 
89Zr-labelled onartuzumab, named as 89Zr-Df-onartuzumab, displayed a 
strong signal in the high c-Met expresser MKN-45 tumours, from day 1 
onwards after injection. The uptake at the tumour site increased steadily and 
reached a value of 23%ID/g at day 5 post tracer‟s injection [255]. This is 
partly due to the trapping of radioactive metabolites from internalisation 
[256]. Accumulation in the blood, heart, lung, muscle and gastrointestinal 
tract decreased slowly overtime. Despite its specificity, the prolonged 
circulation time and slow clearance can lead to longer timeline prior to 
imaging and could therefore limit their clinical applicability as diagnostic 
agents. [215].  
 
The pitfalls of the use of antibodies as PET tracers are their very slow 
pharmacokinetics, due to their large molecular weight. This consequently 
results in the exposure of a higher dose of radiation to the patient, along with 
a delay in the acquisition of a PET scan, making management in clinics not 
so straightforward.  
 
Kim et al used a c-Met-binding peptide, similar to our study, in a glioma 
xenografts model [257]. Several linkers were introduced in their tracer 
forming three versions of the tracer: one that was unchanged (125I-cMBP), 
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the other had glycine (125I-cMBP-GGG) and another had 8-
aminooctanoicacid (125I-cMBP-AOC) introduced in their sequence. Those 
peptides were then radiolabelled with Iodine-125 and evaluated for tumour 
uptake using SPECT. Out of the three, the c-Met binding peptide with the 
insertion of glycine (125I-cMBP-GGG) showed tumour uptake while the other 
tracers did not. Despite the detection of the tumour by 125I-cMBP-GGG, the 
uptake at the tumour site was not as clear as the one observed in our study 
[16]. They speculated that this could be due to their choice of the 
radioisotope.  
 
18F-FDG was first manufactured in 1978 [229] and has become the most 
commonly used radiopharmaceutical for PET oncology studies. The use of 
18F-FDG was approved by the Food and Drug Administration, in March 2000, 
to assist in the evaluation of malignancy in patients with known or suspected 
abnormalities [258]. 18F-FDG is commonly used in the clinic and is used for 
the diagnosis, staging and restaging in a range of tumours, such as lung, 
colorectal, head and neck, esophageal cancers, lymphoma and melanoma 
[258]. 18F-FDG PET has the ability to recognise a fundamental alteration in 
the cellular metabolism of glucose which is identified in all neoplasms [258]. 
The rationale behind the use of 18F-FDG PET in various cancers was 
discussed in a review conducted by Fletcher et al [258]. This review confirms 
that enough evidence has been provided for the routine use of 18F-FDG PET 
in the detection of recurrence and metastasis in breast cancer patients, and 
showed a pooled sensitivity of 90%, while the specificity was 87%. These are 
very high values and clearly are convincing. However, other studies have 
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demonstrated 18F-FDG PET‟s limitations regarding the detection of small 
(especially <10mm) and microscopic tissue involvement [167, 168, 251]. 
Additionally, tumours with a low metabolic rate, which could be observed in 
necrotic tumours, such as the ones observed in our study, would not be 
detected by 18F-FDG PET [258].  
 
In addition to this, the advantage that a molecular target imaging agent has 
over 18F-FDG is that it will address key questions related to the expression 
and inhibition of drug targets and early assessment of the tumour response. 
Targeting cellular processes are more specific than the readout of glucose 
metabolism, provided by 18F-FDG. Indeed, imaging a molecular target, such 
as c-Met, will enable to stratify patients based on the level of c-Met 
expressed by their tumours, resulting in the administration of suitable 
therapies, such as specific c-Met inhibitors [230]. Inhibition of the target can 
be monitored by imaging the blocking of probe uptake by the study drug 
[259]. Moreover, a molecular imaging agent will provide information on the 
intrapatient heterogeneity of the expression of target proteins, which would 
be useful to know, for dosage and drug of choice purposes. Many clinical 
trials fail to achieve a desired response due to the inadequacy of the dose 
schedule, which results in the lack of target inhibition, and the drugs given 
might inhibit the target but not the tumour growth [260]. These issues can 
only be prevented through the use of specific molecular target imaging 




One of the few limitations from our study was the lack of a c-Met negative 
tumour which is a very convincing way to show evidence of the specificity of 
the tracer for the c-Met positive tumour. In addition to this, it might have been 
useful to increase the amount of radioactivity injected into the basal-like 
breast tumour-bearing mice and imaged them at 3 hours post injection of the 
tracer. We could speculate that there would be a lower retention in the blood 
pool enabling a considerably higher tumour-to-blood ratio uptake of the 
tracer. This type of timepoint experiment would only be possible if the 
biological half-life of the c-Met binding peptide matches with the timepoint for 
the PET scanning. Additionally, it is possible to re-engineer the c-Met binding 
peptide for the prolongation of its biological half-life [214].  
 
Future studies include the assessment of the effect of treatment on the 
locoregional recurrence (c-Met inhibitor), at its early stages after detection 
with the tracer, on the rate of survival of the tumour bearing mice. This would 
have provided us and others invaluable insight into the potential clinical 
effect of early detection and treatment on basal-like breast patients‟ survival.  
 
Additionally, since 18F-FDG gained clinical acceptance, and has become an 
important imaging tool in routine clinical oncology, it would have been useful 
to assess FDG uptake in our basal-like breast cancer model and compare its 
uptake at the tumour site, especially after surgery, to the uptake observed 
with [18F]AH113804. This comparison would have potentially led to a 




On the other hand, GE137, which is the optical, Cy5 labelled version of 
[18F]AH113804 successfully detected polyps in colorectal patients [213]. In 
addition to GE137‟s specificity to human c-Met, it also shows no signs of 
toxicity in patients. Excluding the potential effect of the radiolabelling which 
needs to be assessed in patients, the biological c-Met binding peptide 
appears to be safe for use in patients. In addition to this, c-Met is a 
particularly useful marker in the locoregional recurrence in BLBC and TNBC 
as a higher c-Met expression level is detected in recurrent tumours than in 
primary tumours [261].  
 
Overall, the early detection of loco-regional recurrence in basal-like breast 
cancer, observed in this study, shows great promise on the use of 
[18F]AH113804 in the clinic for the assessment of recurrent basal-like breast 
cancer, and other cancers with c-Met overexpression which include lung, 
ovary, kidney, colon, thyroid, liver, and gastric carcinomas [3-8, 10-12, 14, 
68]. [18F]AH113804 should also be tested to monitor c-Met expression 
following anti-c-Met therapy in-vivo and if successful, [18F]AH113804 could 
be used as a companion tool in such events. Due to the ability of 
[18F]AH113804 to detect very small tumour lesions expressing c-Met, which 
were not visible by CT, [18F]AH113804 could also be assessed for the 
detection of metastatic lesions, as long as the retention of the tracer in the 









Chapter 5: The validation and use of 
a single chain fragment variable 
antibody, with an engineered Fc 
domain, against human c-Met in 
basal like breast cancer 
 
5.1 Introduction and aims: 
 
c-Met has a primordial role in the progression of cancer. There is numerous 
evidence now validating a correlation between poor prognosis and 
overexpression of c-Met in many cancers, such lung, breast, ovary, kidney, 
colon, thyroid, liver, and gastric carcinomas [3-6]. 20-30% of breast cancer 
displays an upregulation of Met and its ligand HGF [45]. Numerous studies 
have demonstrated a preferential overexpression of c-Met in the basal-like 
subgroup [46, 56]. The aggressive nature of basal-like breast cancer 
combined with a lack of targeted therapy causes a reduced free survival rate 
in women with BLBC. Due to these reasons, there is a growing interest in the 
design and production of c-Met inhibitors. 
Preclinical and early clinical studies show tumour regression in 64% of the 
patients with Metastatic Breast Cancer (MBC) when administered with 
Cabozantinib, which is a multitargeted tyrosine kinase inhibitor (TKI) against 
c-Met, VEGFR2 and RET [233]. Four phase II clinical trials have recently 
been completed for the treatment of advanced TN breast cancer, targeting c-
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Met. They consist of Tivantinib (also known as ARQ197) [86], cabozantinib 
(known as XL184) [81], MetMab (onartuzumab) [232] and foretinib (XL880) 
[80].  
In parallel to the development of c-Met targeted drugs, there is an emergent 
rise in the number of preclinical studies focusing on the development of 
antibodies, fragment antibodies and non-antibody derivatives against c-Met 
for diagnostic purposes. Women with BLBC that have had surgery for the 
removal of the primary tumour tend to display a high rate of locoregional 
recurrence [31, 36]. The inability to detect locoregional recurrence or 
metastatic lesions at an early stage leads to progression of the cancer and 
consequently a reduction in survival rate. Performing a biopsy in women with 
BLBC at regular intervals after surgery of their primary tumour is not 
advisable as it is highly invasive and comes with a risk of internal bleeding 
and other typical surgical risks.  Hence, the use of a non-invasive targeted 
agent is beneficial for the early detection of a recurrent tumour. There is 
therefore a great need to find molecular imaging agents that have the 
sensitivity to accurately detect the presence of low numbers of basal-like 
breast tumour cells in the basal-like subtype of breast cancer. 
Both optical and radionuclide imaging are non-invasive methods of 
investigation for detection and therapeutic purposes. Although their aims are 
the same, they display a variety of differences which explain the existence of 
both techniques. The optical imaging method faces a few challenges: light is 
highly absorbed and experiences great scattering in biological tissues which 
limits the depth of penetration through the body [169]. However, it is often 
used in small animals as the required path-length of light is much shorter 
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making this technique more feasible. It is also a very cost-effective method 
for assessing in-vivo physiologic and biochemical processes. The nuclear 
imaging method can be challenging due to its high cost, need for a local 
cyclotron to generate short-lived positron emitting radionuclides and a 
synthetic unit to produce the biologically useful probes. However, 
radionuclide technology enables a better depth of penetration and accuracy 
for detection of the target of interest in a subject. 
Regarding the molecular agent, it is crucial to engineer a molecule that will 
have a high specificity for the target of interest, with the ability to provide high 
contrast imaging, which can be achieved by high tumour penetrance, high 
tumour to blood ratio and relatively fast clearance kinetics. A current issue 
faced by clinics is the long half-life of some molecular imaging agents 
delaying the acquisition of meaningful images. This also increases the length 
of exposure to radioactivity for the patient‟s unaffected organs and the overall 
cost of the treatment [262]. Hence, in our study, we decided to use a single 
chain variable fragment Fc protein (scFv-Fc),  in the hope of retaining a 
similar level of specificity to c-Met as one of a full-length antibody, along with 
a reduction in the blood circulation due to its smaller size. In Chapter 4 of this 
thesis, we used a 18F radiolabeled c-Met binding peptide to detect BLBC 
which demonstrated very fast clearance kinetics, potentially reducing tumour 
uptake, leading us to engineer a scFv-Fc in this current chapter. The scFv-Fc 
should demonstrate a slower clearance rate than the c-met binding peptide, 
enabling a higher tumour uptake. 
Biological tissues exhibit a high photon absorbance in both the visible 
wavelength range (350–700 nm) and in the infrared range (> 900 nm).  Cy5 
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has maximum absorbance at 650 nm and maximum emission at 670 nm. It 
can be detected in-vivo at subnanomole quantities and at depths sufficient 
for experimental or clinical imaging depending on the NIR fluorescence 
image acquisition techniques. Hence, in our study we initially choose to 
investigate the targeting ability of a single chain fragment variable fusion 
protein coupled to Cy5, against human c-Met, in a basal like breast tumour 
xenograft model. The basal-like breast cancer cell line used, HCC1954, was 
tagged with luciferase to ensure that the location of the tumour will be 
identified, via bioluminiscence, prior to the fluorescent imaging.  
Following the optical imaging, we decided to conjugate our scFv-Fc to the 
radionuclide Indium-111 (In-111) for use in SPECT imaging. This 
radioisotope has a half-life of 2.8 days and is particularly suitable for 
biodistribution studies. In the case of our scFv-Fc, the use of Indium-111 will 
allow the tumour-bearing mice that were injected with the radiolabeled scFv-
Fc to be imaged at several timepoints up to 24 hours after injection due to its 
rather long half-life in comparison to other SPECT radioisotopes [263, 264]. 
In order to conjugate the single chain variable fragment against human c-Met 
with In-111, it was necessary to use a chelator, and in this case we opted for 
CHX-A‟‟-DTPA. The reason this chelator was selected was due to its 
successful binding 111-In described in various studies [265-267]. Previous 
studies investigated the use of a radiolabelled c-Met-selective humanized 1-
armed monoclonal antibody, 89Zr-Df-onartuzumab [255], c-Met binding 
peptides 125I-cMBP-GGG [257] and 18F-AH113804 [16], the radiolabelled 
anticalin 89Zr-PRS-110 [214] in cancers which express high level of c-Met. 
While 18-F and 125-I have shorter half-lives than In-111, 89-Zr displays a 
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favourable half-life (3.3 days)  which is compatible with the time needed to 
achieve optimal tumour-to-background ratios for intact mAbs (typically a few 
days) and other large fragment antibodies [268]. However, 89-Zr displays a 
major disadvantage over 111-In as its high energy gamma emission at 
908.97 keV, results in a reduction in the radioactive dose that can be 
administered into patients.  
Following successful radiolabelling and serum stability test, we designed a 
SPECT imaging experiment in which immunodeficient mice were used to 
model basal-like breast cancer. In order to effectively compare the uptake of 
the tracer at the site of the basal-like breast cancer tumour, a c-Met negative 
tumour was also grown in parallel, through the use of MCF-7 cells. The 
uptake of the tracer in those tumours was visualised at different timepoints 
and a quantitative analysis for the amount of radioactivity in the tumours and 
other organs was performed at the end of the study using a gamma counter.  
 
The aim of this chapter is to demonstrate receptor specificity against human 
c-Met and tumour accumulation of both the Cy5 labelled scFv-Fc and the 










5.2.1 Selection of a highly specific scFv-Fc against human c- Met 
from a phage display library 
 
McCafferty et al has kindly provided a phage display library that consists of 
over 1.1 x 1010 human antibodies, which was created by cloning a repertoire 
of VL regions, followed by VH regions into a pSANG4 vector [269]. This led 
to the production of plasmid DNA with a scFv format (VH and VL fragments 
joined by a flexible linker peptide). Antibodies were selected to 404 antigen 
targets and were subcloned into the expression vector pSNAG14.3F, which 
fuses the scFv to a tri-FLAG tag sequence along with a dimeric enzyme 
alkaline phosphatase. This resulted in the primary screening (using ELISA) 
and sequencing of 94 clones, for each antigen target, and the identification of 
22 unique clones per target. Those clones were then assessed for their 
specificity to target antigen, using a secondary specificity screening and 
another set of sequencing using 6 primers. In this secondary specificity 
screening, each antibody clone was tested against the target antigen, the 
fusion partner used, 8 irrelevant purified proteins and total protein lysates 
from zebrafish and yeast in order to identify potential cross-reactivity (using 
ELISA). 64% of antibodies to mammalian-produced antigens were confirmed 
as antigen-specific and confirmed the results of the initial high throughput 
screen for the majority of clones. Sensitive detection was displayed in a bead 
based flow cytometry assay, followed by immunohistochemistry on tissue 
microarrays, for which 37% of antibodies were found to show positive 
staining.   
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Regarding human c-Met, McCafferty et al, used the phage display vector 
pSANG4 into the mammalian Fc expression vector pBIOCAM5 (Dyson and 
McCafferty, unpublished) for the subcloning of c-Met scFv. Those individual 
clones were then auto-induced and their supernatants, that contain the scFv-
Fc, were analysed by ELISA .This led to the identification of 222 anti c-Met 
scFv-Fc fusions. 
 
Figure 5-1. Set up for the phage display library assay that contained 
over 200 scFv-Fc subclones against human c-Met. 
A) The phage display library that consists of over 200 scFv-Fc subclones against 
human c-Met provided by McCafferty et al was used and transfected into HEK293 
cells, in three 96 well plate, to produce the respective scFv-Fc of each clone. The 
supernatant for each clone, which contains the scFv-Fc, was then assessed for c-
Met specificity, through the use of MCF-7 cells, that were overexpressed with c-Met, 
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using Fugene 6 as explained in the Material and Methods, using a 384 well plate. B) 
The supernatant of each clone was collected from the 96 well plates and was to 
stain the MCF-7 cells, seeded in a 384 well plate. The supernatant was used as a 
primary antibody for the detection of anti-FLAG. Pipetting and handling of 
supernatant and transfection reagent was performed using the JANUS Automated 
Workstation (PerkinElmer) in the 384 well plate. 
 
In order to assess the production of the scFv-Fc of each clone provided by 
McCafferty‟s library, each clone was transfected in each of the 96 well plates 
in which HEK-293 cells were seeded, as demonstrated in Figure 5-1A. A 384 
well plate was used to seed MCF-7 cells (Fig 5-1B), whose wells were then 
transfected with c-Met DNA, to obtain an overexpression of c-Met in those 
cells, before they could be used to assess the c-Met binding of the various 
FLAG-tagged scFv-Fc clones. To ensure the consistency and accuracy of 
the pipetting in the 384 well plate, the JANUS Automated Workstation 
(PerkinElmer) was used for this assay. Once the wells from the 384 well 
plates were fixed and stained, it was then visualised using a microscope 





Figure 5-2. Identification of scFv-Fc subclones with high affinity human 
c-Met using Immunofluorescence. 
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Detection of scFv-Fc via immunofluorescence. c-Met overexpressed cells were 
stained with subclones from the display phage library. Anti-FLAG antibody, followed 
by goat anti-mouse Cy3 was used to visualise the localisation and presence of 
scFv-Fc. Wells highlighted in red are some of the subclones that display positive 
staining for the anti-FLAG epitope of the scFv-Fc. Images were captured using an 
automated epifluorescence microscope. Scalebar: 60µm 
 
Figure 5-2 displays the staining produced using the anti-FLAG antibody that 
detects the scFv-Fc generated by the supernatant of each subclone. From 
this screen, we were able to identify 28 clones that show positive staining for 
anti-FLAG, out of the 240 clones that were transfected to generate a scFv-Fc 
against human c-Met.  
It was then important to quantify the amount of scFv-Fc produced from these 
28 clones using SDS-PAGE. The subsequent goal of this assay was to 
narrow down the number of clones prior to their amplification using the 
miniprep and maxiprep techniques. The clones with the highest specificity for 



















Figure 5-3. Identification of 28 clones against human c-Met with 
detection of scFv-Fc observed via immunofluorescence and SDS-Page. 
A) High-content phage display library screen tested on MCF-7 cells that were 
transfected with c-Met plasmid, to obtain an overexpression of c-Met, in order to 
validate the presence of scFv-Fc, in those c-Met positive cells, via 
immunofluorescence. Numbers highlighted in yellow represent the clone number 
that stained positive for scFv-Fc against human c-Met (anti-FLAG antibody was 
used). B) SDS-PAGE used to validate and quantify amount of scFv-Fc expressed in 
the clones that tested positive for the FLAG epitope in the immunofluorescence 
staining. C) Quantification of the ratio between the mean immunofluorescence 
intensity of c-Met staining by the scFv-Fc, from images in Figure 5-2; and the 
protein expression level of the corresponding scFv-Fc observed in the SDS-PAGE 





Following the identification of 28 clones that showed positivity for the anti-
FLAG epitope of the scFv-Fc (Figs 5-2 & 5-3A), the next step was to load an 
equal amount of those clones in a SDS-PAGE gel and assess the amount of 
scFv-Fc produced. Figure 5-3B clearly confirmed the identification of the 
scFv-Fc, via the detection of the anti-FLAG epitope, in each of those 28 
clones, albeit to varying degrees. It was then necessary to narrow down the 
number of clones for further characterisation and this was performed by 
calculating the ratio of mean intensity for the scFv-Fc, from the 
immunofluorescence, with the expression level of scFv-Fc observed in the 






Figure 5-4. Identification of 8 subclones that show highest specificity 
for c-Met with co-localisation of c-Met and anti-FLAG epitope. 
A) Positive staining for anti-FLAGFLAG (top panel) and c-Met (bottom panel) for all 
8 scFv-Fc subclones (clones 3, 7, 25, 42, 68, 146, 147 and 206) against human c-
Met. Co-localisation observed in all clones, albeit to varying degrees. Higher zoom 
for clones 3, 42 and 206. Scalebar: 60µm. B) Clones selected for further 
characterisation based on highest ratio between mean intensity staining for scFv-Fc 
and expression level displayed by the band intensity for anti-FLAG, produced by 
SDS-Page. Images were acquired by an epifluorescence microscope. 
 
Eight subclones, from McCafferty‟s phage display library, were selected for 
further investigation. The supernatants generated from the previous screen 
were used to stain for anti-FLAG and human c-Met in order to detect 
potential co-localisation between both epitopes. As observed in Figure 5.4A, 
all clones showed co-localisation between c-Met and anti-FLAG. Figure 5-4B 
displays the values for each subclone, taking into account the ratio average 
intensity for c-Met (using the D1C2 antibody) and anti-FLAG, which was then 




We decided to narrow down to 5 subclones for further investigations. The 
following subclones 7, 25, 42, 146 and 206 were selected based on their 
production of scFv-Fc and specificity against human c-Met. Clone 3 was not 
selected due to poorer colocalisation of c-Met stained cells with cells that 
expressed the anti-FLAG epitope, as observed in the area from the merged 
image that was magnified (Figure 5-4A). At higher zoom level clones 42 and 
206 showed a higher amount of co-localised cells (between c-Met positive 






Figure 5-5. Validation of the presence of scFv-Fc and c-Met in the five 
subclones, amplified using the miniprep technique. 
Those clones were previously identified with high c-Met specificity and co-
localisation of scFv-Fc and human c-Met. A) Positive staining for c-Met and anti-
FLAG in the 5 clones. Left panel shows staining for human c-Met, middle panel 
display staining for scFv-Fc (via anti-FLAG) , right panel shows nuclear staining for 
each clone and lastly, the far right panel shows the merged images for all the 
stainings. Higher zoom for clones 7 and 42 on the far right.  Scalebar: 60µm. B) Dot 
blot (described in M&M) assessing the presence of scFv-Fc in the five subclones of 
interest (7, 25, 42,146 and 206) from the supernatant of HEK293 cells that were 
transfected with the plasmids of interest. Images were acquired by an 
epifluorescence microscope. 
 
Following our previous experiment and further immunofluorescence staining, 
we decided to focus on those five subclones (7, 25, 42, 146 and 206) and 
amplified their DNA plasmid. This was our first step towards the scaling up of 
our desired clone. Initially, we decided to use the „Miniprep‟ technique to 
validate the immunofluorescence detection of anti-FLAG and human c-Met in 
those 5 clones and then focus on one or two clones which would then be 
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amplified using the „Maxiprep‟ method. The miniprep was performed 
successfully and did not affect the production of scFv-Fc for those 5 
subclones, as shown in Figure 5-5. The specificity of the FLAG epitope is 
observed clearly as it co-localises with c-Met positive cells. To further 
validate the production of scFv-Fc from the supernatant collected after 
transfection of the cells with those DNA plasmids from the minipreps, a dot 
blot assay was performed in which the anti-FLAG antibody was used for the 
detection of scFv-Fc (Figure 5-5B). Dot blots are a quick and efficient way to 
assess the expression level for the scFv-Fc and do not require large amount 
of samples, hence minimising sample loss. It is clear that all five plasmids 
successfully generated the scFv-Fc against human c-Met. 
Due to previous quantification, as listed in Figure 5-4B and repeats of 
immunofluorescence staining for those five clones, we were able to identify 
clones 7 and 42 as suitable for the potential use in the in-vivo study. Despite 
clone 25 showing a high ratio fluorescent staining intensity (c-Met/scFv-Fc) 
to the expression level of the scFv-Fc, additional immunostaining 
experiments revealed a poorer co-localisation between c-Met and anti-FLAG 
positive cells, in comparison to other clones. Clones 7 and 42 showed co-
localisation of c-Met and anti-FLAG epitopes as well as a high ratio for 
average intensity for c-Met/anti-FLAG over level of scFv-fc expression 
quantified by densitometry. Clones 7 and 42 were therefore selected for 




Figure 5-6. Validation of the presence of scFv-Fc and c-Met in two 
subclones, amplified using the maxiprep technique. 
Those clones were previously identified with high c-Met specificity and co-
localisation of scFv-Fc and human c-Met. A) Positive staining for c-Met and anti-
FLAG in the 2 clones. Left panel shows staining for human c-Met, second middle 
panel display staining for scFv-Fc (via anti-FLAG), middle right panel shows nuclear 
staining and the far right panel displays the merge for all stainings. Scalebar: 60µm. 
B) Dot blot assessing the presence of scFv-Fc in the two subclones of interest (7 




Scaling up the plasmid DNA for clones 7 and 42 using the Maxiprep method 
was successful, as shown in Figure 5-6. Those images show clear staining of 
human c-Met and anti-FLAG epitope of the scFv-Fc in both clones. The 
staining is specific for c-Met as untransfected cells were not positive for the 
anti-FLAG antibody. Clone 42 shows a higher intensity staining for the anti-
FLAG epitope than clone 7 (Fig 5-6A). Figure 5-6B shows evidence of the 






Figure 5-7. Protein Sequence for the variable region of the scFv-Fc 
generated by subclone 42 from the phage display library. 
This represents the sequence of the heavy (left panel) and light (right panel) chains 
of the scFv-Fc of interest. The sequence was analysed by four different methods 
called chothia, kabat, ABM, and contact, as observed by the four lines beneath the 
sequence. Those methods use different ways to determine a complementary 
determining region (CDR), highlighted in red. Inserted amino acids are highlighted in 
yellow. The sequence of the Fc domain was omitted as it is constant across all 
subclones generated in the phage display library.  
 
We decided to focus on subclone 42 only for the Cy5 labelling designed to 
be used in the in-vivo imaging of c-Met positive tumour cells. Clone 7 
expressed a much lower amount of scFv-Fc in comparison to clone 42, and 
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was therefore not used in further experiments.  Figure 5-7 shows the 
sequence of the variable domains of the heavy and light chains of the scFv-
Fc. A CDR is an immunoglobulin (Ig) hypervariable domain that determine 
specific antibody (Ab) binding. As observed in this sequence, each chain 
shows three CDRs (which is expected). Due to the fact that the sequence 
was analysed by four different methods, we observe a slight variation in the 
length, start and finish of the CDR. It was important to sequence this scFv-Fc 
in order to identify the presence of lysine residues that are necessary for Cy5 
labelling.  The lysine residues or free amino groups would bind to the NHS-
ester present in the Cy5 dye. This subclone shows the presence of lysine 
residues in its heavy and light chains. 
5.2.2 Whole body in-vivo optical imaging of basal-like breast cancer 




Figure 5-8. Specificity of the Cy5 labelled-scFv-Fc generated by clone 
42 against human c-Met. 
Subclone 42 generated scFv-Fc against human c-Met that was labelled with Cy5. 
The tracer shows positive staining for anti-FLAG (middle panel) and co-localises 
with c-Met positive cells (Left panel and far right panel). Nuclear staining was 





The initial aim of this study was to identify the „best‟ clone that would be able 
to recognise overexpressed c-Met or c-Met positive cells (such as the ones 
in basal like breast cancer) in-vitro in order to use it in-vivo. In this 
experiment, it was possible to fluorescently (Cy5) label the scFv-Fc 
(described in Material and Methods) produced by the subclone 42 without 
altering its specificity for human c-Met, as shown in Figure 5-8 (left panel). 
Figure 5-8 showed the detection and clear co-localisation of the scFv-Fc 
(anti-FLAG-Cy5) with human c-Met. In addition, a coomassie staining was 
performed for this Cy5-labelled scFv-Fc to ensure that the scFv-Fc did not 
aggregate with other molecules, during the Cy5 labelling. The band 
displayed was strong and slightly higher than the 52kDa expected due to the 
addition of the Cy5 dye. As those results were convincing, this same batch 
was used to perform the in-vivo experiments, using the IVIS imaging system.  
Prior to the in-vivo optical imaging, it was needful to identify a cell line that 
could be used as a negative control for the experiment. A suitable negative 
control would be a cell line that does not display a high level for c-Met level 
so that it would be possible to compare the uptake of the tracer in the 




Figure 5-9. Low c-Met expression level in MCF-7 in comparison to 
HCC1954. 
A) Immunoblot displaying the expression level of c-Met in HCC1954 and MCF-7. 
Cell lines highlighted in red are cell lines that will be used in the in-vivo work 
concerning the labelled scFv-Fc tracer against human c-Met. B) Quantification of c-




The MCF-7 cell line is a type of invasive breast ductal carcinoma. It has been 
shown in the literature that MCF-7 expresses a low amount of c-Met [270]. 
Nevertheless, we thought it useful to compare the amount of c-Met protein 
level in the MCF-7 cells with our cell line of interest, the HCC1954. Fig 5-9A 
shows a clear difference between the expression level of c-Met in HCC1954, 
highlighted in red, in comparison to the MCF-7 cell line. With the 
normalisation of total c-Met against tubulin, Fig 5-9B showed approximately a 
5 fold increase in the level of total c-Met in HCC1954 in comparison to MCF-
7. This result and the literature gave sufficient confidence in the use of MCF-
7 cell line as negative control as a low c-Met expresser.  
Following this and the ability of the scFv-Fc to retain its specificity for human 
c-Met after its Cy5 labelling as shown in Fig 5-9, the same batch of Cy5-
labelled scFv-Fc was used to inject intravenously 50µg per tumour-bearing 











Figure 5-10. Targeting of c-Met positive basal-like breast tumour via the 
Cy5-labelled-c-Met scFv-Fc. 
A) Timeline of the in-vivo study to assess the specificity of the Cy5 labelled scFv-Fc 
to the overexpressed c-Met tumour cells in-vivo. Four mice were subcutaneously 
inoculated at day 0 with 4 million HCC1954 cells on their right hand side, and 4 
million MCF-7 cells on their left hand side. 50µg of the Cy5-labelled c-Met scFv-Fc 
was intravenously injected into each of those tumour bearing mice. IVIS imaging of 
the mice were performed at day 10 and day 19 post tumour inoculation. Finally, 
mice were sacrificed at day 20 post tumour inoculation, following the last imaging 
timepoint, 24h post-injection (p.i.). A biodistribution was performed using the IVIS 
equipment. B) The bioluminescent signal is detected in the HCC1954 tumour at day 
19 post tumour inoculation. The bioluminescent signal is represented in a colour 
scale with red the most intense signal and yellow the weakest signal.  C) Images of 
a representative mouse, with a palpable tumour at day 10 (top panel) and at day 19 
(bottom panel) after tumour inoculation. There is a detectable fluorescent signal at 
day 19 post tumour inoculation at all timepoints (exposure: 3 seconds, binning 
factor: 4 and excitation filter: 640 using Living Image® software). On both days, 
images were acquired 1h, 2h, 4h, 8h and 24h post tracer‟s injection.  Images were 
normalised using the same scale. D) Ratio of tracer uptake between tumour and 
muscle in c-Met positive tumour (HCC1954) and c-Met negative tumour (MCF-7), 
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n=4, cumulative timepoints at 1, 2, 4,8 and 24h and paired t-test P < 0.05. E) Ratio 
uptake of tracer between tumour and muscle in c-Met positive tumour (HCC1954) 
and c-Met negative tumour (MCF-7) at day 10 and day 19 p.i (combined data) 
across all timepoints (1,2,4,8 and 24h post tracer‟s injection), n=4 F) HCC1954 and 
MCF-7 tumour growth curve of the representative mouse from day 0 to day 19 post 
tumour inoculation.   
 
Figure 5-10A outlines the timeline of this study which lasted 20 days. Four 
mice were inoculated bilaterally and subcutaneously with the HCC1954-
luciferase tagged cell line on their right hand side of their 4th set of mammary 
fat pad, while the MCF-7 cell line was injected, in parallel, on their left hand 
side. Due to previous work [16], it was possible to estimate the amount of 
cells to be injected into the mice for the appearance of a visible tumour by 
day 10 after inoculation, for a first imaging session.  
One mouse out of four displayed a palpable tumour, which was detectable 
using bioluminescence (Fig 5-10B) and fluorescence emitted by the Cy5-
labelled-scFv-Fc (Fig 5-10C). Another mouse grew a very small HCC1954 
tumour that was not palpable, and was only detectable by bioluminescence 
once dissected and imaged ex-vivo using the IVIS Illumina machine (Figure 
5-11). The signal exhibited by the tracer is specific to the basal-like breast 
tumour (HCC1954-luciferase at the RHS) as not much signal was recorded 
from the ER+ve and c-Met low expresser counterpart, MCF-7 (Fig 5-10B). 
Quantitative analysis revealed a significant difference between the tumour to 
muscle ratio of the tracer uptake in both the c-Met positive HCC1954 tumour 
and the c-Met negative MCF-7 tumour (Figure 5-10C, P < 0.05). Figure 5-
10D shows the ratio uptake in the c-Met positive HCC1954-luciferase tagged 
tumour and in the c-Met negative MCF-7 tumour, at 1, 2, 4, 8 and 24 hours 
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after tracer‟s injection. The tumour to muscle ratio in the basal-like tumour is 
3.1 fold greater than the c-Met negative adenocarcinoma tumour at 1 hour 
post injection. This quantitative difference between both tumours is almost 
constant across the remaining timepoints (2, 4, 8 and 24h). Despite the 
increase in the tumour size of MCF-7 at day 19 (palpable then) (Fig 5-10F), 
the tumour to muscle ratio remains consistent on both day 10 and day 19 
post tumour inoculations which explain the presence of a small standard 
deviation. Figure 5-10E displayed the cumulative mean tumour to muscle 
ratios, across all timepoints of imaging (Fig 5-10E). It shows a 3 fold greater 
uptake of the tracer in HCC1954-luciferase tagged tumour in comparison to 
the MCF-7 tumour (ratio of 2 for HCC1954 while the ratio is 0.75 for MCF-7). 
Following the imaging session at day 19 post tumour inoculation, it was 
necessary to assess the amount of fluorescence emitted by individual organs 





Figure 5-111. Representative images of dissected organs of 3 tumour 
bearing mouse bearing sacrificed 24 hours after intravenous injection 
of c-Met-Cy5. 
Top plate displays varying level of the fluorescence signal from the c-Met-Cy5 
across the c-Met positive basal-like HCC1954 tumour, the c-Met low expresser 
MCF-7 tumour, the liver and the kidney for mouse 1 (M1), mouse 2 (M2) and mouse 
3 (M3). The bottom plate displays the signal from bioluminescence from the same 
organs as the plate above. However, only the HCC1954 tumours show some signal, 
as they were tagged with luciferase, and therefore detectable via bioluminescence.  
 
 24 hours after Cy5-labelled scFv-Fc injection at day 19 post tumour 
inoculation, all mice were sacrificed and the organs of interest from 3 tumour-
bearing mice were excised and collected. Their tumours, whenever present 
(both HCC1954 and MCF-7), liver and right kidney were excised and 
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transferred into a 12 well plate with media, as shown in Figure 5-11. The first 
tumour bearing mice did not grow any tumours. However, the second and 
third tumour bearing mice grew both the HCC1954-luciferase tagged tumour 
and the MCF-7, c-Met low-expresser tumour. Fluorescent and 
bioluminescent images of those plates were then acquired using the IVIS 
Illumina machine. The ex vivo evaluation of excised organs showed that the 
Cy5-labelled tracer was predominantly taken up by the HCC1954 tumour in 
comparison to a low signal observed for the MCF-7 tumours, and that a high 
signal is observed in both the liver and the right kidney for all mice. 
Bioluminescent images confirm the presence of the HCC1954-luciferase 
tagged cells in 2 tumour bearing mice (M2 and M3).  
In order to validate the detection and specificity of the Cy5-labelled-scFv-Fc 
tracer in overexpressed c-Met tumour cells in basal-like breast cancer, it was 
then important to stain both the basal-like HCC1954 tumour tissue and the c-
Met negative MCF-7 tumour tissues, collected from this imaging experiment, 







Figure 5-122. Validation of specificity of c-Met-Cy5 for human c-Met in 
snap-frozen tumour tissue ex-vivo. 
A) The images represent staining performed on a snap frozen HCC1954 tumour 
tissue. Staining (from left to right, clockwise) for nuclear staining (Dapi), c-Met 
(detected with anti-rabbit Cy3 secondary antibody - red), Merge and anti-FLAG 
(which shows the presence of the Cy5-labelled scFv-Fc tracer, in green) were 
performed. The „Merge‟ image was also included to identify co-localisation. A clear 
staining for both c-Met and anti-FLAG is detectable in the basal-like tumour tissue 
B) Staining in the MCF-7 tumour tissue. Those images represent staining performed 
with the same antibodies as the one used in A) Scalebar for all images: 50µm. All 




As depicted in Figure 5-12A & B, there is a clear staining for human c-Met in 
the HCC1954 tumour tissue, while it was not visible in the MCF-7 tumour 
xenografts. Additionally, the c-Met staining detected in the basal-like tumour 
section co-localised with the staining pattern of c-Met-Cy5 (Left panel, Fig 5-
12A). As expected, the lack of c-Met staining in the MCF-7 tumour tissue 
was accompanied by a lack of detection of the ScFv-Fc tracer, as shown in 
the anti-FLAG-Cy5 channel (Fig 5-12B). 
 
5.2.3 Conjugation and Radiolabelling of the scFv-Fc with In-111 
 
The scFv-Fc was reconstituted in HEPES buffer (0.1 M, pH 8.5) using 
disposable PD10 size exclusion columns. Details of the procedure are 
described in Material & Methods, Section 3.10.  
The fraction containing the most scFv-Fc (fraction 6, 0.5 mL, 2.7 mg mL-1) 
was radiolabelled with 111-In. It was found that high radiochemical yields (> 
95 %) and maximum specific activity were achieved when the antibody 
solution was diluted three-fold in ammonium acetate (0.2 M), followed by 
addition of an equivalent volume of 111-In solution (0.1 M HCl). For example, 
addition of 10 µL of scFv-Fc (2.7 mg mL-1, 0.2 M ammonium acetate) to 20 
µL of ammonium acetate (0.2 M), followed by addition of 111-In (15 MBq, 0.1 
M HCl) provided 111-In-CHX-A‟‟DPTA-scFv-Fc in > 95% radiochemical yield, 
with a specific activity of 555 MBq mg-1. Radiochemical purity was assessed 
using size exclusion HPLC (SEC-HPLC). In SEC-HPLC, molecules with a 
higher molecular weight are eluted before molecules of a lower molecular 




Figure 5-133. Successful SEC-HPLC-chromatogram of 111In-CHX-A’’-
DTPA-scFv-Fc against human c-Met. 
Upper graph shows the UV profile of the compound (blue line) (λ=280 nm). Bottom 
panel shows the radioactivity signal from the compound. Values are given as counts 
per second (cps). Retention time for the UV absorbance of 111In-DTPA-c-Met scFv-
Fc is 8.5 min (black arrow). Retention for Free Indium-111 is 12.2 min (blue arrow).  
 
Fig 5-134 displays the SEC HPLC chromatograms of In-111-CHX-A‟‟-DPTA-
scFv-Fc. The top chromatogram shows the elution profile of CHX-DPTA-
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scFv-Fc at 280 nm using a UV-Vis detector. The major species has a 
retention time of 8.1 mins. The bottom chromatogram displays the 
radiochromatogram (using a scintillation detector), in which only radiolabelled 
species are detected. The retention time of the major species (8.5 mins) 
matches that observed in the UV-Vis chromatogram (allowing for slight 
differences arising from the configuration of the different detectors in series). 
Following the successful radiolabelling of CHX-A‟‟-DPTA-scFv-Fc, an 
immunostaining was performed to ensure that CHX-A‟‟-DPTA-scFv-Fc 
retained its affinity for human c-Met. 
 
Figure 5-14. Specificity of CHX-A’’DTPA-scFv-Fc retained against 
human c-Met. 
Positive staining for c-Met and anti-FLAG in the compound. Clockwise, top left panel 
shows nuclear staining (DAPI), top right shows staining for human c-Met (Cy3 dye), 
bottom right shows staining for scFv-Fc (anti-FLAG – Cy5 dye) and bottom left 
panel shows the merged images from all the stainings. Higher zoom for CHX-
A‟‟DTPA-scFv-Fc on the far right. C-Met staining for top far right panel and anti-




The conjugate CHX-A‟‟-DPTA-scFv-Fc was incubated in MCF-7 cells that 
were transfected with c-Met (for overexpression of c-Met in MCF-7 cells), 
and fixed before performing a double immunofluorescence staining in which 
c-Met was stained, while CHX-A‟‟DPTA-scFv-Fc was detected using the anti-
FLAG antibody. As shown in Figure 5-14, the cells that were c-Met positive 
co-localised with the staining pattern of the anti-FLAG epitope, therefore 
validating the integrity of the CHX-A‟‟DPTA-scFv-Fc conjugate‟s specificity 
for human c-Met. 
It was then important to perform a serum stability test in order to validate the 
integrity of the radiolabelled scFv-Fc for up to 24hours in human serum 





Figure 5-15. Serum stability test for the scFv-Fc against c-Met. 
A fraction of the incubated 111In-CHX-A‟‟-DTPA-scFv-Fc was injected at 3h (blue 
line), 7h (red line) and 24h (green line) after incubation at 37°C in human serum into 
the SEC-HPLC column A) UV absorbance for each fraction at all timepoints 
mentioned above B) Radioactivity signal for each fraction displayed using a 
scintillation detector, in which only radiolabelled species are detected. The black 
arrow points towards the peak that corresponds to the 111In-CHX-A‟‟DTPA-scFv-Fc, 
while the blue arrow points to the free Indium-111 (Indium-111 isotope that did not 
label the conjugated CHX-A‟‟DTPA-scFv-Fc).   
In human serum stored at 37°C, the 111In-CHX-A‟‟-DTPA-scFv-Fc was highly 
stable at 3h, 7h and 24h after incubation in human serum, as observed in 
Figure 5-15. HPLC of 111In-CHX-A‟‟DTPA-scFv-Fc used for injection showed 
a UV absorbance (Fig 5-15A) and radioactivity detector signal at the same 
elution time (Fig 5-15B).  
HPLC of the percentage remaining as intact species was over 96% at each 
timepoint (see Appendix). The mean retention time for 111In-CHX-A‟‟DPTA-
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scFv-Fc that was incubated for 3h, 7h and 24h in human serum was 7‟42 
minutes with  96% remaining as intact species. Free Indium-111 (that did not 
react with the conjugated CHX-A‟‟DTPA-scFv-Fc) was eluted at a mean 
retention time of 11‟54 minutes across all timepoints. Chromatograms that 
displayed the yield of labelling and retention times of the eluted radiolabelled 
111In-CHX-A‟‟-DPTA-scFv-Fc for each timepoint (3h, 7h and 24h after 
incubation in human serum) have been inserted in the Appendix (Chapter 9, 
pages 287, 290 & 292). Controls were performed in order to assess the 
retention time of free Indium-111 and free indium-111 in human serum (see 
Appendix, pages 283, 288, 291 & 293).  
Due to this successful result, it was then possible to progress onto a SPECT 
imaging experiment, in which 111In-CHX-A‟‟-DPTA-scFv-Fc was injected into 
female NSG mice that were inoculated with both the c-Met positive cell line, 
HCC1954 (at their right hand side) and the c-Met negative cell line, MCF-7 
















Figure 5-16. c-Met positive tumour uptake observed via SPECT using 
111In-CHX-A’’DPTA-scFv-Fc in a representative tumour-bearing mouse. 
Anticlockwise: transverse, sagittal and coronal sections of a dual tumour bearing 
mouse, imaged 24h after injection. White arrow points at the basal-like breast 
tumour. Negative c-Met cell line was not observed in this slice. The SPECT signal is 
represented in a colour scale with yellow the most intense signal and blue the 




The SPECT images acquired from this experiment shows clear uptake at the 
c-Met positive tumour site, HCC1954. As observed, in Fig 5-16, the white 
arrow which points towards the basal-like breast tumour site shows clear 
uptake of the 111In-CHX-A‟‟DPTA-scFv-Fc. The distribution of the uptake 
looks heterogeneous with the core being devoid of signal. Fig 5-16 also 
shows high uptake in the liver and some blood pool.  
In this experiment, we were interested in assessing the accumulation of the 
tracer in the basal-like breast tumour overtime, and based on the previous 
findings from the optical imaging experiment, we decided to image four 





Figure 5-17. Accumulation of tumour uptake and decline in liver uptake 
in a representative tumour bearing mouse over time after injection of 
111In-CHX-A’’DPTA-scFv-Fc. 
A) The coronal sections were displayed for all. Left panel: SPECT image at 3 hours 
post injection, middle panel: SPECT image acquired at 7 hours post injection, right 
panel: SPECT image acquired at 24 hours post injection. TR represents the c-Met 
positive HCC1954 tumour while TL represents the c-Met negative MCF-7 tumour. 
The SPECT signal is represented in a colour scale with yellow the most intense 
signal and blue the weakest signal.  B) Quantification of tumour uptake in the same 
tumour bearing mouse, using SPECT data, showing accumulation in the tumour 
uptake over time  C) Quantification of liver uptake in the same tumour bearing 
mouse, using SPECT data, showing decline in liver uptake over time. 
 
As displayed in Fig 5-17, there is visible blood pool clearance overtime, with 
a clear decrease by 24h post injection of the tracer. The uptake at the liver 
slowly decreases overtime as observed in the bottom panel for each 
timepoint. There is visible uptake in the colon, as observed at 7h and 24h 
post injection. The uptake at the c-Met positive tumour is visible up to 24 
hours after injection.  
It was possible to quantify the uptake of the tracer across all timepoints for 
one tumour-bearing mouse and we detect a 2 fold increase in tumour uptake 
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from 7h and 24h post tracer injection (Fig 5-17B). In addition, we also 
observe a decline in the uptake in the liver, albeit slow. The uptake in the 
liver decreases by 5% injected dose (ID) between 3 to 24 hours after tracer 
injection (Fig 5-17C).  
All 12 tumour-bearing mice were culled at the end of the imaging session, 
which was 25h post tracer injection. The organs, listed in table 5-2 were 
collected for ex-vivo Biodistribution study using the gamma counter. In 
addition, all the tumours were collected and were either snap-frozen or 
formalin fixed, and stored appropriately for further investigations.  
 
Table 5-1. Organs collected from the 12 tumour bearing mice after the 
last imaging session has taken place. 







Figure 5-18. 111In-CHX-A’’-DPTA-scFv-Fc activity (% ID/g) from ex-vivo 
assay of dissected organs and tissue samples from HCC1954 tumor 
bearing mice, following SPECT imaging. 
Organs were excised at 25h p.i. of the tracer on Day 32 post tumor inoculation. 
Gamma activity was quantified using the gamma counter 10 days after tracer‟s 
injection. Statistical tests include Student‟s t-test (P<0.05), mean ±SD.  
The ex-vivo biodistribution data provide the quantitative information on the 
uptake of the tracer in different organs (Fig 5-18). We observed a high 
radioactivity level per gram in the spleen (41.3%ID/g), followed by the liver 
(12.4%ID/g), the kidneys (9.3%ID/g), the blood (9.0%ID/g) and the bone 
(6.9%ID/g). This trend was observed in the SPECT images. There was also 
some moderate uptake in the right c-Met positive tumour (4.7%ID/g), in the 
lungs (4.5%ID/g). Low uptake was observed in the c-Met negative left tumour 
(3.3%ID/g) and in the heart (3.0%ID/g). Minimal uptake was observed in the 
stomach (1.3%ID/g), and muscle (1.3%ID/g). We also observed a 1.4 fold 
increase in the HCC1954 basal-like tumour uptake in comparison to the 
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In this chapter, we identified and validated a novel radiolabelled scFv-
Fc that has the ability to bind to human c-Met and therefore detect tumours 
with high c-Met expression level. By using smaller antibody fragments with 
shorter serum half-lives, such as a scFv-Fc, PET can be performed at earlier 
time points with similar or even higher contrast than a full length antibody 
[254]. This is an important consideration as it is useful to minimise the 
amount of exposure of radioactivity in healthy tissues. Additionally, scFv-Fc 
fragment antibodies have the advantage of being compatible with many 
different immunoassays such as ELISA and immunoblots, unlike smaller 
fragment antibodies.  
In this project, prior to the labelling, the scFv-Fc was selected from a 
phage display library, kindly donated by Prof McCafferty. Phage-antibody 
(and antibody-fragments) display libraries are a rich source of antibody 
diversity, supplying hundreds of unique antibodies per target [269]. The 
discovery and development of novel antibodies and fragments from a phage 
display library are faster than generating and screening hybridomas, which 
also involve the isolation of the antibody gene, their humanisation and the 
conduction of affinity maturation assays [254]. Our scFv-Fc of interest was 
expressed in the phage display vector pSANG4 which led to the production 
of scFv-Fc, as explained previously.  This did not lead to the production of 
many subclones of scFv against human c-Met. To circumvent this issue, 
McCafferty‟s team engineered an additional Fc fusion to those clones, by 
expressing them into the vector pBIOCAM5, and performed another round of 
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panning in order to produce over 200 clones with specificity against human 
c-Met. In our study, it was useful to be given a scFv-Fc phage display library, 
rather than one made of scFvs. ScFv-Fcs offer bivalent binding and a long 
biological  half-life to achieve higher signal-to-noise ratio [271]. 
Those scFv-Fc clones were transfected into HEK293 cells and their 
supernatant were collected and stained for the detection of the FLAG epitope 
displayed by the scFv-Fc using overexpressed c-Met MCF-7 cells. This led to 
the identification of 28 subclones which were then loaded on an agarose gel 
electrophoresis. We then identified 8 subclones with the highest ratio 
between the mean intensity of the scFv-Fc, from immunofluorescence and 
the expression level of scFv-Fc analysed via SDS-Page. Those subclones 
co-localised with cells that overexpressed c-Met. Rochefort et al performed 
SDS-PAGE of the clones that showed binding to the antigen of interest 
(detected by ELISA) to identify the expression level of their chimeric anti 
CA19-9 scFv-Fc and thereafter select the clones with the highest amount of 
scFv-Fc produced [272]. In our study, systematic immunostainings and SDS-
PAGE were conducted for the clones that showed binding to human c-Met 
which were then narrowed down to the clones that showed highest specificity 
for human c-Met, relative to each other, with a good production level for the 
scFv-Fc.  
Further immunostainings and dot-blot assays were performed for the 
selection of 1 subclone with high specificity for human c-Met and good level 
of expression for scFv-Fc. The in-vitro assays that were performed for this 
particular clone after the screen, miniprep and finally maxiprep consistently 
showed high affinity for human c-Met, with a good expression level for scFv-
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Fc which made us confident in assessing its tumour targeting ability in-vivo 
using optical imaging initially.  
Sequencing this subclone led to the identification of lysine residues that are 
necessary for Cy5 labelling. The production of this subclone was amplified 
and tested for specificity for human c-Met in-vitro prior and after Cy5 labelling 
before injecting it into mice. In this particular study, transient mammalian 
scFv-Fc expression was used due to the failure of generating producer cell 
lines. Due to the time scale given, transient mammalian scFv-Fc production 
seemed to be most suitable for this study and generated up to 0.02mg/mL 
from transfected HEK293 cells. However, if given the opportunity, the use of 
non-adherent HEK293-6E cells could have deemed very useful in this study 
as it has the ability to yield 10 fold more scFv-Fc than HEK293T cells [273]. 
In addition, the use of cationic polymer polyethyleneimine (PEI) ensured 
highly efficient plasmid delivery with low cytotoxicity and simple handling 
[274]. PEI contains a large number of protonable amino groups providing a 
high pH buffering capacity. This seems to protect the DNA from degradation 
in endosomal compartments, mediating an early escape of DNA/PEI 
complexes from lysosomes [275]. 
The use of a luciferase-tagged basal-like breast cancer cell line in mice 
enabled the localisation of the c-Met positive tumour via bioluminescence 
prior to acquiring fluorescent images for the in-vivo tumour targeting of the 
Cy5-labelled scFv-Fc. The signal emitted from the bioluminescence co-
localised with the signal from the Cy5 labelled scFv-Fc. Although 2 out of 4 
tumour bearing mice grew the HCC1954 tumours, detection with the optical 
tracer was only possible for the mouse with the biggest basal-like breast 
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tumour. In this tumour-bearing mouse, the Cy5-labelled scFv-Fc was able to 
specifically bind to overexpressed c-Met cells in-vivo. In addition, the low 
signal observed in the MCF-7 tumour in-vivo provided additional evidence for 
the optical tracer‟s specificity for human c-Met. The ex vivo biodistribution of 
the organs collected from the tumour-bearing animals at the end of the 
imaging session showed high intensity of fluorescence for liver, moderate 
intensity for the right kidney and the basal-like breast tumour, while the level 
of fluorescence intensity was very low for the c-Met negative MCF-7 
tumours. Additionally, the ex vivo immunofluorescence staining performed on 
a frozen section of the HCC1954 and MCF-7 tumour tissues displayed the 
presence of the Cy5-labelled scFv-Fc and its co-localisation with the c-Met 
overexpressed cells from the c-Met positive HCC1954 tumour tissue. The 
MCF-7 tumour tissue did not display any staining with the optical tracer and 
c-Met was not detected in those sections ex vivo.  
The results from the optical imaging experiment in mice demonstrated 
specificity of the scFv-Fc to human c-Met and additionally showed that our 
scFv-Fc had the sensitivity to detect endogenous levels of c-Met within our 
basal-like breast cancer. This is a very exciting finding as optical tracers that 
bind to human c-Met with high affinity are clinically needed. There has been 
a study conducted by Kim et al that investigated the use of a Cy5.5 labelled 
c-Met binding peptide, with the addition of a lipophilic carbon linker, with 
nanomolar specificity to c-Met in glioma [276]. The latest study on optically 
labelled c-Met involved the use of c-Met binding peptide conjugated with a 
fluorescent cyanine dye, GE-137. This fluorescently labelled c-Met binding 
peptide, GE-137, showed specific targeting of overexpressed c-Met tumour 
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cells, allowing for the detection of polyps in colorectal cancer patients, that 
were not visible by light alone [213]. Following this successful study, 
Purushotham et al are currently conducting a pilot study of intraoperative 
GE-137 fluorescence imaging with the aim of improving the accuracy of 
surgical excision of tumours in breast and oral cancer patients [277].  
Despite the limited applications of optical imaging in comparison to nuclear 
medicine, due to tissue scatter, absorption of photons in the visible range 
and potential autofluorescence [278], optical tracers can be used in 
endoscopy, laparoscopy, and the intraoperative setting for the detection of 
superficial lesions. Hence, the identification of an optical tracer against 
human c-Met with a combination of a high tumour targeting ability, relatively 
fast clearance kinetics and good safety profile would attract attention for 
further investigations in the clinic. 
Due to the restricted depth of penetration of the optical tracer, we decided to 
radiolabel the scFv-Fc with Indium-111 (In-111), via conjugation to the 
chelator CHX-A‟‟-DTPA for use in SPECT imaging. A bifunctional chelator 
was used as it would form highly stable complexes with the radioisotope In-
111 and hence minimise the risk for non-target uptake in the subject [279]. 
The use of the HPLC system with a SEC column enabled identification of the 
retention time at which the scFv-Fc would be eluted and assessed its purity 
after labelling. The retention time for the radiolabelled scFv-Fc, identified by 
the UV detector, matched with the retention time detected by the gamma 
detector which implies that the scFv-Fc was successfully radiolabelled. This 
conjugate (that has the chelator CHX-A‟‟DTPA), was then tested in-vitro and 
was found to retain its specificity for human c-Met in overexpressed c-Met 
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cells. In addition to this, the serum stability test showed stability and integrity 
of the scFv-Fc in human serum at body temperature up to 24hours after 
incubation. 
  
This successful chemical conjugation led to the final imaging experiment 
using the SPECT imaging modalities. Instead of injecting 50 microgram of 
the radiolabelled c-Met binding scFv-Fc per mouse (used in the optical 
imaging experiment), we opted for a lower dose (20 micrograms) due to 
concerns that the non-radiolabelled „cold‟ scFv-Fc would compete with the 
radiolabelled tracer, potentially reducing the detection of overexpressed c-
Met cells.  The SPECT imaging of 4 tumour-bearing mice with dual 
subcutaneous inoculation for the c-Met positive basal like breast tumour and 
the c-Met negative adenoma carcinoma tumour displayed increased uptake 
of the radiolabelled scFv-Fc in the basal-like breast tumour.  In addition, the 
quantification of the uptake of the radiolabelled scFv-Fc in the HCC1954 
tumour in one of the tumour bearing mice showed a 2-fold increase from 3 to 
24 hours after injection of the tracer. In parallel, we observed a decline in the 
uptake in the liver, suggesting that the uptake in the c-Met positive tumour 
was specific. The results from the ex-vivo biodistribution assay corresponded 
with the data acquired from the SPECT images, displaying a high amount of 
activity in the liver, and suggested hepatobiliary clearance, which is expected 
in antibody fragments with a molecular weight of 60 kDa or above [279]. We 
also observed a moderate uptake in the kidneys, which suggests clearance 
of the tracer. However, at this specific timepoint, there was moderate uptake 
in the blood and heart which suggests that the tracer had not yet been fully 
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cleared. It also suggests that the optimal tumour to blood ratio would occur 
later than 24 hours post injection.  
To date, no other radiolabelled scFv-Fc against human c-Met used in SPECT 
imaging has been designed. Jacoda et al investigated the use of a c-Met 
binding peptide that has been radiolabelled with Tc-99 and showed good 
tumour targeting. This tracer showed a tumour uptake (in high c-Met 
expresser MNK-45 tumours) of 10.13 %ID/g 30 minutes after injection, which 
decreased considerably (by 46% and 63% respectively) after 2 and 3 hours 
post injection of the tracer [280]. A very high uptake in the kidneys was 
observed at all timepoints and suggested clearance of the tracer. The major 
weakness in this study was the high uptake in the kidneys, masking potential 
metastatic lesions in these organs and the rather short half-life of the 
radioisotope, preventing the use of this tracer for the monitoring of 
therapeutic treatments.   
Despite the lower dose of radiolabelled scFv-Fc administered to the mice in 
comparison to the optical tracer, the tumour targeting ability of the 
radiolabelled scFv-Fc was not compromised. This might suggest that the 
higher dose applied in optical imaging was due to Cy5 labelling reaction 
stopping before complete labelling is achieved. This led to a certain 
population of scFv-Fc not carrying a Cy5 dye and therefore resulting in the 
use of a higher dose of optical tracer [281]. Another explanation for a higher 
dose of the optical tracer could be due to variable tissue attenuation of the 
fluorescent signal [280].  
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Surprisingly, despite the administration of oestrogen pellets, the MCF-7 
tumours did not grow as quickly as expected, and therefore did not reach the 
size of the HCC1954 tumours. Although it was clear that the uptake of the 
radiolabelled scFv-Fc was low in MCF-7, it would have been better to 
compare the positive and negative tumours of a similar size. Additionally, 
one can recommend the use of a c-Met knockdown HCC1954 cell line as a 
c-Met negative tumour in our xenografts. This cell line is currently being 
developed in our laboratory. 
It would have been informative to identify the biological half-life of the scFv-
Fc by performing a longer timepoint experiment which would require extra 
SPECT scans at 48 and 72 hours. It would also be informative to perform an 
ex-vivo biodistribution study at various timepoints, alongside the timepoints 
selected for the SPECT imaging.  
Additionally, future studies would require the injection of the radiolabelled 
scFv-Fc into a naïve mouse to assess its pharmacokinetics. It would also be 
useful to assess the trajectory of free In-111 in a tumour bearing mouse to 
assess potential non-specific binding sites.  
Future studies include the identification of the values for the binding affinity 
(Kd) for the In-111 labelled scFv-Fc via ELISA for example. Additionally, it 
would be important to assess any possible off-target effects in-vitro and in-
vivo. Future research also includes the mutation of the Fc constant in order 
to decrease the half-life of the scFv-Fc in serum. This type of mutation has 
already been performed before by Kenanova et al, who modulated the half-
life of carcinoembryonic antigen (CEA) scFv-Fc by mutating their Fc-FcRn 
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binding site. Five mutants were engineered and biodistribution studies 
revealed the half-life in the mutants to range from 83.4 to 7.96 hours, while 
the wild types displayed a half-life of 12 days. The mutant with the shorter 
half-life demonstrated a rapid tumour targeting and a better signal:noise 
ratio, in comparison to the other mutants and wild type [202, 282]. 
The high uptake of the 111In-CHX-A‟‟DTPA-scFv-Fc in the bone, spleen and 
liver was also observed in another study, in which the tracer was labelled 
with indium-111 [265] 
These findings derived from the use of 111In-CHX-A‟‟DTPA-scFv-Fc against 
human c-Met in a basal-like breast cancer model using SPECT imaging are 
promising. Compared with traditional biopsy and immunohistochemistry, 
antibody-fragment-based Single Photon Emission Computed Tomography 
offers a unique opportunity to assess the in-vivo expression levels of various 
biomarkers. Importantly, c-Met molecular imaging in basal-like breast cancer 
patients will enable a more personalised treatment strategy for each patient. 
The existence of a highly specific and selective tracer, with a favourable rate 
of clearance will have a favourable impact on the management of patients 
through the use of SPECT and PET imaging modalities. These types of 
imaging agents could be used to monitor a patient‟s response to neoadjuvant 
chemotherapy or anti-c-Met therapies in basal-like breast cancer as it 









Chapter 6: Effect of PTPN11 
knockdown in EGFR and c-Met 
phosphorylations in basal-like 
breast cancer 
 
6.1 Introductory section: 
 
Over the past decades, much effort was devoted into developing effective 
and safe tyrosine kinase inhibitors (TKIs). In particular, TKIs against EGFR 
and c-Met have been designed to target basal like breast cancer [56, 283]. 
Indeed, cetuximab, an epidermal growth factor receptor (EGFR) inhibitor has 
been tested in 102 patients with stage IV TNBC. They were given cetuximab 
and carboplatin on a weekly basis. Despite the combination being well 
tolerated, it produced a response in fewer than 20% of patients. Biopsies 
revealed that most TNBcs had EGFR activation after treatment which implies 
the existence of alternate mechanisms that do not depend on ligand-
dependent EGFR-mediated activation [17]. 
A recent study has shown that Met amplification was responsible for 
acquired resistance to first-generation EGFR TK inhibitors in up to 20% of 
EGFR-mutant NSCLCs [284]. Another study also revealed that MET 
amplification is causative for the acquired resistance to anti-EGFR 
monoclonal antibodies cetuximab and panitumumab in metastatic colorectal 
cancers [25]. Lately, a preclinical study was conducted to investigate the 
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efficacy of targeting c-Met in overcoming resistance to EGFR therapy in 
TNBC cell lines. They successfully demonstrated the efficacy of a 
combination of EGFR and c-Met inhibitors in TNBC cell lines that have 
functionally active ligand-receptor-downstream signaling pathways [285]. 
De-regulation of EGFR and/or c-Met expression or signaling has been 
implicated in cancer progression [69, 90]. The dysregulated expression of 
upstream receptors and kinases can result in the activation of the 
Ras/Raf/MEK/ERK, Ras/PI3K/PTEN/Akt/mTOR and other signaling 
pathways. These can contribute to malignant transformation [286]. 
Approximately 30% of breast cancers over express EGFR and this correlates 
with poor prognosis [287, 288] and over half of the cases of triple-negative 
breast cancer (TNBC) overexpress EGFR [289], which is higher than the 
rates observed in other breast cancer subtypes [31].   
The EGFR signalling pathway is mentioned in greater detail in the 
introduction of this thesis (section 1.3.3). Greater focus will be given on the 
Tyr 1173 phosphorylation site of EGFR in this chapter, which is a site for 
EGFR autophosphorylation [290]. Upon EGF stimulation, phospho-Tyr 1173 
binds to the cytosolic signalling molecules SHC and Grb2 which leads to 
ERK activation [291, 292] through the EGFR–SHC–Grb2–SOS–RAS–RAF–
MEK–ERK pathway (SOS, son of sevenless) [293]. Phospho-Tyr 1173 also 
is the main binding site for SHP1, which results in the reduction of EGFR-
dependent ERK activation [294]. Hochgrafe et al showed that EGFR Y1173 
phosphorylation is significantly higher in the basal-like breast cancer in 
comparison to other subtypes of breast cancer [69].  
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c-Met, a receptor that binds to its ligand HGF, also named as scatter factor, 
is overexpressed and upregulated in the basal like breast cancer cell lines 
[69-73]. c-Met has the ability to promote breast cancer motility, invasion, 
metastasis and in-vivo tumourigenesis [235]. A strong link between c-Met 
overexpression and poor survival in BC patients, and more particularly 
TNBCs exists [75]. c-Met inhibitors are being developed and discussed in 
more details in section 1.2.2 of this thesis. A recent study conducted by 
Watermann et al showed the detection of c-Met phosphorylation at 
Y1234/1235 in 14% of the investigated NSCLC tumour samples [295]. 
Another study conducted by Hochgräfe et al demonstrated an increased c-
Met phosphorylation in the basal-like subtype in comparison with other 
breast cancer subtypes [69]. The tyrosine residues Y1234 and Y1235 get 
transphosphorylated, following HGF binding to the extracellular portion of c-
Met, which in turn leads to the transphosphorylation of another two tyrosine 
residues Y1349 and Y1356, located in the C-terminal region. The latter 
create a multisubstrate docking site which would bind to numerous 
substrates (e.g. Grb2, Gab1) enabling the activation of a wide range of 
signalling pathways [296]. These include the MAPK cascade pathway, via 
Gab1-Shp2-Ras [58, 297], Grb2-SOS-Ras [298] or SHC-Grb2-SOS-Ras 
[299], the PI3K pathway and the activation of STAT3 [296] which modulate 
motility, migration, cellular proliferation, invasion and tubulogenesis [56, 60].  
EGFR deregulation observed in many cancers, including basal like breast 
cancer can be a by-effect of other oncogenes. Here, in this chapter, we will 
be focusing on the phosphatase PTPN11. It has been shown that PTPN11 
231 
 
regulates RTK expression and signalling in BTBC, which suggests its 
potential involvement for targeted therapy in BTBC [300]. Additionally, recent 
reports suggest PTPN11 plays a role as an EGFR regulator, by promoting 
Ras activation through blocking the Ras GTPase-activating protein 
(RasGAP)-induced downregulation of Ras, via dephosphorylation of the 
docking site Tyr992 on the EGFR [143]. Additionally, the SH2 domain-
containing phosphatases Shp1 (PTPN6) and Shp2 (PTPN11) are recruited to 
activated EGFR and promote its dephosphorylation in a negative feedback 
loop [301]. Reports show an upregulation for PTPN11‟s expression in breast 
cancer [302] and a positive role in breast cancer cell transformation [140]. 
In this project, siRNA and shRNA-based inhibition studies will be conducted 
in order to show the importance of PTPN11 in BLBC and its relation to c-Met 
and EGFR‟s phosphorylation status, expression level and cellular 
proliferation rates. 
Lastly, due to the aggressive nature of BLBC, and the ability for EGFR to 
promote epithelial-mesenchymal transition (EMT) by the activation of ERK 
and the induction of an EMT transcription factor, ZEB1 [293], the level of 
expression for the EMT marker e-cadherin [303, 304] will be assessed in the 
control and PTPN11-silenced cells in this project. EMT is the morphologic 
switch from a polarised epithelial phenotype to a mesenchymal fibroblastoid 
phenotype [305]. EMT plays a vital part in tumour progression [306]. E-
cadherin, a 120 kDa glycoprotein, is required for the maintenance of stable 
junctions. Indeed, in epithelial cells, early contacts are mediated by e-
cadherin molecules that cluster into small junctional complexes which then 
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expand to establish stable adherens junctions, forming desmosomes [307]. 
The loss of e-cadherin increases tumour cell invasion and migration. The 
expression of e-cadherin is also inversely correlated with tumour grade and 





6.2.1 PTPN11 is an EGFR regulator 
 
 
Figure 6-1. Protein Interaction Network Analysis of proteins that 
interact with EGFR. 
  The selection of a 533 gene based siRNA screen was taken from the interaction of 
seed proteins (including EGFR, triangular shaped) to other proteins that were 
reported as having a binary interaction with the seed proteins up to the second 
neighbour. The selection of seed proteins was based on their importance in 
processes related to cancer cell migration, proliferation and stemness. A hit is a 
protein whose knockdown abolishes EGF-dependent increase in EGFR activity or 
causes a constitutively activated baseline. Cytoscape was used to visualise those 
14 seed proteins (shown as red triangular nodes) that can be 'non-hit' (nodes 
outlined in black) and connected to 'hit' proteins (nodes outlined in red). Red edges 
represent protein-protein interaction between a 'hit' protein and another protein 
(which could either be a „hit‟ or a „non-hit‟). Black edges connect two 'non-hits'.  
HPRD database enabled to identify all the proteins with a binary-binary interaction 
with the seed proteins, as explained in Section 1.3.5.  Please see for a more 
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detailed description of the bioinformatics basis of this in-house network-based 
siRNA screen design [116, 117]. 
A siRNA library that consisted of 533 genes interconnected with EGFR was 
used to identify proteins affecting the EGFR signalling pathway. In this 
screen, a sensor was used to conduct this high-content FLIM screen. The 
screen was performed by Anthony Cheung (a former student of Professor 
Ng).  Briefly, EGFR catalytic activity in cells was measured by using a FRET 
biosensor known as Picchu (Phosphorylation Indicator of Crk Chimeric Unit) 
[309]. The Picchu biosensor has been modified in our laboratory to express 
mRFP1 and eGFP fluorescent proteins to make it suitable for FRET 
quantification by Fluorescence Lifetime Imaging Microscopy (Picchu-FLIM, 
similar to our previously published Raichu-FLIM [116, 310, 311]).   
Each protein knockdown was compared to the readout provided by its 
respective control. Using appropriate statistical tests, those proteins were 
either classified as „hits‟ (whose knockdown abolish EGF-dependent 
increase in EGFR activity or constitutively activated baseline) or non-hits. 
Figure 6-1 displays the interaction found between the „hits‟ or between 
protein seeds (regardless of them being a hit) and  hits, identified after the 
screening of 320 proteins. „Non-hits‟ seed proteins (triangles outlined in 
black) were also included. The interactions observed between the nodes, via 
an edge, were established based upon literature search. These interactions 
can be either direct (observed via a Yeast 2 hybrid for example) or indirect 
(observed via SILAC)  [145].  
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PTPN11, a phosphatase, was identified as a „hit‟ (figure 6-1) from this siRNA 
screen, implying that PTPN11 has an effect on EGFR signalling. Despite a 
previous study suggesting PTPN11‟s potential interaction with EGFR [145], it 
is the first time that we observe this interaction in the basal-like breast cancer 
cells, HCC1954.  
 
Figure 6-2. (A) Plot summarizing differences in the Pearson correlation 
coefficients (r) obtained from lifetime–intensity data for EGF-treated 
and non-treated cells for each of the indicated siRNA experimental 
groups. 
Pearson correlation coefficients and associated confidence intervals were obtained 
to assess correlation between intensity and tau for each siRNA group both with and 
without EGF stimulation. To determine the effects of EGF treatment on biosensor 
activity for a given siRNA experimental group, the difference between r values 
obtained for tau vs. intensity data in EGF-treated and -untreated subgroups was 
computed (filled circles). Fisher‟s r-to-z transformation statistics was used to 
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estimate confidence intervals (bars) for the differences in r. (B) Fluorescence 
lifetime–intensity scatter plots and associated regression analysis of four example 
siRNA experimental groups where cells were treated with or without EGF. Each 
data point represents a single cell and shows the mean fluorescence lifetime plotted 
against the mean fluorescence intensity for that cell. Pearson correlation coefficients 
were obtained to assess the association between lifetime and intensity for the EGF-
treated (red) and non-treated (black) subgroups, and the difference in the resultant r 
values then used to evaluate the effects of target protein knockdown on EGFR 
activity (as summarized in B).  
The Picchu-X sensor was a direct target for EGFR kinase activity and was 
used to assess the FRET efficiency (explained in more details in Section 
1.3.5) changes upon stimulations with EGF. In order to assess whether the 
knockdown of a protein had an effect on EGFR, FRET-FLIM imaging of 
Picchu-X sensor in individual basal-like breast cancer cells, transfected with 
a specific siRNA, was used to  study the regulation of EGFR activity on a 
single cell level. Once the FLIM acquisition was performed, the fluorescence 
lifetime was calculated and as expected, EGF had a significant effect on tau 
in cells transfected with non-targeted siRNA (Figure 6-2A). However, Figure 
6-2B does not show a change in the FRET efficiency independently of the 
effect of intensity (which can cause intermolecular quenching; which is 
different from EGF-dependent fluorescence lifetime quenching of the eGFP 
donor fluorophore, owing to an intramolecular association between the 
phosphorylated residue on the Crk-based sensor and the SH2 domain, 
bringing the eGFP and mRFP1 of the sensor to closer proximity), after EGF 
stimulation in cells that were transfected with siPTPN11. Therefore the 
knockdown of PTPN11 abolished the EGF-induced activation of EGFR 
(Cheung et al, publication under submission).  
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Prior to investigating the effect of PTPN11 knockdown on the HCC1954 
basal-like breast cancer cells, it was necessary to determine the optimal 
timepoint for the EGF and HGF stimulation in those cells, as those ligands 
will be used to investigate the EGFR and c-Met signalling pathways in this 
project.   




Figure 6-3. Optimisation of EGF and HGF stimulation in HCC1954 cells. 
 (A) Immunoblot displaying the expression level for total and phosphorylated EGFR 
at their basal level and after EGF (100ng/ml) or HGF (50ng/ml) stimulation from 0 to 
4 hours. (B) Analysis of western blot data via densitometry for total and 
phosphorylated EGFR level after EGF stimulation (C) and after HGF stimulation 
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from 0 to 4 hours. Red line represents the phosphorylated EGFR expression level 
while the blue line represents the total EGFR expression level.  
Figure 6-3 (A&B) shows a sharp increase in phosphorylated EGFR from 0 to 
5 minutes after EGF stimulation, with a 38 fold increase in comparison to 
basal level, followed by a slower increase from 5 to 10 minutes after 
stimulation and another sharp increase from 10 to 30 minutes, at which point 
it reached its peak (94 fold increase to basal level). It was then followed by a 
small decline in the amount of phosphorylated EGFR from 30 to 60 min 
which was then followed by a sharp decrease up to 4 hours after stimulation. 
At 4 hours post EGF stimulation, the amount of phosphorylated EGFR was 
17 fold higher than the basal level, but dramatically lower than the levels 
observed at 30 and 60 minutes after EGF stimulation. It was also interesting 
to observe the slight but noticeable increase (5 fold higher than what was 
observed at basal level) in phosphorylated EGFR 10 minutes after HGF 
ligand stimulation in the HCC1954 cells (Figure 6-3 C). This was then 
followed by a steady decrease in the expression level of phosphorylated 
EGFR which then reached „basal‟ level 4 hours after HFG stimulation. 
The expression level for total EGFR did not fluctuate as much as the 
expression level for phosphorylated EGFR after EGF stimulation, which was 
expected (Fig 6-3B), although some small increase was observed 60 
minutes after EGF stimulation. Additionally, the level of expression for total 
EGFR after HGF stimulation was rather consistent across all timepoints, 
albeit a very small increase at 5 minutes which remained relatively constant 
up to 60 minutes after HGF stimulation (Fig 6-3C). 
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It was possible to identify 30 minutes as the optimal timepoint for EGF 
stimulation for EGFR phosphorylation. On the other hand, despite the 
increase in EGFR phosphorylation after HGF stimulation at 60 minutes, the 
increase was very slight if we were to compare to the expression level 
observed between 10 to 60 minutes after HGF stimulation. This implied that 
the optimal timepoint for HGF stimulation to assess EGFR phosphorylation 
can be between 10 to 60 minutes (Fig 6-3). 
Following the identification of the optimal timepoints for EGF ligand, the next 
step was to investigate the effect of PTPN11 knockdown on EGFR 
phosphorylation in our cell line of interest.  
6.2.3 EGFR hyperphosphorylation in PTPN11-silenced cells 
 
 
Figure 6-4. EGFR hyperphosphorylation following EGF stimulation in 




 (A) Immunoblotting displaying the expression level of total EGFR and 
phosphorylated EGFR before and after 30 minutes of EGF stimulation in control vs 
PTPN11-silenced cells. A clear knockdown for PTPN11 is observed in the PTPN11-
silenced cells, through a transient transfection using a siRNA smart pool against 
PTPN11. (B) Analysis of western blot data via densitometry for EGFR 
phosphorylation in both the controls and PTPN11-silenced cells before and after 
EGF stimulation. Data are the mean values ± S.E.M., over 3 independent 
experiments; *= P < 0.05.  
Figure 6-4 shows a clear increase in EGFR phosphorylation in the PTPN11-
silenced cells. There is a significant (P < 0.5) and a 3 fold increase in the 
phosphorylation of EGFR in the EGF-stimulated PTPN11-silenced cells in 
comparison to the EGF-stimulated control cells. There was an obvious 
difference in EGFR phosphorylation between the unstimulated cells and the 
EGF-stimulated cells in both the controls and the PTPN11-silenced cells, 
however, the difference was significant in the PTPN11 knockdown cells. 
Another observation extracted from this figure was that the basal level of 
phosphorylated EGFR in both the controls and the PTPN11 knockdown cell 
line was very similar (Figure 6-4B).  
Since we observed a clear hyperphosphorylation of EGFR in the PTPN11 
silenced cells 30 minutes after EGF stimulation, we were interested in 
assessing EGFR phosphorylation for a longer period of time (which was up 






6.2.4 Defect in EGFR dephosphorylation in PTPN11-silenced cells 
 
 
Figure 6-5. Defect in EGFR dephosphorylation in PTPN11-silenced cells 
in comparison to the control basal-like breast cancer cells. 
 (A&B) Immunoblot to assess EGFR phosphorylation status in the control cells 
versus the PTPN11-silenced cells (siRNA for panel A and stable transfection for 
panel B) over the course of 60 minutes after EGF stimulation. Level of total EGFR 
and phosphorylated EGFR were probed. PTPN11 was successfully knockdown in 
the PTPN11-silenced cells. Tubulin shows even loading across the lysates. (C) 
Analysis of western blot data via densitometry for EGFR phosphorylation at 2, 30 
and 60 minutes after EGF stimulation in the control and PTPN11-silenced cells. 
Data are the mean values ± S.E.M., over 2 independent experiments. 
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In Figure 6-5, we assessed EGFR phosphorylation up to 1 hour after EGF 
stimulation in both the control and PTPN11 silenced cells. As observed, 
there was an obvious hyperphosphorylation of EGFR 2 minutes after EGF 
stimulation in the PTPN11 silenced cells, which was 2 fold higher in 
comparison to the control cells at the same timepoint. The level of 
phosphorylated EGFR, in the PTPN11-silenced cells, remained the same 30 
minutes after EGF stimulation and showed a 70% increase 60 minutes after 
EGF stimulation in comparison to the level displayed at 30 minutes in the 
PTPN11 silenced cells.  On the other hand, the control cells showed a peak 
in EGFR phosphorylation 2 minutes after EGF stimulation, which was then 
reduced to basal level at 30 minutes post EGF stimulation and a very slight 
increase at 60 minutes after EGF stimulation. 
In comparison to the control cells, the PTPN11 silenced cells displayed an 
EGFR hyperphosphorylation that was 4 fold higher at 30 minutes and 60 
minutes after EGF stimulation in comparison to the control cells at those 
timepoints (Fig 6-5). 
Lastly, this figure suggested a defect in EGFR dephosphorylation, as it took 
longer for EGFR to be dephosphorylated in the PTPN11 silenced cells in 
comparison to the control cells. 
Since high levels of EGFR had been associated with aggressive biological 
behaviour and adverse clinical outcome (PMID: 9625170), we found it 
necessary to assess the expression level of total EGFR in the PTPN11-




Figure 6-6. Expression level for total EGFR in the controls and PTPN11 
silenced cells before and up to 60 minutes after EGF stimulation. 
 (A) Confocal sections of basal-like breast cancer cells (with transient transfection) 
stained for total EGFR (red) and DAPI (blue). Cells were starved overnight, 
stimulated or not with EGF ligand. Scalebar: 20µm (B) Immunoblot to assess the 
expression level for total EGFR in the control cells versus the PTPN11-silenced 
cells over the course of 60 minutes after EGF stimulation. Tubulin shows even 
loading across the lysates. (C) Analysis of western blot data via densitometry for 
total EGFR level across after EGF stimulation. Data are the mean values ± S.E.M., 
over 3 independent experiments. 
 
 We used cells that were transiently transfected with siEGFR to confirm the 
specificity of the staining for total EGFR (Fig 6-6A – top image). As expected, 
anti-EGFR did not stain cells that were transiently knockdown for EGFR. We 
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observed a clear cytoplasmic and membranous staining for total EGFR in the 
control cells, before and after EGF stimulation. We also observed a 
cytoplasmic and a more distinct membranous staining in the PTPN11-
silenced cells (Fig 6-6A). In the control cells, we observed a 21% increase in 
the level of expression for total EGFR two minutes after EGF stimulation in 
comparison to its basal level and this is followed by a 19% increase (in 
comparison to previous timepoint) at 30 minutes after EGF stimulation before 
another slight increase at 60 minutes after EGF stimulation. On the other 
hand, a major reduction (42% decrease) in the total EGFR expression level 
in the PTPN11-silenced cells occurred two minutes after EGF stimulation (in 
comparison to its basal level) which was then followed by a sharp increase in 
the total EGFR expression level at 30 minutes (16% increase in comparison 
to the previous timepoint) after EGF simulation over time and a slight 
increase at 60 minutes after EGF stimulation (an additional 5% increase in 
comparison to the total EGFR expression level at 30 min post EGF 
stimulation). It was also interesting to see a higher basal level for total EGFR 
in the PTPN11-silenced cells in comparison to control cells.  
In addition to assessing the effect of PTPN11 silencing on the EGFR 
signalling pathway, we also wanted to assess the effect of PTPN11 
knockdown on the c-Met/HGF axis due to the potential synergy between both 
pathways observed in many reports [312]. We were interested to investigate 
and compare c-Met phosphorylation in the PTPN11-silenced cells in 
comparison to the control cells.  
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6.2.5 c-Met hyperphosphorylation in PTPN11-silenced cells 
 
 
Figure 6-7. c-Met hyperphosphorylation in PTPN11-silenced cells 
 (A) Fluorescent staining for nucleus (top) and phosphorylated c-Met (bottom) in 
control cells and PTPN11-silenced cells before and after EGF stimulation. Scalebar: 
60µm (B) Immunoblot assessing the expression level of phosphorylated c-Met and 
total c-Met in the control and PTPN11-KD cells. Tubulin was used as a loading 
control. (C) Analysis of western blot data via densitometry for c-Met phosphorylation 
in both the control and PTPN11-KD cell lines, before and after EGF stimulation. 
Data are the mean values ± S.E.M., over 3 independent experiments; *= P < 0.05.  
Figure 6-7A provides evidence for c-Met hyperphosphorylation in the 
PTPN11-silenced cells. Indeed, the immunofluorescence staining clearly 
shows a stronger intensity staining for phosphorylated c-Met in the PTPN11-
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silenced cells in comparison to the control cells with and without EGF 
stimulation. This is also observed by Western Blot in Figure 6-7B, where 
there is a clear increase in c-Met phosphorylation in the PTPN11 silenced 
cells. Quantifying the bands from the western blot showed a 8 fold increase 
in phosphorylated c-Met in the unstimulated PTPN11 knockdown cells in 
comparison to the unstimulated control cells. This difference was significant 
(P < 0.05). We observed an increase in the expression level for 
phosphorylated c-Met in the EGF-stimulated control cells in comparison to 
the unstimulated control cells, although statistically non-significant. We also 
observed a greater increase in c-Met phosphorylation in the EGF-stimulated 
PTPN11 knockdown cells in comparison to the EGF-stimulated control cells, 
which was not statistically significant. Finally, we observed a rather similar 
expression level for phosphorylated EGFR in the EGF-stimulated and 
unstimulated PTPN11-silenced cells. 
Similarly to the way total EGFR expression level was assessed in the control 
and PTPN11-silenced cells (with and without EGF stimulation), we thought it 
useful to assess the level of total c-Met in those sets of cell lines as the 
overexpression of c-MET was shown to contribute to the development of an 




6.2.6 Total c-Met level increased in PTPN11 knockdown cells 
 
Figure 6-8. Increase in total c-Met in PTPN11-silenced cells after EGF 
stimulation. 
 (A) Confocal section of control and PTPN11KD basal-like breast cancer cells 
stained for total c-Met (red) and nucleus (blue) before and after EGF stimulation (30 
minutes). A clear increase in the amount of total c-Met in the PTPN11 knockdown 
cells following EGF stimulation. (B) Immunoblot to assess level of expression of 
total c-Met in the control and knockdown cells before and after EGF stimulation. 
Scalebar: 50µm (C) Analysis of western blot data via densitometry which were 
normalized to Tubulin, used as a loading control for the level of total c-Met. Data are 




Figure 6-8A shows an increase in the total c-Met expression level in the 
EGF-stimulated PTPN11 silenced cells in comparison to the stimulated and 
unstimulated controls cells and the unstimulated PTPN11 silenced cells. The 
images also display a clear membranous staining for total c-Met in all cells. 
An increase in cytoplasmic staining for total c-Met is demonstrated in the 
EGF-stimulated PTPN11-silenced cells. Figure 6-8B displays bands for the 
expression level of total c-Met in the control and PTPN11 knockdown cells 
before and after EGF stimulation. It is clear that the level of total c-Met is 
upregulated in the EGF-stimulated PTPN11 knockdown cells, and displays a 
1.5 fold increase in comparison to the non-stimulated PTPN11 cells, however 
this was not significant statistically (P = 0.06). Figure 6-8C displays a small 
increase in the total c-Met expression level in the EGF-stimulated control 
cells in comparison to the unstimulated control cells. However, there is a 
more obvious increase in the EGF-stimulated PTPN11 silenced cells in 
comparison to the unstimulated ones.  
Previous reports have shown that the increased expression of EGFRs and c-
Met are key to enhancing both tumour cell replication and metastasis [90]. In 
order to assess whether the increase in EGFR and c-Met phosphorylation 
observed in the PTPN11-silenced cells is accompanied with a change in the 





6.2.7 Decrease in growth rate of PTPN11-silenced cells in 
comparison to control cells, when both were treated with the 






Figure 6-9. Cell growth rate for control and PTPN11-silenced basal like 
breast cancer cell lines. 
Cells were grown over 4 days, after which they were incubated in Alarmar Blue 
solution for four hours prior to measurement. The fluorescence was measured using 
a plate reader and normalised relative to the fluorescence emitted from the RPMI 
media incubated with the Alarmar Blue solution, as described in Material & 
Methods. (A) Cell proliferation for control and PTPN11-silenced cells, with and 
without SGX-523 treatment (c-Met inhibitor) (B) Cell proliferation in both sets of cell 
lines stimulated with HGF ligand. (C) k values calculated to determine growth rates.  
Data are mean values ± S.E.M., over 4 independent experiments. 
 
Three sets of cell lines were seeded at the same time and stimulated with 
HGF (at a concentration of 50ng/ml) or treated with SGX-523 (a c-Met 
inhibitor at 5µM) in both the control and PTPN11-silenced cells to assess 
potential differences in their growth rates. Figure 6-9A displays the amount of 
fluorescence emitted from day 1 to day 4 after seeding of the control cells, 
control cells with the addition of SGX-523, PTPN11-silenced cells, and finally 
PTPN11-silenced cells with the addition of SGX-523. The growth curves for 
both the untreated and treated control cells look very similar. Additionally, we 
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do not observe any major difference between the growth curves of the 
untreated PTPN11-silenced cells and the treated cells. However, the growth 
curves for the untreated control cells seem to be higher than the PTPN11-
silenced cells. We observe a similar shift when both cell lines are treated with 
SGX-523.  Figure 6-9B also displays a similar shift in the growth curves of 
the control and PTPN11 silenced cells when stimulated with HGF. Due to the 
observed shifts, the K values for those growth curves were calculated to 
assess potential difference in the growth rate between cell lines (Fig 6-9C). 
Despite the visible difference in the growth curves in those sets of cell lines, 
the calculated K values show that the growth rates for the non-stimulated 
control and PTPN11 silenced cell lines are the same, as well as when they 
were both stimulated with the HGF ligand. However, there is a decrease in 
the growth rate for both the control and PTPN11 knockdown cell lines when 
treated with SGX-523, in comparison to the HGF-stimulated and non-
stimulated cell lines. This decrease is not statistically significant. Additionally, 
we also observe a decrease, which is not statistically significant, in the 
growth rate of the PTPN11 knockdown cells treated with the c-Met inhibitor in 
comparison to the control cells that also were treated with the c-Met inhibitor.  
As downregulation of E-cadherin is a hallmark of EMT, we next assess the 






6.2.8 Increase in e-cadherin level in PTPN11-silenced cells 
 
 
Figure 6-10. Increase in e-cadherin in PTPN11-silenced cells in 
comparison to control. 
 (A) Confocal sections of PTPN11-KD and control cells stained for e-cadherin (grey) 
and DAPI (blue)  (B)  Analysis of fluorescent staining for e-cadherin via mean 
intensity per area, using „NIS Element‟ software in both sets of cell lines (C) 
Immunoblotting for the protein expression level of e-cadherin  in both control and 
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PTPN11-KD cells. (A-C) Data are mean values ± S.E.M., over 3 independent 
experiments. Scalebar: 50µm 
To confirm a change in the e-cadherin expression level in the control and 
PTPN11-silenced cells, both confocal sections were stained with e-cadherin 
and a western blot were conducted. As shown in Fig 6-10, there is a clear 
increase in the intensity of the staining for e-cadherin in the PTPN11 
knockdown cells (Fig 6-10A&B). As expected, the staining for e-cadherin is 
localised at the membranes and at the cell junctions. Figure 6-10C 
demonstrates the increase in the expression level of e-cadherin in the 
PTPN11 knockdown cells in comparison to the control cells, which display a 












This chapter investigated the effect of PTPN11 silencing on c-Met‟s and 
EGFR‟s phosphorylation status, expression level, proliferation rates and 
metastatic property, in basal-like breast cancer cells.  
PTPN11, a phosphatase, was identified as a „hit‟ from the high content 
siRNA screen, which consisted of 533 genes interconnected with EGFR. The 
knockdown of PTPN11 abolished the EGF-induced activation of EGFR, 
suggesting that PTPN11 had a potential effect on EGFR signalling. Despite 
the fact that PTPN11 was previously reported as an EGFR regulator [300], it 
is the first time that this interaction has been observed in the basal-like 
breast cancer cells, HCC1954. 
It was important to identify the optimal timepoint for EGF stimulation to 
compare the EGFR phosphorylation in the PTPN11-deficient cells and in the 
control cells. The optimal timepoint was identified as 30 minutes after EGF 
stimulation. 
One of the main findings of this study was the significant increase in the 
phosphorylation of EGFR at Tyrosine 1173 in the EGF-stimulated PTPN11-
silenced cells in comparison to the EGF-stimulated control cells. Studies 
have demonstrated the ability of PTPN11 to mediate the dephosphorylation 
of EGFR in COS-1 and NIH3T3 cells and have suggested this role to be 
translated in breast cancer cells [143]. However, many recent reports also 
revealed the major pro-oncogenic role that PTPN11 has in human 
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malignancies, including in breast cancer [314]. PTPN11 translates growth 
and survival signals from multiple RTK to mediate Erk1/Erk2 and the Akt 
pathway [314]. Additionally, previous reports gave phospho-Tyr 1173 two 
conflicting roles in EGFR signalling and specified that Tyr 1173 
phosphorylation may cooperate with phospho-Tyr 992, Tyr 1068, Tyr 1086 
and Tyr 1148 to promote ERK signalling through recruitment of SHC and 
Grb2, or may work alone to diminish ERK activation through SHP1 binding 
[290]. In agreement with the literature, it is possible that the 
hyperphosphorylation of EGFR in the PTPN11-silenced cells, detected in our 
study, might lead onto the attenuation of ERK activation, to satisfy the 
oncogenic role that PTPN11 have displayed in previous reports.   
This EGFR hyperphosphorylation was further investigated by conducting a 
timecourse EGF stimulation experiment which resulted in the identification of 
a possible defect in EGFR dephosphorylation in the PTPN11-silenced cells.  
The EGFR phosphorylation was constantly higher in the PTPN11-silenced 
cells than in the control cells which lasted up to 60 minutes after EGF 
stimulation. Although recent studies reported that dephosphorylation 
precedes degradation under normal conditions [315], it is unclear as to 
whether this order needs to be maintained. Speculations could be that the 
EGFR may be targeted for degradation even if the receptor remains 
phosphorylated for an abnormally long time after EGF stimulation in 
PTPN11−/− cells. This could be made possible if other phosphatases 
substitute for this role of PTPN11 [316]. In addition to this, we must bear in 
256 
 
mind that other RTK-inactivating mechanism could help compensate for the 
absence of PTPN11 [317]. 
It was also interesting to see, within this same timecourse for EGF 
stimulation, a major reduction in the expression level for total EGFR in the 
PTPN11-silenced cells in comparison to the control cells 2 minutes after EGF 
stimulation. We also observed a slightly lower expression level for total 
EGFR at 30min and 60min post EGF stimulation in the PTPN11-silenced 
cells in comparison to the control cells. This might suggest that there is a 
higher turnover and/or recycling rate for EGFR in the control cells than in the 
PTPN11-deficient cells or could also suggest a higher degradation rate for 
EGFR in the PTPN11-deficient cells, as suggested previously [300].  
Due to the effect observed in the EGFR phosphorylation in the PTPN11-
silenced cells, we hypothesized that PTPN11 deficiency in basal-like breast 
cancer cells might have an effect in c-Met phosphorylation due to EGFR and 
c-Met well documented cross-talk [90]. This project identified a significant 
increase in c-Met phosphorylation in the PTPN11-silenced cells in 
comparison to the control cells. Previous findings have demonstrated the 
increased levels of c-Met phosphorylation in PTP1B-null mice that were 
injected with 15 nm HGF via the hepatic portal vein [318]. However, in our 
study, this hyperphosphorylation was ligand-independent. It is possible that 
c-Met in those PTPN11-silenced cells, was transactivated with other 
receptors (e.g members of the family of semaphorin receptors), to bypass 
the need for a ligand-dependent activation [319].To confirm such statement, 
the identification of such receptors would be necessary in an 
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immunoprecipitation experiment. Besides, c-Met hyperphosphorylation was 
also observed in melanocytes whose tumour suppressor gene, Plexin 1B, 
was knockdown. It also displayed lower levels for PTPN11 accompanied by 
a decrease in cell proliferation and an abrogation for c-Met dependent 
activation of Erk1/Erk2 and Akt in melanocytes [320].  
Additionally, in this study, we detected a potential increase in total c-Met 
expression level in the EGF-stimulated  PTPN11-silenced cells. EGFR might 
be causative for this increase as it was not observed in the unstimulated 
cells. This is consistent with the finding from Xu et al, in which they showed 
that activated EGFR enhanced c-Met levels [321]. Besides, the higher 
expression level for total c-Met might suggest a defect in the removal of c-
Met from the cell surface and subsequent degradation through endocytosis 
which could lead to sustained oncogenic signalling [90]. 
To further elucidate the role of PTPN11 knockdown, we wanted to 
investigate its effect on cell proliferation. We identified a slight decrease in 
the growth rate of the PTPN11 knockdown cell lines when treated with the c-
Met inhibitor, in comparison to the controls that were also treated with the c-
Met inhibitor. This difference was not statistically significant but this might be 
due to the low sample size. If this decrease is real, this suggests that c-Met 
inhibitors might be more efficient in reducing proliferation in basal like breast 
cancer cells that are depleted of PTPN11. Previous studies have reported a 
major reduction in cell proliferation (3-4 fold) in the PTPN11-silenced basal-
like breast cancer cells in comparison to the EGFR-silenced cells (1.5 fold). 
In addition, they assessed the formation of colonies in the PTPN11 and 
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EGFR-silenced cells and discovered that the PTPN11-silenced cells formed 
fewer and smaller colonies than the EGFR-silenced cells, suggesting that the 
inhibition of PTPN11 had a greater impact on supressing cell transformation 
than EGFR inhibition [300].  
Finally, it was interesting to see an increase in the intensity of the staining 
and expression level for e-cadherin in the PTPN11 knockdown cells. This is 
in line with a study performed by Zhao et al, which demonstrated the 
restoration of epithelial morphology in PTPN11-silenced MDA-MB231 cells, 
which are basal-like, while the control and parental cell line exhibited a 
spindle shaped mesenchymal morphology [322]. This reinforced the idea of 
PTPN11‟s migratory role in BTBC cells [322]. 
It is surprising to identify a high phosphorylated c-Met along with an increase 
in e-cadherin expression in the PTPN11-silenced cells. Both phenotypes 
contradict each other. It is well documented that c-Met is involved in the cell 
proliferative and motility in cancer cells [323] and should therefore be 
accompanied with a reduced e-cadherin expression [323]. If time permitted, it 
would have been useful to investigate further the migratory properties of 
PTPN11-silenced cells by performing a wound-healing assay. It would have 
also been informative to modulate c-Met phosphorylation, by using the c-Met 
inhibitor sgx-523 in the PTPN11-silenced cells and perform a scratch assay 
on those cells and compare it with the ones whose c-Met remains activated.  
We could speculate that c-Met phosphorylation in those PTPN11-silenced 
cells does not have an effect on the downstream signalling pathways that 
regulates cell proliferation due to a defect in the activation of those pathways. 
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This is in line with the study conducted by Soong et al, et in which they show 
that PTPN11 is necessary for full activation of Erk1/Erk2 and Akt in 
melanocytes in response to HGF [320]. 
Based on the results obtained in this chapter, it can be concluded that there 
is a defect in EGFR phosphorylation in cells depleted of PTPN11 that 
suggests PTPN11‟s involvement in the maintenance of EGFR regulation in 
basal-like breast cancer. In addition, the c-Met hyperphosphorylation in 
conjunction with a lack of effect on cell proliferation in cells depleted with 
PTPN11, which mimic the findings from the study conducted by Soong et al 
[320] suggests that more work, focusing on the mechanistic regulation of 
PTPN11, needs to be done in order to understand those phenotypes.  The 
link between the increase in e-cadherin expression and c-Met 
hyperphosphorylation in the PTPN11-silenced cells in basal-like breast 
cancer needs further elucidation. E-cadherin downregulation is known to be 
related to ubiquitin ligases Hakai, or MDM2 (reviewed in [324]). The  
interaction of Numb with e-cadherin or the Par protein complex which is 
dynamically regulated by HGF/c-Met activation may modulate e-cadherin 
stability via the same interaction motif (NVYY) that Hakai binds to target e-
cadherin [324, 325]. The biochemical interplay between PTPN11, c-Met and 



































In this thesis, we initially report: 
1. The novel finding of the use of [18F]AH113804, a c-Met binding 
peptide tracer with high affinity to human c-Met (Kd = 2nM) in the detection of 
locoregional recurrence of basal-like breast cancer at an early stage [16].  
2. A novel c-Met scFv-Fc binding tracer which successfully detects c-
Met positive cells in basal-like breast cancer in-vivo. 
 
In greater details, [18F]AH113804 was able to detect the recurrent 
HCC1954 tumour lesion 6 days after removal of the primary tumour, while 
this is not detectable by eye nor by CT.  We also observed a statistically 
significant difference in the uptake of the tracer at the tumour site in 
comparison to the control site, at all timepoints excluding 50 days after 
removal of the primary tumour. The reason given for the lack of statistically 
significant difference at this latter timepoint is the lower, inhomogenous 
distribution of radioactivity in the tumors, indicative of the presence of 
necrosis in the c-Met positive tumours, HCC1954.  
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Additionally, the non-specific blood pool distribution of [18F]AH113804 
decreased over time, after injection of the tracer, while we observed an 
increasing signal within the site of the basal-like breast cancer tumours.  
c-Met expression level, quantified from the ex vivo histology performed on 
the resected recurrent tumours and primary tumours, correlated with the 
uptake of the tracer in those tumours in-vivo (P = 0.005, r = 0.83). These 
results combined gave us confidence in the reliability of this tracer for the 
detection of c-Met positive cells and show potential utility for the detection of 
loco-regional recurrence, in basal like breast cancer, from an early stage. 
Further preclinical work is necessary to determine whether [18F]AH113804 
uptake in the regrowth provides a useful predictive tool for anti-c-Met 
therapeutic intervention [16]. 
 
Following this, we focused on the design of an optically and radiolabelled 
scFv-Fc with specificity to human c-Met for the detection of basal-like breast 
cancer in-vivo. The choice of a scFv-Fc is based on its high targeting ability 
for the detection of c-Met positive tumour lesions, and a longer biological 
half-life (than a c-Met binding peptide for example) enabling the potential 
monitoring of anti-c-Met therapies. The two versions of the tracer, which 
consists of an optical Cy5-labelled scFv-Fc and the radiolabelled 111-In-
CHX-A‟‟-DTPA-scFv-Fc show a higher uptake in the c-Met positive HCC1954 
tumours, in comparison to the c-Met negative MCF-7 tumours, which is 
statistically significant.   
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The scFv-Fc was selected from a phage display library, which led to the 
production of plasmid DNA with a scFv format, via the use of the vector 
pSANG4, and then subcloned into pBIOCAM5 for the production of c-Met 
scFv-Fc. This led to the identification of 222 anti c-Met scFv-Fc fusions, as 
described in chapter 5. The selection of our FLAG epitope-tagged scFv-Fc 
was based on displaying one of the highest ratio average intensity for c-Met 
(using the D1C2 antibody) and anti-FLAG, relative to the scFv-Fc expression 
level, detected by western blot, and the presence of good co-localisation 
between c-Met positive cells and cells that expressed the anti-FLAG epitope. 
This subclone was amplified and optically labelled with the Cy5 
fluorochrome.  
After injection of the optical tracer Cy5-scFv-Fc, we observed an uptake in 
the c-Met positive basal like breast cancer HCC1954-luciferase expressing 
tumour while no uptake was seen in the c-Met negative MCF-7 tumour in the 
tumour bearing mice. The difference in the uptake of the optical tracer in both 
tumours was statistically significant. The fluorescent signal emitted at the site 
of the c-Met positive tumour was identified at the same location as the 
bioluminescent signal from the HCC1954 tumour. The ex vivo biodistribution, 
performed at 24 hours after injection, confirmed a high uptake in the 
HCC1954 tumour, as well as the liver and moderate uptake in the kidneys. 
The ex vivo staining performed on the frozen HCC1954-luciferase tagged 
tumour sections, collected from the tumour bearing mice, showed c-Met 
overexpression which co-localised with the staining for the Cy5-labelled 
scFv-Fc. We did not observe c-Met staining in the MCF-7 frozen tumour 
section which validated the specificity of Cy5-scFv-Fc to human c-Met.  
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Following the successful conjugation (with the chelator CHX-A‟‟-DTPA) and 
radiolabelling (111-In) of the scFv-Fc, we observed specific tumour targeting 
of the radiolabelled tracer in the c-Met positive HCC1954 tumours in the 
tumour bearing mice while a very low uptake was observed in the c-Met 
negative MCF-7 tumours, at 3h, 7h and 24h after tracer‟s injection. The 
serum stability test confirmed the stability of 111-In-CHX-A‟‟-DTPA-scFv-Fc 
in human serum at 37°C up to 24 hours, which was the latest timepoint 
determined by the length of the experiment. Quantification of the tracer‟s 
uptake revealed an increase at the tumour site over time while in parallel, the 
uptake in the liver decreased. The ex-vivo biodistribution data revealed a 
statistically significant difference between the uptake of the tracer in the c-
Met positive HCC1954 tumours and the uptake in the c-Met negative MCF-7 
tumours.  
The novel use of the c-Met binding peptide tracer [18F]AH113804 in the 
detection of locoregional recurrence of basal-like breast cancer at an early 
stage and the design of a novel c-Met specific scFv-Fc binding tracer, 111-In-
CHX-A‟‟-DTPA-scFv-Fc, for the detection of c-Met positive tumour cells  are 
of significant values.  
Indeed, the ubiquity of c-Met dysregulation in numerous cancers and its 
known influence in tumour progression makes it an attractive target for 
diagnostic and therapeutic intervention.  Decades have been spent on the 
elucidation of c-Met signalling in normal and in tumour cells [49, 56, 60, 326, 
327]. c-Met overexpression, amplification and dysregulation in many cancers 
resulted in the development of c-Met binding tracers in the aim to assess, 
non-invasively, c-Met expression level and localisation in-vivo [16, 212, 214, 
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254, 328]. Recent literature shows the use of c-Met specific radiolabelled 
tracers such as anticalin [214], 89-Zr Onartuzumab [214, 255], cMBP-GGG 
[257] in the detection of tumour lesions that overexpress c-Met but sadly, 
those tracers presented flaws that prevent them from being assessed in 
patients as described in more details in Section 4.3 of this thesis.  
Despite the use of 18F-FDG in breast cancer staging and recurrence, it is not 
currently used for the screening of primary breast cancer [258]. In addition to 
this, despite the sensitivity and specificity of FDG in the detection of tumour 
cells, it lacks the ability to detect lesions that are smaller than 1cm [167, 168, 
251], and is not a direct readout for the expression level of a target protein, 
hence making its use rather inadequate for the monitoring of, for example, c-
Met inhibition in-vivo. 18-FDG cannot be used for the in-vivo quantification of 
a protein expression level. A molecular targeted agent would enable the 
assessment of an appropriate dose schedule in a patient, as the tracer would 
provide quantifiable values of the protein expression level that is targeted by 
the drug at a specific dose. 
Additionally, prognostic biomarkers for patient stratification are a necessity in 
clinical trials, in order to eliminate non-responder phenotypes before the 
assessment of specific molecular-targeted therapies.  This is particularly 
useful in assessing the efficacy of inhibitors whose target is overexpressed in 
the tumour. Hence, c-Met stratification in patients would enable an increase 
in the efficiency of anti-c-Met therapies and possibly anti-EGFR therapies in 
patients. Indeed, reports show that some patients develop resistance to 
EGFR inhibitors and in some of those cases, the resistance is assigned to c-
Met over-activation or amplification, bypassing the need for the activation of 
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EGFR as c-Met promotes cell proliferation and other tumour driven pathways 
[329]. Hence, such molecular targeted imaging agents could also be used in 
image guided therapy, allowing the discontinuation of ineffective treatments 
early on in the course of treatment. Additionally, molecular targeted imaging 
agents would also offer an early indication of potential normal organ toxicities 
(in case of the equivalent radioimmunotherapies, by estimating the dose 
delivered to for instance bone marrow), hence preventing the subject to go 
through fatal illnesses owed to toxicity level [330]. Lastly, the use of a c-Met 
targeted tracer would circumvent the need for a biopsy, which is invasive and 
not necessarily achievable, especially if the tumour lesions are not visible by 
eye nor by CT.  
Lately, numerous clinical studies have been focusing on antibody 
engineering for the optimisation of molecular targeted imaging agents. 
Indeed, it is necessary for the imaging agent to display a high tumour 
targeting, fast clearance kinetics, a high tumour to blood ratio in order to 
acquire high quality images. Although c-Met binding peptide tracers show 
fast clearance kinetics and therefore allow the use of a short half-life 
radioisotope for the acquisition of a PET scan within minutes to hours after 
tracer‟s injection, they do not display a very high tumour targeting ability, 
unlike intact monoclonal antibodies (mAbs) and cannot be used to monitor 
long-term therapies due to their short biological half-life. The major challenge 
faced by mAbs is their persistent circulation time in the serum, despite their 
high affinity for the target. Fragment antibodies provide a solution to those 
issues [279]. It is possible to maintain the targeting ability of a mAb, by 
engineering it into a scFv-Fc fusion antibody for example, as observed in this 
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study. Additionally, faster clearance and good image contrast can be 
achieved by blocking the FcRn salvage receptor with Fc-engineered 
antibodies [331, 332], or by removing it altogether, like in the case of a 
minibody or diabody and other smaller fragment antibodies, as described in 
Section 1.11 in this thesis.   
 
Lastly, in this thesis, we report: 
 3. The potential oncogenic role of PTPN11 in basal-like breast cancer 
 
Briefly, chapter 6 in this thesis (Section 6.2) described the novelty of PTPN11 
being an EGFR regulator in BLBC. It also described the increase in EGFR 
phosphorylation following EGF stimulation in PTPN11-silenced cells, and the 
fact that this hyperphosphorylation was maintained for longer in comparison 
to control cells. This hyperphosphorylation might be a direct effect of 
PTPN11 knockdown as a study has shown the ability of PTPN11 to regulate 
the amount of phosphorylated EGFR [315]. Speculations are that PTPN11 
would diffuse on the surface of endosomes, dephosphorylating 
phosphorylated EGFR molecules before being itself inactivated in the 
absence of further interaction with phosphorylated EGFR [315].  
Additionally, reports had shown that EGFR phosphorylation might lead to the 
attenuation of Erk activation [290]. Despite the increase in EGFR 
phosphorylation, it is still possible that EGFR may be targeted for 
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degradation as other phosphatases could substitute for this role of PTPN11 
[316].  
We also observed c-Met hyperphosphorylation in PTPN11-silenced BLBC 
cells. This mimicked previous findings, although ligand-independent in our 
study, in which increased levels of c-Met phosphorylation was observed in 
PTP1B-null mice that were injected with 15 nm HGF via the hepatic portal 
vein [318]. The hyperphosphorylation observed in our study could be due to 
transactivation of c-Met with other receptors [319].  
It was also interesting to observe an increase in e-cadherin expression level 
and mean fluorescent intensity in PTPN11-silenced BLBC cells. This 
suggests the migratory role of PTPN11 in BLBC cells and is in agreement 
with other studies in which they demonstrate the restoration of epithelial 
morphology PTPN11-silenced basal like breast cancer MDA-MB231 cells 
[322]. More mechanistic studies are however needed  to elucidate the 
biochemical interplay between PTPN11, c-Met and E-cadherin before being 
able to consider therapeutic strategies using PTPN11 as a target.  
Due to drug resistance observed in patients who are given TKIs, it is crucial 
to identify biochemical interplays and proteins that prevent the efficiency of 
TKIs, such as cetuximab (an anti-EGFR TKI) and cabozantinib (an anti-c- 
Met, VEGFR2 and Ret TKI) in cancer patients, especially in BLBC patients. 
PTPN11 is an interesting target as it modulates both c-Met and EGFR 
activation, as observed in our study.  A study conducted by Furcht et al 
revealed that PTPN11 knockdown leads to the decrease in ERK 
phosphorylation in NSCLC cells expressing wild-type EGFR , basally 
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accompanied by an increased in cellular sensitivity to gefitinib [333]. 
Interestingly, PTPN11 was also required for sustained activation of ERK and 
epithelial morphogenesis downstream from the c-Met receptor tyrosine 
kinase [334]. It has been shown that C-Met is highly dependent on Gab1 for 
signalling [335] as Gab1 becomes phosphorylated upon c-Met binding 
providing binding sites for multiple signalling proteins such as PTPN11 [336]. 
A specific study has shown the importance of the association of Gab1 with 
PTPN11 and PI3K for cell cycle progression and the inability of Gab1 mutant, 
which cannot bind to PTPN11 to activate MAPK downstream of c-Met [336]. 
These suggest the involvement of PTPN11 in tumour progression and the   
potential role of PTPN11 inhibitors as therapeutic targets [337, 338].   
 
7.2 Future work 
 
Based on the findings in this thesis, [18F]AH113804 has the ability to detect 
locoregional recurrence in BLBC as early as 6 days following primary tumour 
removal. It would be informative to assess the survival rate in those tumour 
bearing mice following the early administration of therapeutic treatment, due 
to early detection of LRR. This would have provided us and others invaluable 
insight into the direct effect of early detection and treatment on basal-like 
breast patients‟ survival. 
Since 18F-FDG gained clinical acceptance, and has become an important 
imaging tool in routine clinical oncology, it would have been useful to assess 
FDG uptake in our basal-like breast cancer model and compare its uptake at 
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the tumour site, especially after surgery, to the uptake observed with 
[18F]AH113804. Additionally, it would also be very useful to monitor anti-c-
Met therapies in-vivo in BLBC using both tracers and delineate the exact use 
of [18F]AH113804 in the clinic. 
 
Before 111In-CHX-A‟‟DTPA-scFv-Fc against human c-Met could be assessed 
in man, it would be useful to reduce its biological half-life and liver uptake via 
directed mutagenesis of the Fc fragment, as described in Section 5.3 [202, 
282] and assess any potential off-target effects in-vitro.  
Although SPECT is more cost-effective than PET, the latter displays a better 
spatial and contrast resolution enabling the acquisition of higher quality 
images [339]. Hence, it might be useful to radiolabel our scFv-Fc with a PET 
radioisotope and compare the images acquired with the images from the 
SPECT to assess the best modality for the optimal use of the scFv-Fc in 
cancer imaging.  
 
Lastly, for a better understanding of the mechanisms behind c-Met 
hyperactivation in PTPN11-silenced cells, it would be useful to identify 
potential transactivation of c-Met with other receptors via 
immunoprecipitation. It would also be useful to identify downstream signalling 
pathways that are being upregulated following c-Met activation.  
Additionally, to better understand the functional phenotype of PTPN11-
silenced cells, it would be needful to perform migratory assays in our model, 
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both in-vitro and in-vivo. Previous studies have revealed the role of PTPN11 
in cell motility in-vivo, as well as cell migration and invasion in-vitro, through 
the activation of several SRC-family kinases and downstream targets [340]. 
It would also be informative to gain a better understanding of the interplay 
between c-Met, PTPN11 and e-cadherin by performing immunoprecipitation 
assays and identify the proteins involved in the maintenance of e-cadherin, 
as observed in this study, in the PTPN11-silenced cells as compared to the 
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Chapter 9: Appendix 
 
9.1 Chromatograms from the serum stability assay 
 
Integration c:\GINA_NT\MICHELLE SEC2000\160512_IN111_FREE, 
160512_In111_free    Start: 12/05/2016 11:28  
Indium-free: Labelling control 
 
Sample description 
Measurement: 160512_In111_free, injection : 12/05/2016  11:28 
Method: MICHELLE SEC2000 from: 03/03/2016  12:02 
Dead time of column:  01'00 s 




Substance R/T Type Area %Area Conc 




































 s  Counts %  
Reg #1 12'12 DD(M) 2803397 100.00 No comp. 
      
Integration c:\GINA_NT\MICHELLE SEC2000\160512_APPI_IN11_EXTRA, 
160512_appi_In11_extra    Start: 12/05/2016 12:03 
QC reaction of 111In-CHX-A’’DTPA-scFv-Fc 
 
Sample description 
Measurement: 160512_appi_In11_extra, injection : 12/05/2016  12:03 
Method: MICHELLE SEC2000 from: 03/03/2016  12:02 
Dead time of column:  01'00 s 




Substance R/T Type Area %Area Conc 
 s  Counts %  










































Reg #1 07'43 DD(M) 1597145 94.07 No comp. 
Reg #2 12'08 DD(M) 100722 5.93 No comp. 
Integration c:\GINA_NT\MICHELLE SEC2000\160512_S1, 160512_s1    Start: 
12/05/2016 13:12 
111In-CHX-A’’DTPA-scFv-Fc in human serum for 1h 
 
Sample description 
Measurement: 160512_s1, injection : 12/05/2016  13:12 
Method: MICHELLE SEC2000 from: 03/03/2016  12:02 
Dead time of column:  01'00 s 





Substance R/T Type Area %Area Conc 
 s  Counts %  













































Reg #1 07'42 DD(M) 1101729 96.23 No comp. 
Reg #2 12'10 DD(M) 43147 3.77 No comp. 
 
Integration c:\GINA_NT\MICHELLE SEC2000\160512_IN111_S11, 
160512_In111_s11    Start: 12/05/2016 14:16 
Indium-111 in human serum for 1h 
 
Sample description 
Measurement: 160512_In111_s11, injection : 12/05/2016  14:16 
Method: MICHELLE SEC2000 from: 03/03/2016  12:02 
Dead time of column:  01'00 s 




Substance R/T Type Area %Area Conc 
 s  Counts %  










































Reg #1 08'43 DD(M) 753021.6 95.08 No comp. 
Reg #2 12'10 DD(M) 38927.2 4.92 No comp. 
Integration c:\GINA_NT\MICHELLE SEC2000\160512_IN111_S7, 
160512_In111_s7    Start: 12/05/2016 15:39 
111In-CHX-A’’DTPA-scFv-Fc in human serum for 3h 
 
Sample description 
Measurement: 160512_In111_s7, injection : 12/05/2016  15:39 
Method: MICHELLE SEC2000 from: 03/03/2016  12:02 
Dead time of column:  01'00 s 




Substance R/T Type Area %Area Conc 
 s  Counts %  
Reg #1 07'42 DD(M) 893670.9 97.49 No comp. 
Reg #2 11'54 DD(M) 22976.2 2.51 No comp. 










































Integration c:\GINA_NT\MICHELLE SEC2000\160512_IN111_S12, 
160512_In111_s12    Start: 12/05/2016 16:12 
Indium-111 in human serum for 3h 
 
Sample description 
Measurement: 160512_In111_s12, injection : 12/05/2016  16:12 
Method: MICHELLE SEC2000 from: 03/03/2016  12:02 
Dead time of column:  01'00 s 
Radio detector: raytest Gabi Star Serial Nr.: #30484 raytest GINA star 
20.04.09 Firmware V4.8 
 
Integration Int 
Substance R/T Type Area %Area Conc 
 s  Counts %  
Reg #1 08'43 DD(M) 954432.0 96.66 No comp. 
Reg #2 12'10 DD(M) 32948.8 3.34 No comp. 
Integration c:\GINA_NT\MICHELLE SEC2000\160512_IN111_EXTRA_QC2, 
160512_In111_extra_QC2    Start: 12/05/2016 17:24 
 










































QC of 111In-CHX-A’’DTPA-scFv-Fc (no human serum) 
 
Sample description 
Measurement: 160512_In111_extra_QC2, injection : 12/05/2016  17:24 
Method: MICHELLE SEC2000 from: 03/03/2016  12:02 
Dead time of column:  01'00 s 
Radio detector: raytest Gabi Star Serial Nr.: #30484 raytest GINA star 
20.04.09 Firmware V4.8 
Integration Int 
Substance R/T Type Area %Area Conc 
 s  Counts %  
Reg #1 07'39 DD(M) 3099254 97.60 No comp. 
Reg #2 12'32 DD(M) 76355 2.40 No comp. 
Integration c:\GINA_NT\MICHELLE SEC2000\160512_IN111_S8, 




















































Measurement: 160512_In111_S8, injection : 12/05/2016  19:48 
Method: MICHELLE SEC2000 from: 03/03/2016  12:02 
Dead time of column:  01'00 s 
Radio detector: raytest Gabi Star Serial Nr.: #30484 raytest GINA star 
20.04.09 Firmware V4.8 
Integration Int 
Substance R/T Type Area %Area Conc 
 s  Counts %  
Reg #1 07'44 DD(M) 889189.8 97.16 No comp. 
Reg #2 11'59 DD(M) 26004.3 2.84 No comp. 
Integration c:\GINA_NT\MICHELLE SEC2000\160512_IN111_S13, 
160512_In111_S13    Start: 12/05/2016 20:25 
 
 










































Indium-111 in human serum for 7h 
 
Sample description 
Measurement: 160512_In111_S13, injection : 12/05/2016  20:25 
Method: MICHELLE SEC2000 from: 03/03/2016  12:02 
Dead time of column:  01'00 s 
Radio detector: raytest Gabi Star Serial Nr.: #30484 raytest GINA star 
20.04.09 Firmware V4.8 
 
Integration Int 
Substance R/T Type Area %Area Conc 
 s  Counts %  
Reg #1 08'41 DD(M) 65788.49 94.59 No comp. 
Reg #2 12'26 DD(M) 3762.15 5.41 No comp. 
 
Integration c:\GINA_NT\MICHELLE SEC2000\160513_IN111_S9, 
160513_In111_s9    Start: 13/05/2016 13:04 
 










































111In-CHX-A’’DTPA-scFv-Fc in human serum for 24h 
 
Sample description 
Measurement: 160513_In111_s9, injection : 13/05/2016  13:04 
Method: MICHELLE SEC2000 from: 03/03/2016  12:02 
Dead time of column:  01'00 s 
Radio detector: raytest Gabi Star Serial Nr.: #30484 raytest GINA star 
20.04.09 Firmware V4.8 
 
Integration Int 
Substance R/T Type Area %Area Conc 
 s  Counts %  
Reg #1 07'44 DD(M) 915397.3 96.96 No comp. 
Reg #2 11'56 DD(M) 28744.8 3.04 No comp. 
Integration c:\GINA_NT\MICHELLE SEC2000\160513_IN111_S14, 
160513_In111_s14    Start: 13/05/2016 13:38 
 
 










































Indium-111 in  human serum for 24h 
 
Sample description 
Measurement: 160513_In111_s14, injection : 13/05/2016  13:38 
Method: MICHELLE SEC2000 from: 03/03/2016  12:02 
Dead time of column:  01'00 s 
Radio detector: raytest Gabi Star Serial Nr.: #30484 raytest GINA star 20.04.09 
Firmware V4.8 
Integration Int 
Substance R/T Type Area %Area Conc 
 s  Counts %  
Reg #1 08'46 DD(M) 762102.4 97.91 No comp. 
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